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General Introduction
Accurate detection of tumor tissue is a key feature in the diagnosis of cancer, and 
surgery is one of the major pillars in further management of the disease. Using 
preoperatively obtained images, the area of interest can be linked to the anatomy of the 
patient, enabling planning of the surgical intervention. 
During surgical exploration morbidity may be caused by the unnecessary removal of 
healthy tissue and/or the unintentional damage to delicate anatomical structures. 
Furthermore, the inability to completely excise the cancerous tissue increases the need for 
invasive re-excisions. More accurate surgical visualization of the area’s of interest can 
supplement the surgeons eyes and help improve surgical outcome. 
Accurate preoperative identification, surgical planning, and intraoperative 
visualization can be integrated using hybrid imaging agents that contain both a radio- 
and fluorescent label. This hybrid interventional molecular imaging concept was initially 
validated in sentinel lymph node (SLN) biopsies, but can be further expanded by the 
implementation of imaging agents that specifically visualize tumor cells. In this thesis 
both the preclinical and clinical introduction of this hybrid concept is described.
Part I of this thesis is focused on combined pre- and intraoperative imaging of the 
SLN. Chapter 2 provides an overview of radioactive, fluorescent and size-dependent 
properties of non-targeted hybrid nanoparticles and their (potential) value in SLN 
detection.
In Chapter 3 conventional preoperative lymphoscintigraphy with technetium 
labeled albumin colloids is quantitatively compared with optical intraoperative guidance 
using the near-infrared dye indocyanine green (ICG) in a mouse model for metastatic 
breast cancer. A self-assembled hybrid complex (ICG-99mTc-nanocolloid) is applied, in order 
to attain identical dynamics of the radioactive and fluorescent components.
In a spontaneous mouse prostate tumor model (Chapter 4), the lymphatic 
distribution pattern of the hybrid imaging agent ICG-99mTc-nanocolloid was quantitatively 
compared to that of the visible dye patent blue, ICG, and dual labeled human serum 
albumin particles (ICG-99mTc-Vasculosis). 
In a clinical reproducibility study, described in Chapter 5, lymphoscintigraphic 
drainage patterns of 99mTc-nanocolloid and ICG-99mTc-nanocolloid are compared, showing 
that the addition of ICG does not alter the drainage properties of the radiocolloid.
Chapter 6 describes the added value of combined pre- and intraoperative imaging 
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using ICG-99mTc-nanocolloid in patients who underwent robot assisted laparoscopic 
prostatectomy (RALP) with (S)LN dissection for prostate cancer. 
An additional feature of ICG-99mTc-nanocolloid is demonstrated in Chapter 7, wherein 
the location of the ICG-99mTc-nanocoloid tracer deposit in embedded prostate samples is 
related to the lymphatic drainage pattern as seen on lymphoscintigraphy. 
In Part II of this thesis the preclinical evaluation of a number of differently labeled 
Ac-TZ14011-based CXCR4 targeting imaging agents, including hybrid derivatives, are 
described. 
In Chapter 8 expression of CXCR4 in preclinical (tumor) models is compared to the 
clinical situation. Furthermore, peptide structures and receptor affinities of CXCR4 
targeting T140 peptide derivatives are evaluated.
The ability to accurately stain the CXCR4 receptor in both cells and tumor tissue 
using a fluorescently labeled version of Ac-TZ4011 (Ac-TZ14011-FITC) is compared to 
CXCR4 targeting antibodies in Chapter 9.
In a mouse tumor model resembling human ductal carcinoma in situ (DCIS; Chapter 
10), an indium labeled version of Ac-TZ14011 (111In-Ac-TZ14011) is used to longitudinal 
monitor lesion development by way of CXCR4 expression levels.
Chapter 11 describes the synthesis and evaluation of hybrid Ac-TZ14011 derivatives 
that contain both a DTPA chelate and a fluorescent dye. Like the untargeted hybrid agent 
ICG-99mTc-nanocolloid, the hybrid version of the targeting peptide (MSAP-Ac-TZ14011) 
enables integration of pre- and intraoperative imaging. 
The effect of multimerization; increasing the amount of targeting peptides per 
molecule to reduce the negative influence of the hybrid label on the receptor affinity and 
distribution is studied in Chapter 12.
An expansion of the targeted hybrid imaging approach is discussed in Chapter 13 
wherein MSAP-Ac-TZ14011 is used to assess the CXCR4 expression pattern in fresh tumor 
tissue specimens. This approach enables target validation and accurate staging of the 
lesions prior to imaging.
In the future perspectives (Chapter 14), additional suggestions for expansion of the 
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nanoparticles and their potential in combined 
pre- and intraoperative imaging during 
sentinel lymph node resection
Adapted from: 
Buckle T, van Leeuwen AC, Chin PT, Janssen H, Muller SH, Jonkers J, van Leeuwen FWB. 
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Abstract
A clear clinical precedent for the use of nano-sized imaging agents is localization of 
the tumor draining sentinel lymph nodes (SLNs). Specific removal of the SLN during 
breast cancer surgery presents physicians with the opportunity to detect early metastatic 
disease. In this application, radiocolloids such as 99mTc-nanocolloid are commonly used to 
plan the surgical procedure and to provide acoustic gamma guidance to the SLN during 
the intervention. An additional injection of a (visible) dye is used to provide optical surgical 
guidance. Hybrid nanoparticles, which are contain both a radioactive and fluorescent 
label, provide the potential to combine both radioactivity based surgical planning and 
intraoperative fluorescence guidance. In this chapter an overview is provided of the 
radioactive, fluorescent, and size properties of such (non-targeted) hybrid nanoparticles, 
and their (potential) value in SLN detection. 
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Introduction
In oncology, the presence of (lymphatic) metastases is considered an important 
predictor of distant tumor spread and consequently the life expectancy of the patient. The 
sentinel lymph node ((S)LN) is the first tumor draining lymph node and is generally the 
first LN affected by metastasizing tumor cells draining from a primary tumor. Based on the 
presence of tumor cells within the SLN, the likelihood of metastatic spread throughout 
the lymphatic system can be predicted and further treatment can be adapted accordingly.1 
Evaluation of the tumor presence in SLNs is a standard procedure during the clinical 
management of breast cancer patients and is also being investigated for many other 
tumor types e.g. melanoma and prostate cancer.1-3 Accurate pathological analysis of the 
SLN depends on their accurate removal during surgical resection, which in turn relies 
heavily on the guidance provided during the surgical procedure. 
Clinically, for SLN mapping lymphoscintigraphy is most frequently performed using 
radioactive colloidal particles.4-6 In Europe, 99mTc-nanocolloid is the current clinical 
standard, whereas in the US 99mTc-sulfurcolloids are most frequently used.7 Peritumoral/
subdermal injection of these non-targeted colloidal particles results in transport via the 
lymphatic system, followed by accumulation in the SLN.8 
Surgical resection of the SLN requires combined pre- and intraoperative imaging.9-11 
Commonly, the surgical procedure is planned according to preoperatively acquired 
lymphoscintigraphy using the radiocolloid.12 Intraoperative surgical guidance is then 
obtained using an acoustic gamma probe and/or via co-injected dyes.13-15 Such dyes offer 
the potential to add (superficial) optical intraoperative guidance. Unfortunately, the 
small organic dyes, such as methylene blue15, patent blue14, fluorescein (λem= 530 nm)
15, 
and the near-infrared (NIR) dye indocyanine green (ICG; λem= 808 nm)
16 do not appear to 
accumulate in the SLNs, limiting their use in real-time lymphatic mapping studies.17 
Differences in lymphatic migration translate to a different effective time window for both 
the radioactivity based and optical procedures. Hence in clinical practice pre- and 
intraoperative imaging consists out of two separate diagnostic approaches (radiocolloid 
and dye based), rather than a single integrated approach. Nano-sized hybrid imaging 
agents can, however, be used to combine radioactive and fluorescence properties in a 
single particle.18 In such particle the radiolabel will enable surgical planning and guidance 
during the excision in the dm - cm range, while fluorescence will enable accurate 
intraoperative localization (cm - mm range; Figure 1).
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Figure 1. Schematic presentation of combined pre- and intraoperative imaging of the SLN using hybrid imaging 
agents that contain both a radioactive and fluorescent label (Figure adapted from Buckle et al.24) Both the SPECT/
CT and the fluorescence image show the injection site (tumor), the draining lymphatic vessel (arrows) and the 
SLN.
Pre- and intraoperative imaging can be combined using non-targeted radioactive/
fluorescent nano-sized materials. The physical requirements of these particles are 
considered to be a good guideline for the future development of nanotechnology-based 
imaging agents and their implementation in SLN imaging. Several reviews have been 
written discussing hybrid imaging agents.18-20 Moreover, there are a number of reviews 
that discuss the use of nanoparticles for SLN imaging that also include MRI/optical hybrid 
particles.21,22,23 As the standard clinical SLN procedure is based on radioactivity-based 3D 
imaging, rather than MRI, this Chapter is focused on the combination of radioactive and 
fluorescent antennae. We discuss the chemical properties of a variety of non-targeted 
hybrid nanoparticles and discuss their (potential) value in combined pre- and 




In Europe, the most widely applied protein-based nanoparticle in nuclear medicine 
is 99mTechnetium (99mTc; 140 keV; SPECT) labeled colloidal human serum albumin 
(nanocolloid; average diameter 14 nm).24 Although it is not accurately described, the 99mTc-
radiolabeling randomly occurs at the many available nitrogen- and/or sulfur-groups. We 
have recently shown that self-assembly can be used to generate a hybrid derivative of this 
compound, namely ICG-99mTc-nanocolloid (Figure 2a).24,25 Due to the large number of non-
covalent binding sites,26 a single albumin particle can contain a number of non-covalently 
bound guest molecules.27 As nanocolloid consists out of multiple albumin particles, this 
results in a further concentration of dye molecules. 
Figure 2. Schematic representation of non-targeted radioactive/fluorescent organic nanoparticles. A) Protein-
based self-assembled ICG-99mTc-nanocolloid particles.24 B) Polysaccharide-based dextran particles covalently 
functionalized with Cy5.5 and a 99mTc-DTPA label.28 C) Synthetic polymer-based nanoparticles: I) hybrid co-block 
polymers with an 111In-DTPA label and a covalently linked fluorescent label (Cy7)31 and II) EPMA-based latex 
nanoparticles with non-covalently internalized dye (RhB) and surface coordinated radiolabels.32 The radiolabels 
are represented in blue, the fluorescent antennae in red and the carrier molecules in gray. 
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Combined pre- and intraoperative imaging of the SLN with ICG-99mTc-nanocolloid 
has been validated in mouse models for metastatic breast and prostate cancer.24,25 The 
migration properties of the hybrid derivative was found to be highly similar, if not identical 
to 99mTc-nanocolloid (Figure 1). Incorporation of multiple ICG molecules on the nanocolloid 
resulted in a huge improvement in the signal-to-background-ratio compared to free ICG. 
Polysaccharide based
Polysaccharides like dextran contain a large number of reactive hydroxy groups that 
can be utilized for covalent functionalization. Vera et al.28 generated 12 nm dextran 
particles (Mw = 70 kDa), labeled with four DTPA moieties and two Cy5.5 (λem 690 nm) dye 
molecules (Figure 2b). In theory any type of dye functionalized with a reactive group can 
be linked to this dextran backbone, allowing the generation of particles with emission 
wavelengths ranging from visual to the NIR. The large number of appropriate reactive 
groups allows introduction of increasing numbers of fluorescent antennae and radioactive 
labels. Unfortunately in vivo examples using these hybrid nanoparticles are not described.
Although not (commonly) used for clinical applications, dextran particles with a 7 
nm size have proven their value in lymphatic (flow) imaging; both radioactive (99mTc) and 
fluorescent derivatives have been described.29,30 Since the dextran scaffold is the driving 
factor for these properties, a dual-labeled derivative should perform equally well. 
Moreover, size alteration of the dextran-scaffold can be used to improve the accumulation 
in SLNs.
Synthetic polymer-based
Synthetic polymeric nanoparticles, such as polymer micelles31 and latex32 with 
combined radioactive/fluorescent labels have also been reported (Figure 2c). For example, 
PEG-coated core-crosslinked polymer micelles (24 nm) can be formed by crosslinking the 
block copolymer poly(PEG-methacrylate)-b-poly triethoxysilyl propylmethacrylate 
(PPEGMA-b-PESPMA) and 3-(triethoxysilyl)propyl-Cy7 (λem 780 nm).
31 Crosslinking resulted 
in incorporation of approximately 27 Cy7 molecules into the particle core. Primary amine 
groups available on the (cross-linked) polymer surface were subsequently functionalized 
with 19 chelating DTPA-moieties per particle, which in turn allowed efficient incorporation 
of 111In at the particle surface. When linked to a 3-(triethylsilyl)propyl group other dyes can 
potentially also be incorporated in a similar manner. Again the number of dye molecules 
and radiolabels can be varied in this set-up, but no in vivo data is described.
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Emulsion copolymerization of poly-2,3-epoxypropylmethacrylate (EPMA) and 
Rhodamine B (RhB; λem 590 nm) has been used to form latex particles with a diameter of 
144 nm.32 The dye, which does not contain a reactive end group, remains trapped within 
the particle structure after crosslinking of the EPMA molecules. As RhB incorporation does 
not appear to be based on a specific interaction between the polymer and the dye, a 
similar procedure could be performed using other dyes. These latex particles contain a 
large number of carboxyl end groups on their surface and the authors have shown that 
these can function as chelating moiety for radioisotopes such as 68Ga and 111In. However, 
no data on the stability of these alternative metal-complexes has been reported, nor is an 
in vivo application mentioned. 
Fluorescent polystyrene microspheres (20 - 200 nm) have shown potential value in 
lymphatic mapping procedures.33 However, the hybrid derivatives have not yet been 
studied in this particular application. These polymeric hybrid particles (24 nm or 144 nm) 
can most likely provide synthetic alternatives to the albumin- or dextran-based 
nanoparticles. In addition to the possibility to chemically optimize the different polymer 
components of these synthetic derivatives, their size can potentially also be exploited to 
optimize lymphatic migratory properties even further.
 
Inorganic nanoparticles
In the last few decades a popular new class of inorganic dyes has been developed, 
referred to as quantum dots (QDs). In contrast to the earlier discussed protein-, saccharide-, 
and synthetic polymer-based nanoparticles, QDs do not rely on the inclusion of a dye for 
fluorescence. These nano-sized inorganic semiconductor crystals are inorganic fluorophores 
on their own. QD fluorescence induces great flexibility; alterations in size and materials 
allows tuning of the fluorescence from the visible part of the spectrum into the NIR.34
Introduction of a radioactive group on the surface of a QD is relatively easy, resulting 
in direct generation of a hybrid particle. This introduction commonly occurs via covalent 
attachment of a precoordinated reactive chelate complex to the polymer-, lipid- or 
surfactant coating of the QDs (Figure 3). The surface of CdSe/ZnS QDs has been 
radiolabeled with different isotopes, e.g. 99mTc and 64Cu.35,36,37 An advantage of surface 
modification is that it can easily be extrapolated to alternative QDs, e.g. InAs/ZnS.38 A 
radiolabel viz. fluorine (18F; PET) attached to a reactive organic molecule can be introduced 
onto a phospholipid coating.39 Of course the value of such a non-covalent coating relies 
heavily on a good particle stability in vivo. Alternatively, a radioactive isotope can be 
Interventional molecular imaging, a hybrid approach24
introduced in the crystal core during the QD synthesis. In this manner CdTe/ZnS QDs 
containing 125mTe have been generated (Figure 3d).40 This latter type of radiolabeling is 
very elegant as it requires no physical alteration to the QD. However, it appears to be less 
practical than a final-step introduction of a radioactive moiety on preprepared QDs.
Figure 3. Schematic representation of non-targeted inorganic nanoparticles. A) Polymer coated QDs 
functionalized with a 64Cu radiolabel36 B) Thiol-based lipid coated QDs functionalized with a 99mTc radiolabel.35,38 
C) Lipid coated QDs functionalized with a radiolabel (18F).3 D) Core radiolabeled (125mTe) QDs.40 The radiolabels are 
represented in blue and the fluorescent antennae in red. 
The potential value of QDs in SLN imaging was initially been reported by Kim et al.41 
and Ballou et al.42 and has later underlined by a number of different groups.43 While none 
of the SLN studies using QDs included the use of a radiolabel, there is no reason why 
radioactive/fluorescent QDs could not be equally suitable for such an application. Such 
hybrid QDs will also allow quantification of the kinetics in the lymphatic system, a feature 
that is currently lacking. QDs with a covalent coating functionalized with a radiolabel are 




Signal enhancement can be achieved via the creation of molecules that have multiple 
available reactive groups. In such compounds, so called dendrimers, increasing 
generations contain increasing amounts of reactive end groups and an increase in size. 
Moreover, the number of end groups can be well documented and accurately tuned for a 
particular application. While a number of MRI/fluorescent dendrimers have been 
reported44,45 there is, to the best of our knowledge, only one single example of dendritic 
structures labeled with both a radionuclide and a fluorescent dye (Figure 4).46 After the 
introduction of chelating DTPA moieties, generation-6 PAMAM dendrimers containing 
256 end groups were functionalized with Cy5 or one of four different Alexa dyes (Alexa660, 
Alexa680, Alexa700, or Alexa750). This resulted in particles of approximately 8 nm in size 
with a PAMAM/dye/DTPA ratio of 1:4:120. A single indium isotope (111In) was introduced to 
one of the 120 DTPA moieties on the dendrimer. The use of five different derivatives, all 
containing a different dye covered an application from 670 to 780 nm. Moreover, the 120 
chelating moieties present can be used to increase the radioactive signal intensity. 
Figure 4. Schematic representation of non-targeted hybrid generation 6 PAMAM dendrimers functionalized 
with a radiolabel (111In) and one of five different dyes; Cy5, Alexa660, Alexa680, Alexa700, or Alexa750.46 The 
radiolabels are represented in blue, the NIR fluorescent antennae in red, and the linker molecule in black/gray.
After injection of five differently ‘colored’ dendrimers into the front paw of mice, 
Kobayashi et al.44 were able to obtain accurate information with respect to the location of 
five separate lymphatic basins. In turn, the radiolabel provided a quantitative read out on 
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the lymphatic migration. When sufficient retention of these relatively small dendrimers in 
the SLN is obtained over time, this type of molecule is a good candidate for combined 
pre- and intraoperative imaging. This is strengthened by the large degree of synthetic 
control and the simultaneous use of differently colored dyes. The latter may be used to 
simultaneously identify the lymphatic draining sites of e.g. multifocal tumors.
General design guidelines that can be derived from literature examples
Based on the different radioactive/fluorescent nanostructures that have been 
reported, a number of general design guidelines can be derived, of which the most 
important are listed below.
Detection sensitivity: Radioactivity vs. fluorescence
Recent developments in sensitive surgical fluorescence cameras,47 and the ability to 
optimize both the color and intensity of the fluorescence signal, make fluorescence 
imaging an attractive optical supplement to acoustic (intraoperative) radioactivity based 
detection. Despite the similar contrast sensitivity,48 the signal penetration through tissue 
of radioactivity- and fluorescence-based imaging techniques differs quite dramatically.49 
The 25 - 511 keV gamma emission used in gamma camera imaging, single photon emission 
computed tomography (SPECT), and positron emission tomography (PET) provides total 
body penetration. In fluorescence imaging, the penetration of emitted photons remains 
confined within the cm - mm range, even those with NIR wavelengths. This difference 
influences the (clinical) application of these modalities. Whereas gamma camera imaging, 
SPECT, and PET are extremely suitable for non-invasive total body imaging (e.g. 3D surgical 
planning), fluorescence imaging is predominately suitable for superficial detection (e.g. 
intraoperative imaging).
In SLN applications dye concentrations used are generally much higher than the 
concentration of radiocolloids. The hybrid imaging agent ICG-99mTc-nanocolloid, enables 
detection of the SLNs using both radioactivity- and fluorescence-based imaging without 
changing the administered nanocolloid dose. While in ICG-99mTc-nanocolloid multiple dye 
molecules are present per particle, a 1:1 ratio between the radioactive and fluorescent 
imaging label was also proven sufficient in a recent review on peptide based tumor 
specific hybrid imaging agents.20 
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Chemical properties and SLN retention
The optimal particle size for SLN imaging applications is estimated to be approxi-
mately 40 nm. Smaller particles are expected to migrate throughout the complete 
lymphatic trajectory while migration speed of larger particles will possibly be too slow.50 
Nunezet et al. underlined that nanometer sized particles are more preferable than 
microsized particles.51 Nanocolloid is said to have a favorable hydrodynamic diameter for 
SLN imaging51; via TEM analysis a mean particle size of 14 nm was found.24 The diagnostic 
value of nanocolloid particles suggests that perhaps there is more to the accumulation in 
the SLN than size alone. Recognition of nanoparticles by the immune system may play a 
role in the accumulation of particles in the SLN.8 The administered concentration of 
nanocolloid was also shown to be of influence on the visualization of SLNs.10 Combined, 
size, recognition by the immune system, and injected concentration, seem to be the most 
dominant features in the feasibility of visualization of SLNs.
Radiolabel
The choice of a radiolabel is largely dictated by the radioactive half-life of the isotope. 
Due to the time needed for lymphatic migration and to bridge the timespan between 
pre- and intraoperative imaging, isotopes that can still be detected 4 - 6 hrs after 
administration, e.g. 99mTc and 111In, are preferred. Several of the chelating moieties can 
complex different isotopes, rendering the compound suitable for a use in either SPECT or 
PET imaging, depending on the demand of the user. In general a single radiolabel is 
sufficient for accurate detection.
Dyes
Different to radioactivity based imaging procedures that directly detect the emitted 
gamma photons from the imaging agent, fluorescence imaging requires an external 
excitation light source (λex) to obtain a fluorescent signal (λem; Figure 1). In the body 
significant tissue absorption and a strong autofluorescence is observed between 400 and 
650 nm. As a consequence, NIR fluorescent dyes (λem > 700 nm) are considered most 
suitable for ‘deep’ tissue imaging (cm range) in vivo, explaining the mainstream focus on 
NIR dyes for surgical image guidance.53
In combined radioactive and fluorescent imaging agents, the radioactive component 
already allows for initial guidance towards the lesion. The fluorescent component is only 
required for superficial visualization of the SLN (Figure 5).44 
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An interesting expansion of the radioactive/fluorescent labeling technology was 
suggested by Liu et al., who demonstrated that 131I-isotopes can also be used to excite 
QDs.54 Although not performed on the same molecule, such a hybrid cocktail application 
can be of use in, for example, tumor marker seeds,55 which in turn can be used to mark 
lymph nodes (LNs).56
Figure 5. Example of superficial visual fluorescence guidance towards the SLN using InP/ZnS QDs (Figure 
adapted from Chin et al.).43
In general, the type of organic dye used on the nanoparticles is not expected to alter 
the lymphatic distribution. This is mainly due to the dominance of the parental scaffold 
molecule. However, an important feature to keep in mind is the loading rate of the dye. 
When dyes are not physically separated in the hybrid particles, (self-)quenching of the 
fluorescence signal may occur. For the inorganic QD-based systems, the size related 
properties are used to tune the fluorescence to the desired wavelength. The fluorescence 
of QDs can be further tuned by inclusion of a dopant57 in to the QD core or by the creations 
of QD hetero structures, which are often referred to as type II QDs.58 
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Particle stability
Especially for the (non-covalent) self-assembled systems, the type of linkage 
between the radiolabel and the fluorophore may be instrumental for final in vivo 
stability of the complex. For example, in self-assembled amphiphilic lipids, the most 
investigated (hybrid) nano-platforms for biomedical purposes59, dissociation may occur 
during SLN applications via exchange with fatty tissue leading to particle aggregation.39 
Unfortunately in vivo monitoring of the stability of non-covalent assembled particles 
can be difficult. To validate the value of non-covalent complexes in SLN applications, it 
is important that the distribution of all the individual components of these imaging 
agents can be monitored (Figure 1).24 
Toxicity
This Chapter is predominantly focused on the fluorescent, radioactive, and size 
properties of hybrid nanoparticles. However, the clearance and resulting toxicity profile 
will be decisive for clinical implementation of these nanoparticles. The synthetic 
structures that are not based on endogenous proteins, e.g. dendrimers and (inorganic) 
nanoparticles, may suffer from toxic side effects. The highly toxic cadmium in many of 
the commercial available QDs is a prime example of a property that currently stands 
in the way of clinical translation. Significant effort is required to generate hybrid 
nanoparticles with advantageous properties but with a readily translatable toxicity 
profile. For example the combination of clinically applied radiocolloids and a clinically 
applied NIR dye (ICG) yielded a good translational character; currently the hybrid 
imaging agent ICG-99mTc-nanocolloid is being clinically evaluated for use in SLN 
procedures in patients with melanoma in the head and neck area or on the trunk, penile 
or prostate carcinoma, and oral cavity cancer.60-64
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Conclusion
Non-targeted hybrid nanoparticles that contain both a radioactive and fluorescent 
label represent a relatively unexploited area of chemical/nanotechnological development, 
with only a minor amount of compounds being produced. Despite the limited examples 
in literature, the potential to initiate a novel route for medical diagnostics, namely 
combined (preoperative) 3D radioactive imaging and (intraoperative) 2D fluorescence 
imaging is eminent. Diagnostics of the SLN provides a logical clinical application where 
size matters and nano actually performs better than sub nanometer sized molecules. As 
long as the size of the parental scaffold particle induces sufficient lymphatic retention, a 
variety of dyes and radiolabels can be introduced. This allows finetuning to the specific 
demands of a user. 
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Chapter 3
A self-assembled hybrid complex 
for combined pre- and intraoperative 
imaging of the sentinel lymph node
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Abstract
To increase the accuracy of intraoperative sentinel lymph node (SLN) detection, new 
methods with higher sensitivity and specificity are required. To facilitate this, conventional 
detection procedures based on preoperative lymphoscintigraphy with technetium 
labeled albumin radiocolloids (99mTc-nanocolloid) and optical intraoperative guidance 
using the near-infrared dye indocyanine green (ICG) were quantitatively compared in an 
orthotopic mouse model for metastatic breast cancer. Furthermore, a self-assembled 
hybrid complex was evaluated. In this complex ICG was non-covalently bound to 99mTc-
nanocolloid to attain identical dynamics of the radioactive and optical components. The 
SLN specificity of the hybrid complex was similar to that of the parental 99mTc-nanocolloid, 
and the fluorescent signal-to-noise ratio was found to be improved compared to ICG 
alone. Consequently, ICG-99mTc-nanocolloid has the potential to be used for both 
lymphoscintigraphy and surgical visualization via intraoperative fluorescence imaging.
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Introduction
One of the main challenges in surgical oncology is the intraoperative detection of 
preoperatively diagnosed lesions. At present, (molecular) imaging is a rapidly growing 
research field aiming at accurate and non-invasive diagnosis of disease.1 Consequently it 
becomes of increasing importance to develop strategies that enable incorporation of 
such novel imaging approaches into surgical procedures. To achieve surgical incorporation, 
intraoperative imaging procedures must be developed that depict identical features as 
defined during the preoperative image acquisition. The latter is used to plan the surgical 
procedure. The sentinel lymph node (SLN) procedure in breast cancer patients is a good 
example of a clinical application where combined pre- and intraoperative detection is 
desired.2-4 Based on the histological status of the SLN, the possible presence of metastasis 
in the (axillary) lymph nodes can be assessed. The outcome of this assessment is used to 
select further therapeutic approaches. Accuracy of removal of the SLN, however, relies 
heavily on the accuracy of the functional guidance provided during the excision.
Preoperative lymphoscintigraphy following injection of radiopharmaceuticals such 
as nano-sized radiocolloids (e.g. 99mTc-nanocolloid) accurately visualizes the SLN in the 
majority of patients.3,4 However, in some settings the intraoperative use of radiocolloids is 
cumbersome due to high background signals coming from the injection site. Therefore, 
visible blue dyes such as methylene blue and patent blue5-9 are often added to provide 
real time visual guidance during the surgical procedure. A potential downside of this 
additional visual detection approach is the low detection sensitivity. Accordingly, high 
concentrations (10 mg/mL) of visible dyes are required, which frequently results in 
cosmetically undesirable blue colored residues that remain visible for a long period of 
time after the operation.6 Together, these limitations call for alternative methods that yield 
a higher sensitivity and improve detection rates during optical intraoperative guidance.
Near-infrared (NIR) fluorescence signals in the 700 - 900 nm range allow for increased 
tissue penetration and therefore can be detected with a much higher sensitivity than 
visible dyes.1,10 Although tissue penetration of the NIR dyes is insufficient for accurate 
preoperative planning in 3D, it is adequate for superficial intraoperative fluorescence 
imaging procedures.
The NIR fluorescent dye indocyanine green (ICG) has been applied during SLN 
procedures in lung cancer,11 gastrointestinal cancer12-14 and breast cancer.15-18 However, a 
limitation in these studies is the lack of a quantitative and dynamic comparison between 
the ICG technique to conventional approaches.
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By combining the radiopharmaceutical- and dye-based methods, the SLN can be 
detected both pre- and intraoperatively.8,19 Herein is the variation in lymphatic transport 
velocity of the individual agents a limiting factor as differences in dynamic properties 
and/or injection procedures do occur. A hybrid approach using a single imaging agent 
that can be detected both with optical and radioactive methods can overcome these 
problems.20 The use of radiolabeled dyes (e.g. iodinated methylene blue) has been 
described previously.21 However, no application of such an imaging agent has been 
reported for combined pre- and intraoperative imaging procedures.
In this Chapter several approaches for pre- and intraoperative imaging of the SLN 
were evaluated in an orthotopic mouse model for metastatic breast cancer. Preoperative 
SPECT/CT procedures using radiocolloids (99mTc-nanocolloid) were quantitatively 
compared to fluorescence-based intraoperative procedures using ICG. In addition, the 
utility of an integrated approach based on a supramolecular hybrid imaging agent 
consisting of a self-assembled complex comprising of ICG and 99mTc-nanocolloid (Scheme 
1) was demonstrated.
 





Female [FVB x 129/Ola] F1 animals (6 - 12 weeks of age) were used. By means of 
orthotopic transplantation, 1 x 105 KEP1-Luc cells were injected into the fat pad of the left 
fourth mammary gland.22 The incision was closed and mice received an intraperitoneal 
(i.p.) injection of 10 µl of Temgesic (0.3 mg/mL buprenorfin; Schering Plough) in 1 mL of 
5% glucose/saline solution for postoperative pain relief. Tumor progression and spread 
was monitored by bioluminescence imaging (BLI). When the tumors reached a size of 4 - 5 
mm in diameter, initial metastasis could be observed in the axillary region. At this time 
animals were deemed suitable for experiments. Mice were included until tumors reached 
7 - 9 mm or when lung metastasis occurred. Prior to SPECT/CT and fluorescence imaging 
experiments the animals were anesthetized with a 1:1:2 mixture of Hypnorm (Vetapharma), 
Dormicum (Roche) and water (5 µL/g i.p.). BLI scans were performed using isoflurane 
inhalation anesthesia (Forene; Abbott). Experiments were conducted in tumor-bearing (n 
= 15) and control animals (n = 10), where the imaging agent was injected into the tumor 
or mammary fat pad, respectively. The axillary, brachial and the right inguinal lymph 
nodes (LN) were dissected and renamed as (S)LN1, LN2, LN3, LN4 and LN5 (Figure 1). All 
animal experiments were performed in accordance with Dutch animal welfare regulations 
and were approved by the local ethics committee.
Imaging agents
One gram of luciferin (substrate for luciferase; Xenogen Corp., Alameda, CA, USA) 
was dissolved in 66.7 mL phosphate buffered saline (PBS). After filtration using a 22 um 
filter (Millipore), this resulted in a sterile 15 mg/mL solution. A 1 mg/mL (1.3 x 10 -3 mmol/
mL) Cardiogreen (indocyanine green (ICG); Sigma Aldrich) solution was prepared in a 0.9% 
saline solution. Clinical grade human serum albumin nanocolloid (NanoColl; 0.5 mg 
human serum albumin (7.5 x 10-6 mmol); GE Healthcare) was radiolabeled with 99mTc (2 mL) 
according to standard clinical preparation procedures.
Preparation of the hybrid imaging agent
A self-assembled supramolecular complex of ICG and nanocolloid was made according 
to a slightly modified procedure for human serum albumin (HSA) labeling.4 To a clinical grade 
solution of 99mTc-labeled nanocolloid (200 µL; 80 - 100 MBq), 60 µl of a 1 mg/mL ICG solution 
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was added. After 30 min incubation, the ICG-99mTc-nanocolloid complex was separated from 
unbound reagents using a C-18 column, leading to a yield of 59% of the ICG-99mTc-nanocolloid 
complex [elution 9 g/L NaCl and 9 g/L NaCl (10% acetonitrile)]. For the imaging experiments 
a micron centrifugal filter (Millipore) with a molecular weight cut off at 30,000 Mw was used 
to isolate the complex from free dye. After this size-selective separation, the concentrate 
containing the ICG-nanocolloid complex was resuspended in 200 µL saline solution.
Electron microscopy
Nanocolloid powder (0.5 mg; not radiolabeled) was dissolved in 0.9% NaCl from 
which 5 µL was placed on a glow discharged Formvar/carbon coated copper grid (H100). 
It was allowed to attach to the surface whereafter the excess fluid was blotted off. The grid 
was negatively stained with a 1% phosphotungstic acid (w/v) in water solution for 30 sec, 
blotted off and air dried. Specimens were examined with a Philips CM10 electron 
microscope. Size measurements were performed on prints from negatives at a final 
magnification of 119 600 x, by means of a vernier caliper gauge.
UV–VIS spectroscopy
Absorption spectra were recorded using a Perkin Elmer Lambda Bio 20 spectro-
photometer, equipped with an in-house made glass cuvette with an optical path length of 
0.13 mm. For this experiment 1 mg/mL free ICG and ICG-nanocolloid (not radiolabeled) 
solutions in demi water were used. To determine the concentration an ICG absorption 
trend line was made. From a 1 mg/mL ICG solution (1.3 mmol/L) dilutions were made in 
demi water down to 6.5 µmol/L. The obtained trend line (absorption measured at 700 nm) 
had a slope of 9536.5 L/mol/cm.
Fluorescence and bioluminescence imaging
Tumor-bearing mice (n = 5) or control animals (n = 5) were anesthetized and injected 
i.p. with 150 mg/kg luciferin. After 10 min a BLI scan was performed. A blank fluorescence 
scan, performed at standard ICG settings (excitation 710 - 760 nm and emission 810 - 875 
nm) was directly followed by an intratumoral (i.t.) injection of 6 µL ICG solution (7.8 x 10-6 
mmol). Before initiating dynamic scans, a single total body scan was taken, after which the 
torso and injection site were covered. Sequential fluorescence images were recorded 
during a period of 30 min. After the imaging experiments the animals were sacrificed and 
LNs were removed. Explanted LNs were imaged using the IVIS camera prior to histological 
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analysis. Signal intensities were quantified as the sum of detected photons per second 
within the region of interest (ROI) using the Living Image software package. In each image 
the fluorescent signal intensity (photons/s/cm2) was measured in the four axillary and 
brachial LNs with four respective ROIs. The fluorescent signal intensity in the right inguinal 
LN (LN5) was used as the background measurement. Increase in signal intensity in the SLN 
compared to the background signal was then calculated [100% x (signal/background)].
Single photon emission computed tomography/computed tomography 
(SPECT/CT imaging)
Immediately after injection of the imaging agent the mice were placed in a 
temperature controlled (37oC) animal holder (Equipment Veterinaire MINERVE). Based on 
a (sagittal) tomographic planning X-ray image, a field of view (FOV) was selected in such a 
way that the complete body of the mouse was incorporated. SPECT/CT imaging was 
performed on a NanoSPECT/CT system (Bioscan Inc.) equipped with four collimators, each 
containing nine 1.4 mm diameter pinholes. After the acquisition, the data were 
reconstructed using HiSPECT software (Scivis GmbH).
SPECT/CT imaging of 99mTc-nanocolloid
Tumor-bearing mice (n = 5) or control animals (n = 5) were anesthetized and injected 
intratumorally (i.t.) with 20 µL (8 - 10 MBq; 7.4 x 10-8 mmol) 99mTc-nanocolloid. Sequential 
total body SPECT scans of the total FOV were performed, taking 30 min in total. Directly 
after the SPECT imaging sequence, a helical 3D CT acquisition of the same FOV was 
performed for 12 min. The relative signal intensity of the tracer in the SLN was analyzed 
using InVivoScope post-processing software (Bioscan, Inc.). The total activity measured in 
the SLN (MBq) was divided by the total activity measured in the animal (MBq) and 
multiplied by 100%.
SPECT/CT and fluorescence imaging of the ICG–99mTc-nanocolloid complex
After injection of tumor-bearing mice (n = 5) with 20 µL (7.4 x 10 -8 mmol) hybrid ICG-
99mTc-nanocolloid, SPECT/CT imaging was performed as described above with the difference 
that only a single SPECT scan was made (30 min in total), followed by a CT scan (12 min; total 
scan time: 45 min). Immediately after the SPECT procedure the animal was sacrificed and the 
skin was dissected. Single fluorescence images were recorded as described before. LNs were 
removed and checked for fluorescence. Ex vivo BLI measurements were performed by 
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incubating the LN in luciferin solution for several minutes before performing a BLI scan. 
Subsequently, 99mTc activity (counts per minute; cpm) in all dissected LNs was determined 
with a gamma counter (Wizard3 1480 automatic gamma counter; Perkin Elmer).
Correlation between fluorescent and radioactive signal intensities
In order to establish a direct correlation between the fluorescent signal and the 
radioactive signal in the hybrid complex the individual signals were corrected for 
the maximum signal intensity and converted into percentages according to: 100% x 
(signal - background)/(maximum signal - background). Statistical analysis was performed 
by means of a Student’s t-test.
Histology
After imaging, the LNs and tumor were removed and fixed in 4% formaldehyde 
solution overnight, embedded in paraffin and cut into 4 µm sections. Following de-
paraffinization and rehydration, sections were stained with hematoxylin and eosin (H&E). 
The pathological findings were used to cross validate the BLI findings.
 
Figure 1. Biology of the mammary mouse tumor model: A) Representation of the lymphatic tumor spread in a 
mouse in the surgical position. BLI depicts the location of the primary tumor (seeded in the left fourth mammary 
fat-pad) and early metastatic spread to the left axillary LN (LN1; defined as the SLN). Histological investigation of 
the primary tumor, (S)LN 1, LN 2, LN 3, LN 4 and LN5 validate the tumor spread. B) Advanced metastatic spread 




In the clinical setting, pathological investigations are required to establish the 
presence of metastases in the SLN. Here a mammary mouse tumor model was used, which 
is based on the orthotopic transplantation of luciferase expressing mouse invasive lobular 
carcinoma (ILC) cells (KEP1-Luc cells) derived from an E-cadherin and p53-deficient mouse 
mammary tumor.22 The bioluminescence signal emitted by the tumor cells permitted 
accurate intra- and postoperative detection of the primary tumor in the mammary gland 
and detection of metastatic tumor cells in the primary tumor-draining LN located in the 
axillary region (Figure 1A). Due to the high bioluminescent signal emitted from the 
primary tumor and the attenuating effect of the fur and skin, non-invasive BLI of small 
clusters of metastatic tumor cells in the axillary region is quite difficult. However, when the 
primary tumor was covered and the skin dissected, it became possible to identify even 
small metastasis in the axillary LN (LN 1; Figure 1A). Depending on the progression of the 
tumor development in individual animals, additional metastases in other LNs could be 
observed (Figure 1B). In all cases examined (n=3), metastases were first observed in LN 1, 
defining it as the primary lymph node, the so-called SLN for tumor drainage in this tumor 
model. Pathological examination of the LNs verified the BLI findings, showing clusters of 
tumor cells embedded within the lymphatic structures (Figure 1A). The tumor morphology 
and physiology of this model have previously been described by van Leeuwen et al.24 
Formation of the supramolecular hybrid complex
A hybrid complex comprising of the lymphatic imaging agents ICG and 99mTc-
nanocolloid was generated and its efficacy was compared to the individual components.
To create an agent for hybrid imaging of the SLN, ICG was non-covalently bound to 
99mTc-nanocolloid via self-assembly. This resulted in a supramolecular complex that is both 
fluorescent and radioactive (Scheme 1).25 Equimolar amounts of 99mTc-nanocolloid and ICG 
that were used in the free agent studies below were mixed to form the complex. Under 
these conditions approximately 59% of ICG was bound to 99mTc-nanocolloid. Nanocolloid 
is an aggregate of HSA particles, and its particle size was determined using transmission 
electron microscopy (TEM). During TEM examination an average diameter of 14 nm (n = 
100; Figure 2) was found, whereas the reported diameter of single HSA particles is 7 nm.25 
In order to determine an average molecular weight for nanocolloid, a spherical structure 
with a volume of 1.8 x 103 nm3 was assumed; the volume of HSA was calculated to be 
179.59 nm3. Based on this volumetric difference, on average a nanocolloid particle consists 
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out of approximately ten HSA particles and the molecular weight is therefore expected to 
be 10 times larger than that of HSA (67,000 Mw). Accordingly, an average molar ICG : 99mTc-
nanocolloid ratio in the hybrid complex of 61 : 1 was obtained. It is important to note that 
the nanocolloid samples were not mono-disperse and contained particles in a size range 
of 7 - 30 nm, which resulted in different loading rates (Figure 2C). 
The degree of functionalization of nanocolloid increased exponentially with the 
particle size and showed a clear similarity to that reported for the surface modification of 
other nanoparticles, e.g. polystyrene beads (70 nm; 5 x 103 : 1 molar ratio)25; a similar sized 
nanocolloid particle (70 nm) could be functionalized to a ratio of 6 x 103 : 1. The ICG-99mTc-
nanocolloid complex formation was further studied using UV-VIS spectroscopy. Figure 2D 
shows the absorption spectra of free ICG and ICG-99mTc-nanocolloid, both at an ICG 
concentration of 1 mg/mL. Apart from the decrease in intensity of the 700 nm absorption 
peak (representative for stacking of ICG dye molecules) an extra absorption peak emerged 
at 780 nm for ICG-99mTc-nanocolloid (representative for non-aggregated ICG dye 
molecules). This result is similar to previously reported data that use this change in the 
absorption spectrum of ICG to validate that ICG is bound to a protein.27
Figure 2. Complex formation between ICG and nanocolloid: A) TEM image of nanocolloid; B) Corresponding size 
distribution histogram revealing a maximum frequency at 14 nm particle diameter, the red line represents a 
Gaussian distribution fit. C) The calculated average ICG loading per nanocolloid plotted as function of the 
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Preoperative SPECT/CT imaging of the SLN
Using a dedicated small animal SPECT/CT system it is possible to mimic the standard 
clinical SPECT/CT assessment of the SLN in mice with metastatic breast tumors. Analogous 
to the human situation, 99mTc-nanocolloid (Figure 3) was injected i.t. but, rather than in 
human patients where SPECT/CT images are taken up to four hrs after injection3,4 the 
nanocolloid dynamics in KEP1-Luc tumor-bearing mice were imaged during the first 30 
min after injection. In control animals, where 20 µL of tracer was directly injected into the 
mammary gland, no tracer migration into the axillary region could be detected during the 
scan period (Figure 3A). Longer scan times (up to one hr) did not provide additional 
information. This suggests that lymphatic migration is partly dependent on the tumor 
presence. In contrast, all tumor-bearing mice showed highly reproducible tracer uptake in 
the SLN (Figure 3B and C) starting at around 6 min post-injection. This initial uptake was 
followed by a gradual increase, giving maximum values at 30 min (2.1 ± 1.5%). BLI 
measurements in these animals showed only minor degree of metastatic spread within 
the SLN. The only amount of background signal observed, apart from a significant amount 
of radioactivity at the injection site, was a small quantity of radioactivity in the liver, which 
was possibly caused by leakage of the tracer into the bloodstream. This confirmed that 
this procedure is highly selective for the preoperative visualization of the SLN.
Figure 3. Nanocolloid-based imaging of the SLN. A) SPECT/CT imaging after nanocolloid injection in the 
mammary gland of a non-tumor-bearing animal, does not show any accumulation of radioactivity in (S)LN 1 
indicated with an arrow. B) SPECT/CT image after intra tumoral nanocolloid injection in tumor-bearing animals 
clearly revealing accumulation in (S)LN 1 (top arrow) and the left inguinal LN (bottom arrow). The location of the 
primary tumor is indicated with T. C) Relative signal intensities (percentage injected dose) measured in the (S)LN 
1 of the different animals from 5 - 30 min after injection. 
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Intraoperative imaging of the SLN with ICG
After an initial blank scan, mice injected with ICG were examined by dynamic whole-
body fluorescence imaging to visualize the uptake kinetics of ICG in the LNs. Figure 4A 
clearly shows the lymphatic tract running from the tumor to the SLN, which could be seen 
almost directly after injection. The lymphatic tract also remained fluorescent during the 
full duration of the experiment. The dynamics of ICG uptake in the SLN of three different 
animals showed that in all animals the effective imaging time window for ICG could be set 
at 20 - 30 min post-injection. However, the relation between the injection time and the 
SLN uptake was not identical for all five mice. 
The quantified ICG data showed that in four different tumor-bearing mice (numbers 
1, 2, 4, and 5) the fluorescent signal intensity increased by 52% ± 17% compared to the 
background (Figure 4B). In all these mice BLI showed early metastasis in the SLN. A fifth 
mouse (no. 3) showed much more pronounced metastatic tumor spread in the lymphatic 
system. This also resulted in much higher ICG flow rates towards the SLN, resulting in a 
signal-to-background ratio increasing to 190% (Figure 4B).
In the other LNs no clear increase over the background could be detected (Figure 4). 
Covering the injection site and background signal from the abdomen improved the 
intraoperative fluorescence detection of the SLN, as it allowed optimization of the scan 
and threshold settings. Similar to 99mTc-nanocolloid, non tumor-bearing animals did not 
show any ICG uptake above background level for any of the four LNs studied after injection 
in the mammary gland (Figure 4C). In tumor-bearing animals only the (S)LN1 gave a signal 
increase above background level (Figure 4D). Together, these findings suggest that, in this 
tumor model, the inter-mouse variation is linked to differences in the extent of metastatic 
disease between individual animals.
Hydrid imaging with the ICG-99mTc-nanocolloid complex
To achieve identical dynamics for the radioactive and fluorescent signal a 
supramolecular hybrid imaging agent comprising ICG non-covalently bound to 99mTc-
nanocolloid was used. 
Using an i.t. injection procedure, the hybrid imaging complex depicted identical 
features in the SPECT/CT scan as in the experiments where 99mTc-nanocolloid was injected 
(compare Figure 3 and 5). Other than described for the 5 x 6 min scan times used to 
determine the uptake of 99mTc-nanocolloid the continuous 30 min scan used for the ICG-
99mTc-nanocolloid complex did allow visualization of the radiotracer throughout the 
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lymphatic tract. The fluorescence signals emerging from the SLN and draining lymph 
vessels were also clearly visible by eye. At 45 min post-injection, the correlation between 
the fluorescent and radioactive signal of the hybrid complex proved to be very high 
(Figure 5C). The maximum corrected intensity patterns of the radioactive and fluorescence 
signals were very similarly distributed over the four LNs. This demonstrates that the 
supramolecular complex has a good stability in the lymphatic system at 45 min post-
injection. The normalized signal intensities in the different LNs were very similar for the 
radioactive and fluorescent component and the SLN specificity was reproducible in the 
five different animals.
Figure 4. ICG -based NIR fluorescence imaging of the SLN. A) Lymphatic flow in the tumor draining lymphatic vessel 
can be visualized in the first minutes after injection using NIR fluorescence imaging. The SLN is indicated by the 
arrow and the primary tumor indicated with T. B) The dynamic increase in the percentage of fluorescent signal 
intensity/background measured in the (S)LN 1 varies between different animals and is markedly higher in the 
animal with the most advanced metastatic tumor spread. C) Quantified signal intensities (photon/s/cm2) show no 
relative increase in any of the four LN’s after ICG injection in the mammary gland of a non-tumor-bearing control 
animal (example n = 1). D) In a tumor-bearing animal, the quantified signal intensities show that only (S)LN 1 gives 
a signal increase above background after ICG injection into the tumor (example n = 1; mouse #1).
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An additional advantage of this hybrid imaging agent is the enhanced signal intensity 
that is obtained compared to free ICG. Using the same molar amount of dye (7.8 x 10-6 mmol), 
free ICG achieved a signal intensity of 30 - 200%, whereas the hybrid imaging agent 
performed significantly better (1252 - 8080%; p = 0.027). None of the animals in which the 
hybrid agent was tested showed signs of advanced metastatic spread outside of the SLN. 
Excluding the animal with advanced metastatic spread from the free ICG-group, this results 
in an average 86-fold increase in signal-to-background ratio with the hybrid agent. This 
dramatic increase in the signal-to-noise ratio is most likely due to the increased nodal 
retention. The hybrid complex also improved the accuracy of detecting tumor draining 
lymphatic vessels, as evidenced by the fact that a secondary tumor draining lymphatic 
vessel could be detected visually during dissection of one of the animals. The hybrid ICG-
99mTc-nanocolloid complex allowed for highly specific intraoperative visualization of both 
the tumor draining lymphatic vessel(s) and the SLN (Figure 6).
Figure 5. Hybrid imaging of the SLN. A) Preoperative SPECT/CT (directly after i.t. injection) of the SLN using the 
radioactive component of the complex. B) Intraoperative visualization of the SLN and lymphatic tract using the 
fluorescent component of the complex (45 min after injection), ex vivo fluorescence of the individual LNs shows 
the high specificity for the (S)LN 1 (bottom right corner). The SLN is indicated by the white arrow and the primary 
tumor by T. C) Normalized uptake ratios in the different LNs showing a good correlation between the radioactive 
and fluorescent signal intensities. This figure has been modified from the scientific annual report of the NKI-AVL 
Division of Diagnostic Oncology (SAR2009).
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Figure 6. Visibility of the tumor draining lymphatics. The ICG-99mTc-nanocolloid complex enables the visualization 
of multiple tumor draining lymphatic vessels. 
Discussion
Histopathological diagnosis of early lymphatic metastases in the SLN is widely 
used in the management of breast cancer patients. Using a preclinical breast cancer model 
that metastasizes via the lymphatic system, the efficacy of SLN detection by 99mTc-
nanocolloid, ICG and a complex formed by the two compounds was quantitatively 
compared demonstrating the great potential of the hybrid ICG-99mTc-nanocolloid complex 
for combined pre- and intraoperative imaging of the (S)LN.
Imaging agent migration in a preclinical breast cancer model for lymphatic metastasis
Preclinical imaging of lymphatic migration with fluorescent dyes in mice is most 
commonly performed by injecting the agent intravenously or into the footpad.29-33 To 
increase clinical relevance, here the lymphatic migration was studied using injection 
procedures similar to those applied in the clinical situation.3,4 This was combined with a 
mouse mammary tumor model that resembles lymphatic metastasis of human breast 
cancer.
Orthotopic injection of KEP1-Luc mouse mammary tumor cells in syngeneic, 
immunocompetent mice resulted in the formation of a primary tumor in the mammary 
gland and subsequent metastatic spread of tumor cells to the SLN (Figure 1A), which 
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accurately mimics metastatic invasive lobular breast carcinoma (ILC). Furthermore, the 
low vascular density of the KEP1-Luc tumor core reduced the background signal caused 
by non-specific uptake of an imaging agent in the vascular system. This is beneficial for 
the accuracy of the data interpretation. Consequently, the KEP1-Luc mammary tumor 
model allowed accurate comparative analysis of different imaging agents for the 
visualization of lymphatic migration.
To determine the influence of the tumor presence on the migratory properties of the 
imaging agents, a series of control experiments in non-tumor-bearing animals were 
performed. These findings did not reveal any transport of ICG or 99mTc-nanocolloid (data 
not shown). Furthermore, imaging of free ICG in the animals with advanced lymphatic 
metastatic spread showed an approximate three-fold increase in fluorescence intensity 
(Figure 4B; mouse 3). Since the injection procedure was identical for all mice, the increased 
metastatic spread (determined by BLI) seemed to correlate with increase in outflow. This 
observation was also made by Dadiani et al. and Ruddell et al.34,35 
SLN imaging with 99mTc-nanocolloid or ICG separately
Clinically the preoperative radiopharmaceutical (99mTc-nanocolloid) guided method 
has shown a high accuracy for detecting SLNs.4 Our preclinical data showed comparable 
transport of 99mTc-nanocolloid in preoperative SPECT/CT images. Similar experiments with 
99mTc-nanocolloid in Balb/c nude mice transplanted with MDAMB231 cells showed 
comparable migration patterns (data not shown). The high signal penetration of the 
radiolabel (140 keV; 99mTc) makes 99mTc-nanocolloid very suitable for non-invasive planning 
of surgical procedures, but also makes it difficult to accurately determine the origin of the 
signal due to interfering signals from the injection site,3,7,8,36 making it difficult to distinguish 
lymph nodes with the gamma probe. To explore complementary intraoperative imaging 
procedures, we investigated the NIR fluorescent dye ICG. 
NIR fluorescence imaging with ICG enabled specific detection of the SLN and it 
permitted intraoperative visualization of the tumor draining lymphatic vessels. However, 
the relatively low signal-to-background ratio makes the interpretation of the images 
dependent on the expertise of the operator and on the threshold settings of the scanner. 
Quantification by way of ROI measurements and subtraction of the background signal 
intensity was found to be the best way to reduce interpretation bias. Results from several 
clinical studies indicated that a combination of radiopharmaceutical- and dye-based 
methods improved SLN detection rates, compared to the individual technique.2,8,35,37-39 
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Intraoperative use of ICG was found to be complementary to the preoperative situation, 
which is in accordance with previous report on the lack of surgical planning with 99mTc-
nanocolloid. However, these preclinical results differ from the clinical experience. 
Compared to mice, a much larger volume of imaging agent is injected in patients, which 
might result in a local increase in interstitial fluid pressure, thereby providing a driving 
force for lymphatic transport. This is not expected to occur after a maximal injection of 20 
µL in mice.
Migration of the imaging agents via the tumor draining lymphatic vessels to the SLN 
clearly occurred in tumor-bearing mice with lymph node metastasis. In tumor-bearing 
animals visualization of the tumor draining lymphatic vessel(s) was considered highly 
beneficial. However, a comparative dynamic study showed that the lymphatic flow rates 
of both ICG and 99mTc-nanocolloid varied and, more importantly, the signal-to-noise ratios 
obtained with free ICG were vastly inferior to those obtained with 99mTc-nanocolloid.
Hybrid imaging agents for combined pre- and intraoperative SLN imaging
Ohnishi et al. previously showed the potential of intraoperative SLN imaging using 
CW800 labeled albumin nanocolloids (not functionalized with technetium).25 However, a 
limitation of this method is that it does not allow for a preoperative readout similar to 
99mTc-nanocolloid. Furthermore, each albumin nanocolloid was reported to contain only 
2.7 CW800 dye molecules. As an alternative, a supramolecular complex consisting out of 
two clinically approved imaging agents was generated. This approach was based on the 
work of Moody et al. describing the non-covalent interaction between ICG and albumin.23 
The major differences of our approach are: (i) the presence of a radiolabel, resulting in a 
hybrid particle, (ii) the application of this interaction on albumin nanocolloids, and (iii) the 
significantly increased loading rate.
Whereas the injection of separate imaging agents still leaves some doubt regarding 
the overlap of the findings, the hybrid imaging agent ICG-99mTc-nanocolloid allowed 
accurate intraoperative fluorescence detection of features identical to those detected 
during preoperative SPECT imaging. 
Preoperative SPECT/CT imaging of ICG-99mTc-nanocolloid showed comparable 
lymphatic dynamics, distribution, and specificity as compared to 99mTc-nanocolloid alone. 
The hybrid imaging approach provided supplementary information to the existing clinical 
99mTc-nanocolloid procedure, without changing its in vivo behavior. 
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Conclusion
Quantitative comparative studies between 99mTc-nanocolloid and ICG revealed the 
drawbacks of NIR fluorescence imaging with ICG alone. Compared to the high signal 
specificity found with 99mTc-nanocolloid a relatively low signal-to-background ratio was 
obtained with free ICG. ICG-99mTc-nanocolloid retained the optimal imaging properties of 
99mTc-nanocolloid, and complemented them with fluorescent properties. Use of this hybrid 
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Chapter 4
Tracer-cocktail injections for combined 
pre- and intraoperative hybrid imaging 
of lymph nodes in a spontaneous mouse 
prostate tumor model
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Abstract 
In this Chapter evaluation of a more clinically translatable formulation of the hybrid 
tracer ICG-99mTc-nanocolloid is discussed. In order to achieve surgical guidance towards 
prostate draining sentinel lymph nodes (SLNs), TRAMP mice with spontaneous prostate 
tumors were injected intratumorally with: 1) a cocktail of patent blue (Pb) and indocyanine 
green (ICG); 2) a cocktail of albumin radiocolloids (99mTc-nanocolloid), Pb, and ICG; or 3) a 
cocktail of radiolabeled albumin (99mTc-HSA), Pb, and ICG. The lymphatic distribution of 
these imaging agents was studied at various time points after injection. At 60 min post 
injection the SLN detection rate using Pb was only 7%, whereas the detection rate using 
ICG was significantly higher (53%). Moreover, a cocktail of ICG and 99mTc-nanocolloid, 
which yields the ICG-99mTc-nanocolloid complex, improved the fluorescent detection rate 
to 86%, equalling that of the clinically applied 99mTc-nanocolloid. Fluorescence detection 
of the SLNs using a cocktail containing 99mTc-HSA gave similar results as free ICG (58%; 60 
min). In conclusion, a 99mTc-nanocolloid, Pb, and ICG cocktail enriched the standard 99mTc-
nanocolloid approach by adding fluorescent detection of the SLNs. Furthermore, this 
approach improved the fluorescent based guidance and enabled both accurate surgical 
planning and intraoperative detection, based on a single injection. Clinical pilot data 
revealed this approach is also potentially valuable in patients.
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Introduction
The presence of metastasis in the tumor draining sentinel lymph nodes (SLNs) in the 
pelvic region is considered a strong predictor of treatment failure in patients with prostate 
cancer.1 Postoperative histopathological examination of tissue samples obtained during 
surgery is the ‘golden standard’ to assess the metastatic spread. To obtain these samples, 
extensive dissection of lymphatic tissue is required. In up to 51% of procedures, this can 
lead to post-operative complications such as lymphoceles, injuries to the obturator nerve 
and/or the ureter, and lymphedema of the lower extremity.2,3 Surgical pelvic lymph-
adenectomy procedures such as extended pelvic lymphadenectomy4,5,6 can be improved 
by relying on better surgical guidance towards the tumor draining lymphatic tract and 
SLN(s). Ideally, an intraoperative imaging approach will enable the surgeon to visualize 
and excise the SLNs accurately, which may shorten overall procedure time and decrease 
complication levels.
Innovations in SLN mapping mainly find their origin in the evaluation of metastatic 
spread in melanoma and breast cancer.7,8 At present, SLN mapping in e.g. the breast is 
generally performed with a combination of preoperative 99mTc-labelled colloid injection 
and intraoperative injection of blue dyes (e.g. patent blue; Pb) for optical guidance.9 For 
breast cancer this combined approach considerably increased the detection rate 
compared to the dye based (from 79.6% to 93.5%) and for the colloid based method (from 
≈ 95% to 97.7 - 99.2%).10,11 However, these values may be lower for more complex 
resections such a laparoscopic SLN biopsy.
Lymphoscintigraphy at 15 minutes and two hrs after injection of 99mTc-labelled 
colloidal particles enables visualization of the SLNs.12 Integrated single photon emission 
tomography combined with computed tomography (SPECT/CT) is also used to provide 
superior 3D visualization and to provide anatomical data for surgical planning with a 
detection rate of 98%.13 We were not able to find any literature examples of blue dye based 
detection of the SLN in the prostate. 
The intraoperative translation of the radiocolloid procedure requires the use of a 
gamma probe or camera to monitor the transit of a 99mTc-labelled colloid from the injection 
site into the SLN, which can then be dissected and histologically examined.14,15 
Unfortunately, the tracer deposits in the prostate may cause a high background signal 
when the highly sensitive gamma probe is placed on or near the pelvic lymph nodes (LNs). 
The use of near-infrared (NIR) fluorescence imaging is rapidly advancing in medical 
optical imaging.16 Even when much lower concentrations are used, excitation and emission 
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wavelengths in the 800 nm range provide higher tissue penetration than the reflected 
blue light of a visible dye (400 nm).17 Recently, several promising new trials using the NIR 
fluorescent dye indocyanine green (ICG) have been published for SLN biopsy in breast- 
and gastrointestinal cancer.18,19 A limiting factor in these studies is the effective time 
window, which appears to be similar to that of the visible blue dyes.18 Furthermore, this 
approach requires an additional ICG injection next to the lymphoscintigraphic approach. 
In a feasibility study, the US Food and Drug Administration (FDA) suggested that a ‘cocktail’ 
injection of fluorescent and radioactive agents would be preferable over multiple single 
injections.19 However, this study revealed that a cocktail injection of ICG with 99mTc-labeled 
sulfur radiocolloid reduced the fluorescence intensity by a factor ten and yielded poor 
imaging results.21 Although 99mTc-labeled sulfur colloid is the most widely used radiotracer 
for lymphatic mapping in the United States, 99mTc-colloidal albumin (99mTc-nanocolloid) is 
more frequently used for identical procedures in European countries.20,21 The SLN 
specificity of hybrid ICG-99mTc-nanocolloid complexes was shown to be similar to that of 
conventional lymphoscintigraphy in a preclinical setting (see Chapter 3).22 
Animal models are useful tools for investigation of the pathogenesis of cancers and 
the development of new imaging procedures.23,24 One of the best-characterized and 
widely used mouse models of prostate cancer is the transgenic adenocarcinoma of the 
mouse prostate (TRAMP) model. This tumor model provides an ideal preclinical starting 
point to study combined pre- and intraoperative imaging procedures in prostate cancer.
The goal of this study was to improve the accuracy of the intraoperative detection of 
SLNs in prostate cancer. Using the TRAMP model, a cocktail of 99mTc-nanocolloid, Pb, and 
ICG was evaluated and compared to a cocktail of 99mTc labelled albumin (human serum 
albumin; HSA), Pb and ICG. To underline the potential of combined pre- and intraoperative 
imaging, the first results of an ongoing clinical pilot study wherein the ICG-99mTc-
nanocolloid cocktail was used in 6 patients with prostate carcinoma are presented.
Material and Methods
Imaging agents
Pb solutions were obtained as clinical grade dye solution (Guerbet). ICG (preclinical: 
Sigma Aldrich; clinical: ICG-Pulsion, Pulsion Medical Systems AG) solution was prepared by 
dissolving 1.0 mg in 1.0 mL 1% Pb solution. For dye injections, ten mL of this solution [Pb 
(1.76 x 10-4 mmol); ICG (1.29 x 10-5 mmol)] was diluted in 30 mL of a 0.9% sodium chloride 
solution (B Braun). 
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99mTc-labeled human serum albumin (99mTc-HSA; Vasculosis, 7 nm;25 IBA) and 99mTc-
labeled human serum albumin colloids (99mTc-nanocolloid; Nanocoll, median particle size 
14nm; 22 GE Healthcare) were of clinical grade and produced following standard 
preparation protocols (pH 6 - 7). 99mTc-HSA was prepared by adding 2 mL pertechnetate 
solution (2500 MBq) to a clinical grade kit, followed by 30 min incubation at room 
temperature. 99mTc-nanocolloid was prepared by adding 2 mL pertechnetate (1500 MBq) 
to a vial, followed by 30 min incubation at room temperature. The efficacy of both labeling 
procedures was determined via thin layer chromatography using MeOH/water (85 : 15). 
Cocktail injections were prepared by diluting 10 mL of the Pb/ICG solution in 30 mL 
of the respective tracer solution (99mTc-HSA: 1.14 x 10-6 mmol albumin; 12 MBq, 99mTc-
nanocolloid: 1.11 x 10-7 mmol albumin; 8 MBq). For the clinical procedures cocktails were 
prepared under GMP and without the presence of Pb.
To confirm the insitu formation of self-assembled hybrid complexes,26 protein 
separations were performed on the albumin particle containing cocktails in micron 
centrifugal filters (Millipore) with a molecular weight cut of at 30,000 Da. Solutions were 
centrifuged for 8 min at 7 x 103 rpm after which the fluorescent content of the residue and 
the filtrate was determined. 
Mice
Male TRAMP mice expressing the SV40 T antigen (TRAMP+) spontaneously develop 
autochthonous prostate tumors following the onset of puberty.27 Lymphatic metastases 
occur at 24 - 28 weeks of age and by the age of 28 weeks, 100% harbor metastatic prostate 
cancer in the lymph nodes or lungs.28 Previous studies described the caudal and lumbar 
lymph nodes as the preferential sites for metastasis in orthotopic and genetically 
engineered mouse models for prostate cancer.29,30 The lymphatic pathway from the 
prostate drains via the lumbar LNs to the renal LNs, all these LNs were investigated for 
their imaging agent content and no discrimination was made between SLNs and possible 
higher echelon LNs (Figure 1). In this study, TRAMP+ mice between 25 and 30 weeks of 
age were used. Age matched non transgenic (TRAMP-) mice served as control. All animal 
experiments were performed in accordance with Dutch animal welfare regulations and 
approved by the local animal ethics committee of the Netherlands Cancer Institute - 
Antoni van Leeuwenhoek Hospital.
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Figure 1. Schematic representation of a mouse with an exposed abdominal cavity (in gray). Herein the five 
(caudal, lumbar and renal) LNs are depicted that potentially function as the SLNs for the prostate tumors formed 
in the TRAMP mice.
Injection procedures
Animals were anaesthetized with a mixture of hypnorm (Vetapharma), dormicum 
(Roche) and water (suitable for injection; 1:1:2; 5 μl/gr i.p.). An incision of approximately 1 cm 
was made in the skin of the lower abdomen of the mice. Subsequently mice were injected 
intratumorally (i.t.; TRAMP+) or into the prostate (TRAMP-) with the respective imaging 
agents using a 29G needle. The injected cocktail solutions were abbreviated as: ICG (Pb/ICG), 
NC (99mTc-nanocolloid/Pb/ICG), and HSA (99mTc-HSA/Pb/ICG). Non-tumor-bearing mice were 
used as control; abbreviated as NC control (Table1). Abbreviations are followed by the time 
after injection when the SLNs were dissected (e.g. 15 min) in subscript. 
After injection, the injection site was massaged for 5 min to stimulate the lymphatic 
migration. With exception of the animals that were sacrificed 15 min post injection, the 
incision was closed directly after the injection and massage. 
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Table 1. Different study groups and time points used for tumor draining SLN imaging experiments.
Name group Number of 
animals
Imaging agents used Imaging time point 
(min after injection)
Detection method
ICG15 n = 6 Pb/ICG 15 Visual/ NIR 
fluorescence
ICG60 n = 6 Pb/ICG 60 Visual/NIR 
fluorescence
NC60 n = 6 99mTc-nanocolloid/Pb/ICG 60 SPECT/ Visual/ NIR 
fluorescence
NC240 n = 6 99mTc-nanocolloid/Pb/ICG 240 SPECT/ Visual/NIR 
fluorescence
HSA60 n = 6 99mTc-HSA/Pb/ICG 60 SPECT/ Visual/ NIR 
fluorescence
NC60 control n = 6 99mTc-nanocolloid/Pb/ICG 60 SPECT/ Visual/ NIR 
fluorescence
Imaging procedures
Migration of the imaging agents to the SLNs was assessed at different time points 
after injection (Table 1). These specific time points were chosen as they enclose a wide 
time window in which the pro’s and cons of the individual agents can be reviewed. The 
shortest time interval was set at 15 min post injection as this time interval is clinically 
used for dye-based methods. A 60 min time-point was used as previous experiments 
have shown that this time point is optimal for the evaluation of the migration of 
nanocolloid to the SLNs of mice.24  The 4 hrs (240 min) time point was added to show the 
value of approach at later time points. 
Fluorescent and visual detection of the ICG and Pb was conducted alone or directly 
following the SPECT/CT scan. Hereafter, SLNs were dissected using a surgical microscope 
(Universal S3; Zeiss). At 15 and 60 min post injection, the level of blue staining in the SLNs 
was visually evaluated. SLNs were staged as not blue (0), light blue (1) or blue (2) before 
fluorescence imaging of the ICG component was conducted (Table 2). The distribution of 
the fluorescence and radioactivity over the SLNs was studied postoperatively (Table 3). 
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Fluorescence imaging
In vivo fluorescence imaging was conducted after the mice were sacrificed, using a 
preclinical fluorescence scanner (IVIS 200; Xenogen Corp.) using Living Imaging Acquisition 
and Analysis software (Xenogen Corp.). Images were acquired with standard ICG settings 
(excitation 710 - 760 nm and emission 810 - 875 nm). A whole body fluorescence scan was 
performed before dissection of the five involved LNs (Figure 1). To decrease background 
levels and increase the visibility of the SLNs, the prostate and intestines were removed prior 
to imaging. After dissection, the SLNs were scanned and their fluorescent content was 
quantified (photons/s/cm2) and corrected for the background signal in that measurement. 
As the background signal showed some small deviations, subtraction of the background 
sometimes lead to negative values. As only positive fluorescent signals can be used in the 
experimental set-up the negative fluorescent signals were set at the minimum of zero. 
Trendline based linear regression correlations (Excel) were used to establish the correlation 
between the fluorescence intensities and the radioactive count rate findings.
SPECT/CT imaging
After the injection procedure, the mice were placed in a temperature controlled 
(37oC) animal holder (Equipment Veterinaire MINERVE) before performing a SPECT/CT 
scan on a preclinical SPECT/CT system (nanoSPECT/CT; Bioscan Inc.) A region of interest 
incorporating the whole body was selected, based on a (sagital) tomographic planning 
X-ray image. One sequential total body SPECT scan of the same field of view was 
initialized taking 30 min in total. Directly after the SPECT imaging sequence, a helical 3D 
CT acquisition of the animal was performed during 12 min. After acquisition, the CT 
data was reconstructed with HiSPECT software (Scivis GmbH). The SPECT and CT data 
sets were automatically co-registered. The images were analyzed using InVivoScope 
post processing software (Bioscan Inc.). 
Ex vivo radioactivity counting
After dissection, the amount of 99mTc in the individual SLNs was determined (gamma 
counts per minute; cpm) using a Wizard 3 1480 automatic gamma counter (Perkin Elmer). 
Specimens were counted for 120 seconds using a 126 - 159 keV energy window, 
automatically including background signal measurements. For normalization, the 
individual radioactive count rates were corrected for the background and radioactive 




During a clinical pilot study, the nanocolloid-ICG cocktail was evaluated in six patients 
with prostate carcinoma. The criteria for inclusion were the presence of one or more of the 
following characteristics: clinical stage greater than T2b, or Gleason sum score greater 
than six . The cocktail solution (240 MBq; 0.4 mL) was injected peri- and intratumorally; 0.1 
mL was injected in each quadrant of the prostate. Administration was guided by transrectal 
ultrasonography, and each injection was followed by flushing with approximately 0.7 mL 
of saline. During surgical pelvic lymphadenectomy, both the prostate and SLNs were 
excised at about 60 min post injection. In all cases the nodal areas of the interna and 
obturator LNs were included. Intraoperative detection of the SLNs was conducted using a 
gamma probe. Ex vivo examination of the radioactive signal in the excised SLNs was 
detected using a portable gamma camera equipped with a pinhole collimator (Sentinella, 
Oncovision). Distribution of the radioactivity was evaluated by placing the head of the 
gamma camera at a distance of 5 cm above each excised specimen (acquisition time 1 
min). Furthermore, an overview of the radioactivity within all excised nodes was made by 
placing the detector of the camera 10 cm above all excised nodes. Here after fluorescence 
imaging was conducted on the excised specimens (See Fluorescence imaging section). 
Distribution of radioactivity was correlated to the distribution of the fluorescence; 
presence of radioactivity in each node was compared to the presence of fluorescence in 
the node. Patient studies were performed conform protocol after approval by the local 
Medical Ethics Committee comity of the Netherlands Cancer Institute - Antoni van 
Leeuwenhoek Hospital and were carried out after obtaining informed consent.




The lymphatic migration towards the SLNs was studied with visible, fluorescent and 
radioactive imaging agents. Similar to the clinical situation,31 lymphatic migration of the 
imaging agents from the injection site greatly improved by massaging the injection site, 
whereas almost no drainage was observed when no massage was applied (data not 
shown). This was found to be especially important for the 15 and 60 min groups. These 
animals remained anesthetized until imaging, thus limiting the spontaneous massage by 
movement. In the 240 min groups, the animals awoke from their initial anesthetics, and 
were able to walk around freely in the cage (hereby also spontaneously massaging the 
prostate). 
As lymphatic migration depends on the site of injection and may vary between 
individual animals, the measured signal intensities (Table 2, 3 and 4) showed some 
fluctuations within the different groups. The radioactive count rates obtained with 99mTc-
nanocolloid tended to vary (Table 3 and 4), which could, in part, be attributed to a variation 
in particle size as a single 99mTc-nanocolloid preparation consists out of a wide range of 
particle sizes with a reported median of 50 nm. However, in different 99mTc-nanocolloid 
batches the distribution of particle sizes can vary in theory.
Distribution Pb/ICG 
To create an imaging approach that would allow both visible and NIR fluorescence 
detection, a cocktail of Pb and ICG was prepared (defined as ICG - cocktail; Table 1). The 
distribution of the visual component, Pb, was first assessed. When massage of the 
injection site was performed after injection, SLNs stained blue and the lymphatic tract 
became visible. At 15 and 60 min post injection, the visible blue LNs were less blue than 
observed directly after massage (the first 5 min post injection), indicating a quick wash-
out of Pb (Figure 2A and B; Table 2). The visible blue dye could best be observed in SLNs 
in the ICG15 group, wherein Pb uptake was seen in at least two SLNs in five of the six 
animals. However, only 42% of all the excised SLNs were stained blue. After 60 min the 
detection efficacy was found to be reduced to 7% (Figure 2E). 
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Figure 2. Imaging of the SLN with visible Pb and NIR fluorescent ICG: A) Intraoperative detection of Pb in the 
right lumbar LN, directly after massage of the injection site and B) after 15 min, showing the washout of the dye 
during this time period. C) Intraoperative NIR fluorescence imaging of the lumbar LNs with free ICG, which was 
visible up to 60 min after injection. D) The fluorescent content could be detected and quantified in excised SLNs. 
E) Percentages of imaging agent containing (positive) SLNs in the ICG15 and ICG60 groups. In the graphs the 
percentages of the fluorescent component in the cocktail are depicted in green and the percentages for the 
visible component in blue; percentages were calculated using Table 2.
Within the ICG groups all blue SLNs contained fluorescence. Overall the fluorescence 
intensities in the ICG60 group were lower compared to those in the ICG15 group (Table 2). 
The ability to specifically detect the SLNs using the fluorescence signal of ICG also 
decreased over time. After 15 min 67% of the SLNs could be detected, whereas after 60 
min this was only 53%. 
Even though the injected concentration of ICG was 14 times lower than that of Pb, 
fluorescence detection of ICG enabled a much longer functional imaging time period post 
injection. Multiple LNs contained fluorescence with varying intensities. In ten out of 
twelve animals the maximal fluorescence intensity was measured in one or both of the 
lumbar SLNs (Table 2). 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Combined SPECT and fluorescence imaging 
Radiotracer experiments (99mTc-nanocolloid or 99mTc-HSA) were performed using 
cocktail solutions that also contained Pb and ICG. Separation of the albumin from the 
cocktail with a size exclusion filter revealed that while no ICG had passed the filter, Pb was 
present in the filtrate. In the presence of a 14-fold excess of Pb, the ICG had formed a 
complex with the albumin via self-assembly. Since this binding could not have been 
established in a covalent manner, complex formation was based on non-covalent 
interactions caused by the charges and lypophilic groups on ICG and albumin.32 This 
binding is unique to ICG as we could not observe any binding of Pb to the albumin colloids. 
If a small amount of binding between Pb and the albumin did occur, it was not enough to 
aid in visual detection of the SLNs. Hence in the cocktail injections, a hybrid complex is 
present that comprises of a radioactive (99mTc-HSA or 99mTc-nanocolloid) and a fluorescent 
(ICG) component. Based on the results obtained with the ICG-cocktails, it could be 
concluded that > 60 min, the free Pb component in this NC-cocktail only attributes to the 
evaluation of the injection accuracy (e.g. leakage of the injected volume out of the injection 
site), which is not possible with non-dye containing radiopharmaceutical injections.
Preoperative SPECT/CT imaging, using a dedicated small animal SPECT/CT system 
made it possible to mimic the standard preoperative clinical lymphoscintigraphy based 
assessment in mice. Next to lymphatic migration, the injected radiopharmaceuticals 
showed distribution throughout the tumor and seminal vesicles. In combination with the 
relatively small migratory distances and the one mm SPECT resolution, the preclinical 
SPECT/CT scans only allowed for the preoperative determination of uptake in the lumbar 
and renal LNs. Therefore, to quantitatively study the radioactive content in all SLNs 
postoperative scintillation counting was used. This predominantly revealed the highest 
uptake values in either the caudal and/or lumbar LNs (Table 3). 
Within the NC60 group the correlation between the radioactive and the fluorescent signal 
intensities was good (Table 3); in five out of six animals a correlation of R2 > 0.92 was obtained. 
On average, the fluorescence intensities in the NC60 group were higher than those with ICG 
alone at 60 min post injection. Furthermore, in four out of six animals all the SLNs could be 
identified based on both their radioactive and fluorescence signature. Of all the SLNs in this 
group, 86% and 91% contained fluorescence or radioactivity respectively (Figure 3A). 
To study the effective time window for imaging and to provide an indication of the 
stability of the cocktail-approach the uptake in the SLNs was also investigated at 240 min 
post injection (NC240; Table 3). Although a correlation of R
2 > 0.79 was only obtained in 50% 
of animals, the SLN with the highest radioactive content also contained the highest 
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amount of fluorescence. Within this group 95% of the SLNs contained fluorescence and 86% 
contained radioactivity (Figure 3A). 
Within the HSA60 group noticeably lower average signal intensities were measured 
compared to the NC60 group. Furthermore, the correlation between the normalized 
radioactive and the fluorescence intensities in these animals was quite poor as only two out 
of six mice showed a good correlation (R2 > 0.78). Furthermore, only 58% and 71% of all 
SLNs contained, respectively fluorescence or radioactivity. 
As can be seen in Figure 3A, the correlation between the percentage of SLNs that 
contained fluorescence and the SLNs that contained radioactivity was highest at 60 min 
after injection in the NC group. This correlation remained high at 240 min after injection. 
Therefore this complex can be considered stable over the time period measured.
Figure 3. NC60 cocktail based imaging of SLNs: A) Percentages of imaging agent containing LNs in the ICG15 and 
ICG60 groups. In the graphs the percentages of the fluorescent component in the cocktail were depicted in green 
and the percentages for the radioactive component in yellow; percentages are calculated from Table 3. B) 
Visualization of the injection accuracy via the visible Pb component. C) Preoperative SPECT/CT imaging via the 
radioactive nanocolloid component, depicting a.o. a lumbar and a renal LN. D) Intraoperative NIR fluorescence 
imaging of the fluorescent ICG component animal revealing only lumbar and renal LNs. To minimize the 
background signal the animal was covered except for the ROI.
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Preliminary clinical data
The concept of using the NC-cocktail (without Pb) in clinical procedures involving 
the excision of both the prostate and the nearby SLNs is currently under investigation. 
Here initial ex vivo results (n = 6) were reported to substantiate the translational nature of 
the presented preclinical data. Patients were injected with the cocktail solution in the 
operating theatre and the prostate and SLNs were excised at approximately 60 min after 
injection, hence mimicking the preclinical NC60 conditions. Examination of the excised 
tissue sections (Figure 4), demonstrated the overlap between the fluorescent and 
radioactive signals. All fluorescence containing SLNs contained radioactivity and vice 
versa. Although this is preliminary data, the results indicate that the approach can also be 
of value in the clinical situation.
 
	  Figure 4. Ex vivo analysis of excised SLNs. SLNs situated in the extended pelvic lymphadenectomy area (LN 1-4) 
were excised during a laparoscopic procedure, approximately 60 min after the cocktail solution was injected into 
the prostate. Ex vivo evaluation of the excised tissue using a gamma camera (left image) showed a radioactive 
signal in two of the four excised nodes. Fluorescence imaging (right image) resulted in visualization of a 
fluorescence signal in the same LNs as wherein the radioactive signal could be detected.
Discussion 
In the clinic it is important to identify the SLN or group of SLNs infiltrated by 
metastasizing cancer cells via lymph flow. As it has been shown that lymph flow is 
increased in tumor-bearing animals33, experiments were conducted in TRAMP+ mice that 
develop spontaneous tumors in the prostate accompanied by metastatic spread.25 
Although in the TRAMP model the prostate dependant drainage pathways resemble the 
clinical situation, the lymphatic drainage pattern differs slightly from that seen in patients. 
Lymphatic drainage logically occurs via the caudal and lumbar LNs to the renal LNs and 
can occur via either the left or right drainage path. 
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Histological evaluation of lymphatic tissue after surgical pelvic lymphadenectomy 
procedures is acknowledged as ‘golden standard’ in the assessment of LN metastasis in 
the field of prostate cancer. In order to simplify the excision of the SLNs, accurate surgical 
guidance is crucial. Unfortunately, very little intraoperative imaging techniques are 
described for prostate cancer and techniques for combined pre- and intraoperative 
visualization of the tumor draining SLNs are lacking. The TRAMP model can serve as a 
good model for the development and validation of new (intraoperative) SLN imaging 
procedures.
Visual (Pb) vs. fluorescence (ICG) detection
Pb and ICG show chemical similarities; both contain aromatic units with a cationic 
nitrogen atom and two anionic-groups for water solubility. As a result, similar lymphatic 
migration and thus a similar effective time window were foreseen. Unexpectedly, no 
direct correlation could be observed between the detection of Pb and ICG (Table 2). Visible 
blue dye guided SLN dissection in the ICG15 group only resulted in the removal 42% of all 
the SLNs, while via fluorescent detection this percentage improved to 67%. Moreover, at 
60 min after injection the fluorescent dye still enabled visualization 53% of the SLNs 
compared to only 7% with Pb. Since both imaging agents were injected as a cocktail, an 
explanation for the differences in identification of SLNs could be the higher detection 
sensitivity obtained with the NIR dye ICG. This is especially interesting, considering that 
the Pb/ICG-cocktails contain 14-fold excess of Pb compared to ICG. As a result of the poor 
visualization rate, Pb was eliminated from the clinical cocktail as surgery was initiated at 
approximately 60 min post injection.
Diagnostic value radioactive albumin(colloid) containing cocktail injections 
Preoperative SPECT/CT with radiocolloids is a reliable method to detect the tumor 
draining LNs of the prostate. By doing so the surgical procedure can be planned and the 
operating time reduced.34 With the NC- and HSA-cocktail injections the radioactive 
component could be used for surgical planning based on preoperative SPECT/CT images. 
The other two components complemented this clinically proven technique by adding the 
possibility to: 1) validate the accuracy of the injection site via visual detection of Pb; and 2) 
guide the surgical procedure by intraoperative NIR fluorescence imaging (Figure 3). As a 
result the cocktail approach combined the advantages of three different separate 
detection procedures in one single injection.
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Lymphatic migration studies using differently sized imaging agents have led to 
questions regarding the optimal particle size for optimal migration in the lymphatic tract. 
Fujil et al.35 describe that molecules with a hydrodynamic diameter less than approximately 
10 nm (viz. Pb, ICG, 99mTc-HSA) have the potential to travel beyond the SLN, while larger 
molecules <100 nm diameter (viz. 99mTc-nanocolloid) are retained in the SLN. Furthermore, 
Faries et al.36 demonstrated that albumin colloids are actively accumulated by macrophages 
in the LN’s. Indeed, we found that at 60 and 240 min post injection the radioactive count 
rates obtained with the albumin colloids (99mTc-nanocolloid) are, on average, higher than 
those obtained with single albumin particles (99mTc-HSA; Tabel 3). 
Crucial for combined pre- and intraoperative visualization of the hybrid nature of the 
approach is the ability to identify all SLNs based on both their radioactive and fluorescent 
content. Not only was a high correlation found between the fluorescence signal intensities 
and radioactive count rates in the NC-groups (Table 3 and 4), both modalities also showed 
highly similar SLN detection rates, 86% and 95%, respectively (Figure 3A). The overall 
fluorescence intensities in the NC60 group were highly similar to those obtained with free 
ICG at 60 min (Table 2, 3, and 4), suggesting that the emission of fluorescence was not 
negatively influenced by the interaction with albumin. Moreover, the ability to detect the 
SLNs via fluorescence imaging in the NC60 group increased with 33% compared to that 
with free ICG. The HSA-cocktail, on the other hand, did not show an improvement in 
fluorescence detection of SLNs compared to the free ICG at 60 min post injection (Figures 
2E and 3A). The similarity in distribution of fluorescence and the low correlation between 
fluorescence signal intensities and radioactive count rates found for the HSA-cocktail 
suggests that the complex stability in the latter is lower than in the NC-cocktails. 
While all animals in the NC60 group showed a correlation > 0.76 between radioactivity 
and fluorescence content, such a correlation was only obtained in three animals in the 
HSA60 group. Based on the molar ratios used in the cocktails, the ICG : 99mTc-HSA ratio is 
much lower than the ratio between the nanocolloid and ICG. Clearly, the hybrid nature of 
the non-covalent complex is less influenced by dissociation of ICG compared to the 
complexes formed between ICG and HSA (Table 3). At a later time point (NC240) dissociation 
of ICG from 99mTc-nanocolloid also became detectable; only three animals give a correlation 
> 0.79. Even though the correlation decreased, it was still possible to also see the 
radioactivity containing LNs via NIR fluorescence imaging procedures. As long as some of 
the ICG remained bound to the radioactive albumin particles, the SLNs could be detected 
via fluorescence imaging. In these instances the self-assembled complexes could still help 
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guide the surgical resection via intra-operative NIR imaging. 
In the NC60 control group a slightly lower correlation between the fluorescence and 
radioactive signal was found in TRAMP- animals that were injected in the prostate (Table 
3). It seemed that the self-assembled complexes were less stable after injection into the 
highly vascularised prostate. This is in agreement with findings that these self-assembled 
complexes are not stable in the blood stream after intravenous injection (data not shown). 
The efficacy of the self-assembled complexes after intratumoral injections, however, is an 
indication that the physiology in the tumor is favorable for the complex stability. Combined 
this suggests that the physiological conditions of the injection site are of influence on the 
stability of the non-covalent self-assembled complex. Nevertheless, it warrants their use 
in intratumoral injections and lymphatic migration studies.
Clinical applicability
Similar to the suggestion of the FDA,21 the local ethical committee of the Netherlands 
Cancer Institute acknowledged that a single cocktail injection of fluorescent and 
radioactive agents would be preferable over multiple injections. The use of ICG and 99mTc-
nanocolloid containing cocktail was approved for use in a clinical pilot study. It was shown 
that the combination of ICG and 99mTc-nanocolloid yielded the in situ formation of a non-
covalent complex comprising of two clinically approved imaging agents. Hence, different 
from what was found with sulphur radiocolloids, here a cocktail injection provided clear 
added value over free ICG alone.
In this Chapter, only ex vivo validation data were shown to demonstrate the excellent 
correlation between the radioactive and the fluorescence signal in this selected group of 
patients. Further studies will be conducted using an intraoperative fluorescence camera, 
allowing intraoperative visualization of the nodes during the surgical procedure. The 
preliminary clinical data are promising and substantiate the potential the approach might 
have in a clinical application. The clinical value of this approach is being further evaluated 
in Chapters 5, 6 and 7. 
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Conclusion 
In addition of the conventional preoperative SPECT/CT guidance, SLN imaging with 
a cocktail solution of Pb, ICG, and 99mTc-nanocolloid provides additional visual information 
regarding the accuracy of the injection (Pb) and provides the possibility of optical 
fluorescence guidance during the surgical procedure (ICG). Due to the self-assembly of 
ICG and 99mTc-nanocolloid a hybrid complex was generated that enabled both pre- and 
intraoperative detection of the SLNs up to 240 min post injection. 
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Comparing the hybrid fluorescent-radioactive 
tracer indocyanine green-99mTc-nanocolloid 
with 99mTc-nanocolloid for sentinel 
lymph node identification: A validation study 
using lymphoscintigraphy and SPECT/CT
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Abstract
Before the hybrid tracer ICG-99mTc-nanocolloid can be widely applied during sentinel 
lymph node (SLN) imaging in patients, lymphoscintigraphic drainage patterns of ICG-
99mTc-nanocolloid need to be compared to the parental compound 99mTc-nanocolloid, 
which is the standard tracer for lymphoscintigraphy in many European countries. To this 
end, 25 patients with either a melanoma in the head and neck region (n = 10), on the trunk 
(n = 6), or with penile carcinoma (n = 9) were prospectively included in a reproducibility 
study. First, the standard 99mTc-nanocolloid procedure was performed. After injection at 
the lesion site, static and dynamic lymphoscintigraphy was performed, followed by 
SPECT/CT. The scintigraphic procedure was repeated after injection of hybrid ICG-99mTc-
nanocolloid on the same day (ten patients), or the next morning (15 patients). The paired 
images of both injections were evaluated and count rates in the SLN were calculated and 
compared. SLNs were surgically localized using blue dye, a gamma ray detection probe, a 
portable gamma camera and a fluorescence camera. Lymphatic drainage was visualized 
in all 25 patients. All SLNs detected with 99mTc-nanocolloid were also identified with ICG-
99mTc-nanocolloid. Moreover, a high correlation between the radioactive counts rates in 
the SLNs of both scintigraphic studies was observed (mean R2 = 0.83). Intraoperatively, all 
preoperatively identified SLNs could be localized using radio- and fluorescence guidance 
combined. Ex vivo, all radioactive SLNs were found to be fluorescent and vice versa. From 
these data can be concluded that the lymphatic drainage pattern of ICG-99mTc-nanocolloid 
is identical  to that of 99mTc-nanocolloid.
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Introduction
Based on the hypothesis of sequential tumor spread, sentinel lymph node (SLN) 
biopsy is increasingly being used as a staging procedure for various malignancies.1-7 In the 
preoperative setting, the lymphatic drainage pattern can be gradually visualized using 
sequential lymphoscintigraphy, enabling identification of the tumor draining (S)LNs.8 
Single photon emission computed tomography combined with computed tomography 
(SPECT/CT) complements lymphoscintigraphy with three-dimensional anatomical data, 
and can reveal additional SLNs in some occasions.9-11 
Intraoperative SLN identification traditionally relies on the combination of acoustic 
signals generated by a gamma ray detection probe and optical SLN visualization using a 
visible blue dye.12,13 Since the gamma probe has a limited spatial resolution and SLNs are 
not always stained blue, SLNs can be difficult to localize in areas with a complex anatomy 
and when SLNs are located close to the injection site.14,15 The incorporation of a portable 
gamma camera in the intraoperative procedure partially addresses these limitations by 
increasing the detection sensitivity and providing an intraoperative overview image of 
the (radioactive) SLNs. Nevertheless this device does not depict the surrounding 
anatomical structures in the surgical field.16-18
Near-infrared (NIR) fluorescence imaging has the potential to address the drawbacks 
of radioguided SLN detection by providing better spatial resolution and allowing for real-
time optical detection of the SLN within the surrounding anatomy.19-22 As the signal 
penetration of fluorescent probes is limited by tissue attenuation, radio-guidance to the 
general area of interest is still indispensable.23 To combine the beneficial properties of 
both modalities, a hybrid tracer comprising the fluorescent dye indocyanine green (ICG) 
and the human serum albumin based radiocolloid 99mTc-nanocolloid was developed.24,25 
Recently, hybrid ICG-99mTc-nanocolloid was introduced for laparoscopic and open SLN 
biopsies in patients with prostate cancer, head and neck melanoma or oral cavity 
carcinoma.23,26-28
Before this hybrid tracer can be used routinely, it is imperative to ensure that the 
addition of the fluorescent moieties does not alter the biological properties of the parental 
radiocolloid. Therefore, the main purpose of the present study was to assess the concordance 
between the lymphatic drainage pattern of 99mTc-nanocolloid and ICG-99mTc-nanocolloid, 
using lymphoscintigraphy and SPECT/CT. In addition, this study further evaluate the value 
of combined radio- and fluorescence-guided SLN biopsy in various malignancies with 
superficial lymphatic drainage to areas such as the groin, axilla, and neck. 
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Methods
Patients 
Twenty-five patients with either a melanoma in the head and neck region (n = 10), on 
the trunk (n = 6), or with penile carcinoma (n = 9) scheduled for SLN biopsy were 
prospectively enrolled in the study. Patient characteristics are listed in Table 1. The mean 
age of the patients was 54 years (range 26 - 74 years). All patients were clinically node-
negative at the time of SLN biopsy. The study protocol was approved by the medical 
ethical committee of the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital 
(NKI-AvL) and all patients provided written informed consent. 
Tracer preparation
99mTc-nanocolloid was prepared by adding 2 mL pertechnetate in saline (approx. 
1125 MBq) to a commercial vial of nanocolloid containing 0.5 mg of albumin colloid 
(Nanocoll; GE Healthcare). Following 30 min of incubation at room temperature, the 99mTc-
nanocolloid solution (pH 6 - 7) was exposed to air via a needle to get rid of any excess 
reactive elements. Subsequently, a dose of 0.25 mg ICG (ICG-Pulsion, Pulsion Medical 
Systems) was added to form hybrid ICG-99mTc-nanocolloid as described previously.23 All 
preparations were performed under good manufacturing practice and with approval of 
The Netherlands Cancer Institute’s pharmacist. 
Preoperative procedure and image analysis
To determine the concordance between the lymphatic drainage patterns of ICG-
99mTc-nanocolloid and 99mTc–nanocolloid, both tracers were injected in consecutive order 
in the same patients, and the lymphoscintigraphic findings of both tracers were directly 
compared. Firstly 99mTc-nanocolloid was injected, in a volume of 0.4 mL containing 0.05 
mg human serum albumin. Before tracer injection, the planned sites of injection were 
carefully marked with an indelible felt-tip pen (Figure 1). In the melanoma patients, four 
injections were placed intradermally around the scar of the primary melanoma excision. 
For penile carcinoma, the tracer was intradermally administered divided into three 
injections proximally surrounding the tumor. The mean radioactivity dose of the first 
injection calculated on the basis of net administered doses was 71 MBq (range 54 - 88 
MBq). Immediately after injection, anterior and lateral dynamic images were obtained 
with a dual-head gamma camera (Symbia T, Siemens) over ten minutes to visualize the 
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lymphatic flow and to identify lymph nodes (LNs) on a direct lymphatic drainage pathway. 
Subsequently, static planar images were acquired at 15 min. Two hrs after injection of 
99mTc-nanocolloid, delayed planar images were obtained to further differentiate first-
echelon nodes from higher-echelon nodes and to identify SLNs in other basins. In the 
same session, SPECT/CT (Symbia T, Siemens) was performed. The LNs draining directly 
from the injection site were classified as SLNs.8 The first node appearing in the basin was 
considered to be the SLN in case of multiple visible nodes without visible afferent vessels. 
The same afternoon (ten patients: one-day protocol), or the next morning (fifteen 
patients: two-day protocol), the complete scintigraphic sequence was repeated after 
injection of hybrid ICG-99mTc-nanocolloid. Shortly before injection, a five min static image 
was obtained as a point of reference for the second injection in six patients. Hybrid tracer 
administration was then performed at the locations previously marked on the skin, by the 
same nuclear physician, using a similar tracer concentration (0.05 mg HSA in 0.4 mL, mean 
74 MBq, range 57 - 97 MBq). The mean interval between the two injections was 19 hrs 
(median 21, range 2.5 - 24, Table 1). Paired images of both injections were evaluated with 
regard to similarity of the depicted draining LN basins and the location and number of the 
SLNs. Count rates (maximum counts per pixel) were measured from the planar anterior 
images at two hrs after each injection and the reference images before the second 
injection using regions of interest drawn around the SLN(s). Trendline-based linear 
regression correlations (Excel) were used to establish the correlation between the 
radioactive count rates of both scintigraphic studies in patients with more than two 
preoperatively identified SLNs. 
Intraoperative procedure 
Shortly before surgery, 1.0 mL patent blue dye (Laboratoire Guerbet) was injected in 
all patients except those with melanoma located in the face to prevent unaesthetic long 
lasting skin marks. Next, a portable gamma camera (Sentinella, Oncovision) was used to 
guide the skin incisions and to obtain a pre-excision overview image of the SLNs. 
Intraoperatively, the SLNs were firstly pursued using the acoustic guidance provided by a 
gamma ray detection probe (Neoprobe, Johnson & Johnson Medical). During this initial 
exploration, attempts were made to visually detect the SLNs via the blue dye and the 
hybrid tracer’s fluorescent component (ICG) using a hand-held near-infrared fluorescence 
camera (PDE, Hamamatsu). After excision of each SLN, a post-excision image was acquired 
with the portable gamma camera to ensure its complete removal. 


















































































































































































































































































































































































































































































































































































































































































Table 1. Patient characteristics and lymphoscintigraphy results
 
SLN  = sentinel lymph node 
Study 1 = First examination using 99mTc-nanocolloid 
Study 2 = Second examination using ICG-99mTc-nanocolloid 
*  = Correlation (R2) between count rates measured two hrs after each injection  
     could only be calculated in patients with > 2 SLNs
 
Ex vivo analyses and histopathological examination
Excised LNs were postoperatively analyzed for the presence of a radioactive and/or 
fluorescence signal using the portable gamma camera and an ex vivo fluorescence camera 
system (IVIS 200, Caliper Lifesciences), respectively. All harvested nodes were fixed in 
formalin, bisected, embedded in paraffin, and cut at a minimum of six levels at 50 to 150 
mm intervals. Pathological evaluation included haematoxylin-eosin and immuno-
histochemical staining (anti-cytokeratin; CAM 5.2; Becton Dickinson).
Results
Preoperative image analysis
Lymphoscintigraphy and SPECT/CT after injection of 99mTc-nanocolloid showed at 
least one SLN in all 25 patients. The conventional lymphoscintigrams depicted 65 SLNs, of 
which 89% were visualized on the early static planar images. SPECT/CT showed the 
anatomical location of these nodes and revealed one additional SLN that was not 
visualized on the conventional lymphoscintigrams. The 66 SLNs were distributed over 51 
nodal basins (Table 1; average of 2.6 SLNs per patient). In the ten patients with a melanoma 
in the head and neck region, 25 SLNs were observed in various neck LN basins (n = 17), the 
parotid gland (n = 2), submandibular region (n = 2), and suboccipital region (n = 3). In the 
six patients with a melanoma on the trunk, 14 SLNs were identified in nine axillae and two 
groins. In the nine patients with penile carcinoma, 27 SLNs were visualized in 16 groins. 
The second scintigraphic study using ICG-99mTc-nanocolloid yielded an identical 
drainage pattern with the same number of SLNs in the corresponding nodal basins for all 
patients (Table 1, illustrated in Figure 1, 2 and 3). A comparison of the radioactive count 
rates in the individual SLNs at two hrs after both injections revealed a high correlation (R2) 
of 0.85 ± 0.20 for the patients injected twice on the same day (one-day protocol) and 0.83 
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± 0.19 for the patients within the two-day protocol (Table 1). In the one-day protocol, 
radioactive count rates measured two hrs after the second injection (ICG-99mTc-nanocolloid) 
were higher compared to count rates measured two hrs after the first injection (99mTc-
nanocolloid) in 90% of the SLNs. For the two-day protocol this was 66%. Furthermore, 
in the six patients in whom a reference image had been acquired shortly before the 
second scintigraphic procedure (both one and two-day protocol), an increased radioactive 




On average, SLN biopsy was initiated six hrs after injection of the hybrid tracer (range 
4 - 23, median five hrs; Figure 4, Table 2). Intraoperatively, all scintigraphically visualized 
SLNs could be localized and excised using radio- and fluorescence guidance combined. In 
six patients, postexcision imaging with the portable gamma camera identified considerable 
residual radioactivity at the original location of the SLN, resulting in the pursuit and 
removal of a total of 13 additional SLNs. 74 of the total of 79 SLNs (94%) could be localized 
using the gamma ray detection probe. The remaining five nodes were identified using the 
fluorescence camera (Table 2). Three of these SLNs concerned melanomas in the temporal 
region and were located in front of the ear, where the overwhelming radioactive signal 
from the nearby injection site hampered probe guidance. Two SLNs in the inguinal region 
in penile carcinoma patients were difficult to localize using the probe due to the low 
radioactive count rate in the SLNs relative to the (high) background. 
A total of 75 SLNs (95%) could be visualized by fluorescence imaging after initial 
surgical exploration, whereas only 54% of the SLNs were stained when patent blue was 
used (Table 2). The four SLNs that eluded fluorescence imaging were probably not 
sufficiently exposed to enable detection of the fluorescence signal. Nevertheless, a 
fluorescence signal could be visualized in all SLNs (including the four nodes mentioned 
above) ex vivo using the more sensitive IVIS fluorescence imaging system, underlining the 
stability of the ICG-99mTc-nanocolloid complex. 
Histopathological examination revealed metastases in six excised SLNs in four 
patients (Table 2). The use of ICG-99mTc-nanocolloid was not associated with adverse 
reactions. 
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Figure 1. Comparison of the lymphatic drainage pattern of 99mTc-nanocolloid and ICG-99mTc-nanocolloid in a 
patient with a melanoma on the right posterior flank. A) Firstly 99mTc-nanocolloid was injected after the planned 
sites of injection were carefully marked with an indelible felt-tip pen. B) Planar lymphoscintigram two hrs post 
injection showing the four deposits at the injection site (i) and two SLNs, one in each axilla. C) axial SPECT/CT 
image revealing the anatomical information of both SLNs. D) The same patient was injected with ICG-99mTc-
nanocolloid 24 hrs later at the previously marked locations. E) The planar lymphoscintigram two hrs post injection 
reveals the same two axillary SLNs. F) axial SPECT/CT image confirming that both SLNs are located at exactly the 
same locations compared to the first scintigraphic study using 99mTc-nanocolloid.
Figure 2. Comparison of the lymphatic drainage pattern of 99mTc-nanocolloid and ICG-99mTc-nanocolloid in a 
patient with a melanoma on the parietal scalp. A) Planar lymphoscintigram two hrs after injection of 99mTc-
nanocolloid showing two SLNs (arrows) in the left neck region with second-echelon activity in caudal direction. 
B) 3D volume-rendered SPECT/CT image revealing the two SLNs (arrows) in level V of the (left) neck and a 
second-echelon node located more caudally C) 3D volume-rendered SPECT/CT revealing a SLN in level V on the 
right side (which was also visible on the anterior planar image, not shown). D) Planar lymphoscintigram two hrs 
after injection of ICG-99nTc-nanocolloid (23 hrs after the 99nTc-nanocolloid injection) showing the same two SLNs 
on the left side, with increased higher-echelon activity. E) 3D volume-rendered SPECT/CT image showing the 
same SLNs at the same location compared to the first scintigraphic study, with more notable higher-echelon 
activity. F) Injection of ICG-99nTc-nanocolloid also led to the identification of the same SLN on the right side, as 
seen on the 3D volume-rendered SPECT/CT image.  
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Figure 3. Comparison of the lymphatic drainage pattern of 99mTc-nanocolloid and ICG-99mTc-nanocolloid in a 
patient with penile carcinoma. A) Planar lymphoscintigram two hrs after injection of 99mTc-nanocolloid showing 
drainage to three SLNs in the left inguinal region (arrows). B) The next morning, the residual image before ICG-
99mTc-nanocolloid injection showed decreased activity in the three nodes due to radioactive decay. C) Planar 
lymphoscintigram two hrs after injection of ICG-99mTc-nanocolloid showed drainage to the same three SLNs in 
the left inguinal region (later confirmed by SPECT/CT).
Figure 4. Combined intraoperative radio- and fluorescence-guided SLN biopsy in a head and neck melanoma 
patient. A) After initial exploration guided by the gamma probe and portable gamma camera, the hand-held 
fluorescence camera was used to visualize the SLN. B) Near-infrared fluorescence image showing the exact 
location and margins of the SLN within exposure of an infra-auricular SLN. C) The portable gamma camera was 
used to make a pre- and postexcision image of the (radioactive) SLNs. D) By comparing the preexcision (left) and 
postexcision (right) image on the screen of the portable gamma camera, successful removal of each SLN (arrow) 
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Discussion
This study shows that the lymphatic drainage pattern of the hybrid radioactive and 
fluorescent tracer ICG-99mTc-nanocolloid and 99mTc-nanocolloid, the current standard 
radiopharmaceucal in most European countries are identical. Lymphoscintigraphy and 
SPECT/CT after injection of ICG-99mTc-nanocolloid did not reveal any SLNs at other 
locations, and all preoperatively identified SLNs were found to contain ICG after excision. 
This confirms that ICG-99mTc-nanocolloid drains to the same SLNs as 99mTc-nanocolloid, and 
accumulates in the SLNs accordingly. The high correlation between count rates measured 
in the SLNs on the lymphoscintigrams two hrs after each tracer injection in both the one-
day and two-day protocol further substantiated these findings. Combined with the 
absence of adverse reactions, these findings validate the use of ICG-99mTc-nanocolloid as a 
tracer for preoperative lymphatic mapping and SLN identification. 
The reproducibility of repeated lymphoscintigraphy with 99mTc-nanocolloid has 
been studied for penile carcinoma and melanoma.29,30  While our present results are in 
agreement with the 100% reproducibility rate found for penile carcinoma, a discordance 
in lymphoscintigraphy results after the second scintigraphic study could have been 
anticipated for melanoma, as Kapteijn et al. found a reproducibility rate of 88% after 
repeat lymphoscintigraphy after 2 - 4 weeks in melanoma patients.31 A possible explanation 
for the high reproducibility observed in the current study may lie in the significantly 
shorter interval between both injections. The placement of the second injection at the 
exact same locations previously marked on the skin is also likely to have had a positive 
influence on the high reproducibility rate found in the current study (Figure 1).
In recent years, the fluorescent dye ICG has been evaluated as a single agent for 
intraoperative lymphatic mapping and SLN identification.19,20,31 Like vital blue dyes, ICG is a 
small molecule organic dye and migrates quickly through the lymphatic system resulting in 
a relatively short detection window after injection and the necessity for careful timing to 
intraoperatively identify the SLNs. In practice, this may require the use of 50-fold higher ICG 
dosages than the one used in the current study.20 Moreover, rather than visualizing lymph 
flow with fluorescence imaging, the hybrid approach individually illuminated the very 
nodes identified on lymphoscintigrams and SPECT/CT. The high rate of fluorescence 
containing SLNs visualized in the operating room (95%) compared to the relatively low 
percentage of SLNs that were stained blue (54%) underline how the fluorescent component 
of ICG-99mTc-nanocolloid can improve optical identification of the SLNs. In addition, the time 
window for fluorescence detection was possible up to 23 hrs post-injection. The improved 
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tissue penetration fluorescence imaging offers over vital blue dyes and the high resolution 
that can be obtained compared to gamma tracing modalities help enhance (optical) 
identification of the SLNs. This proved to be especially helpful when high radioactive 
background signals impeded SLN localization using the probe, in accordance with previous 
findings in head and neck melanoma and prostate cancer patients.23,27
In the present study, the application of hybrid ICG-99mTc-nanocolloid has successfully 
been extended to anatomical areas such as the axilla and the groin. This encourages 
further extension of this technique to other areas where radioguided surgery can be 
challenging. The introduction of hybrid tracers also poses new technological challenges 
for manufacturers of imaging systems. In the current study, separate devices for 
radioguided and optical sentinel detection were used. In the future, the development of 
hybrid devices combining both techniques may further improve the logistics in daily 
clinical practice.
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Conclusion
The lymphatic drainage pattern of hybrid ICG-99mTc-nanocolloid is identical to that of 
99mTc-nanocolloid. These findings, together with the added value of intraoperative 
fluorescence guidance, warrant further evaluation of hybrid ICG-99mTc-nanocolloid as a 
tracer for SLN procedures.
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Intraoperative laparoscopic fluorescence 
guidance to the sentinel lymph node 
in prostate cancer patients; clinical proof of 
concept of an integrated functional imaging 
approach using a hybrid imaging agent
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Abstract 
Integration of molecular imaging and in particular intraoperative image guidance is 
expected to improve surgical accuracy of minimally invasive procedures such as 
laparoscopic sentinel lymph node (SLN) biopsy. The applicability of combined pre- intra-, 
and postoperative SLN imaging using an integrated diagnostic approach was evaluated 
using the hybrid imaging agent ICG-99mTc-nanocolloid. Eleven patients with prostate 
carcinoma scheduled for robot-assisted laparoscopic prostatectomy (RALP) with an 
increased risk of nodal metastasis participated in a pilot assessment. ICG-99mTc-nanocolloid 
was injected into the prostate prior to surgery. Preoperatively, SLNs were identified using 
lymphoscintigraphy and single photon emission computed tomography combined with 
computed tomography (SPECT/CT). During the surgical procedure a fluorescence 
laparoscope, optimized for detection in the near-infrared range, was used to visualize 
the preoperatively identified SLNs. Fluorescence particularly improved surgical guidance 
in areas with a high radioactive background signal such as the injection site. Ex vivo 
analysis revealed a strong correlation between the radioactive and fluorescent content in 
the excised SLNs. These results indicate that the hybrid imaging agent ICG-99mTc-




Functional (optical) imaging holds great promise to supplement the surgeons’ eye 
and to help improve the surgical outcome.1,2 One practical clinical application where 
imaging can help guide the surgical intervention is the identification of lymph nodes 
(LNs) draining directly from the tumor (referred to as sentinel lymph nodes; SLNs). 
Functional imaging of SLNs depends on lymphatic migration and nodal accumulation of 
an imaging agent.3,4 Because imaging agents which visualize lymphatic drainage do not 
require targeting moieties, they can be relatively simple in design, improving their 
translational character. For this reason SLN imaging provides a platform for the introduction 
of new surgical guidance technologies that may later be expanded to other surgical 
applications.
The identification of SLNs is common practice in for example breast cancer and 
melanoma.5,6 Although the role of SLN dissection in prostate cancer is still under debate, 
lymphadenectomy does enable accurate staging of the lympatic tumor spread.7,8 SLNs 
outside the area of extended pelvic lymphadenectomy have also been described, 
underlining the need to document lymphatic drainage pathways for each individual 
patient.9 We reason that more accurate removal of prostate cancer associated SLNs will 
help identify the value of SLN biopsy in prostate cancer patients and may provide more 
accurate staging. Preoperative single photon emission computed tomography/computed 
tomography (SPECT/CT) imaging provides useful anatomical information regarding the 
location of the SLNs and allows for the identification of SLNs that lie beyond the standard 
dissection margins.10 In addition to their diagnostic purposes, these preoperative images 
can act as a guide during surgery.
Prostatectomy procedures have shifted from use of an open approach towards less 
invasive laparoscopic and robot-assisted techniques.11 Although advances in surgical 
instrumentation have been made, fluorescence guided (robotic) surgery is still in its 
infancy. Integration of optical imaging modalities that specifically visualize the areas of 
interest may provide the next step in the technical evolution of surgical interventions. 
Most clinical studies regarding optical surgical guidance to the SLNs focused on the use of 
the fluorescent dye indocyanine green (ICG).12,13 Limiting in this approach is that the 
rapidly migrating ICG has to be administered intraoperatively and its pharmacokinetics 
and distribution cannot be accurately monitored. To circumvent these problems a hybrid 
imaging agent (ICG-99mTc-nanocolloid) that contains both a radioactive and a fluorescent 
component was developed. The principal advantage of this hybrid imaging agent is that 
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it retains the well-established functional properties of 99mTc-nanocolloid, including 
accumulation in the SLNs, while providing complementary optical properties.14-17
In this Chapter the first clinical results of an integrated method that enables combined 
preoperative detection and intraoperative visualization of the SLNs in prostate cancer 
patients were presented. 
Materials and Methods
Patients
Between June 2010 and Januari 2011, eleven patients with prostate carcinoma 
scheduled for robot-assisted laparoscopic prostatectomy (RALP) with an increased risk of 
nodal metastasis, based on MSKCC/Kattan nomogram estimation were included. Inclusion 
criteria comprised the presence of one or more of the following characteristics: clinical 
stage greater than T2b, prostate serum antigen (PSA) level greater than 10.0 ng/mL, or 
Gleason sum score greater than 6. Patient characteristics are shown in Table 1. The surgical 
intervention was performed using a da Vinci S robotic system (Intuitive Surgical). During 
this procedure, both the prostate and SLNs were excised. Additionally, the nodal areas of 
the internal, obturator, and external LNs were dissected. LNs proximal to the ureter vessel 
crossing were only removed when SLNs were detected in this area. The study was 
performed conform protocol (N09IGF) after receiving approval from the local ethics 
committee of the NKI-AvL and after written patient consent was obtained. 
Tracer preparation
99mTc-nanocolloid was prepared by adding 1 mL pertechnetate (approximately 700 
MBq) in saline to a vial containing albumin nanocolloid (NanoColl; GE-Healthcare). ICG-
PULSION (Pulsion Medical Systems) was prepared by dissolving 25 mg of solid ICG in 5 mL 
demineralized water. The ICG-99mTc-nanocolloid solution was prepared by adding 0.05 mL 
(0.25 mg ICG) of the ICG-PULSION solution to 1 mL 99mTc-nanocolloid solution (pH 6 - 7). 
ICG-99mTc-nanocolloid was formed via non-covalent interactions between ICG and albumin 
molecules.14-16 All procedures were performed under the Kern Energie Wet (Nuclear Energy 
Law) using Dutch guidelines for good manufacturing practice and with approval of the 
local pharmacist. 
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Tracer administration and imaging
Patients (n = 11) were injected with ICG-99mTc-nanocolloid ( ≈ 280 MBq; 0.4 mL) in the 
peripheral zone of the prostate three hrs prior to surgery (Figure1).8 The imaging agent 
was injected under transrectal ultrasound guidance (Hitachi) in both lobes of the prostate; 
each injection was followed by flushing of the needle and tubing with approximately 0.7 
mL of saline. A portable gamma camera equipped with a pinhole collimator (Sentinella; 
Oncovision) was used to confirm adequate concentration of the hybrid imaging agent in 
the prostate using its radioactive 99mTc label. Static planar gamma camera images were 
acquired at 15 min and two hrs post injection. These were used to distinguish between 
SLNs and second echelon nodes as well as to identify unexpected drainage patterns. 
SPECT/CT (Siemens) was performed directly after planar imaging at two hrs post injection. 
SLNs were anatomically localized after image fusion. The first LN in each nodal basin 
appearing on early planar imaging was considered to be the SLN. LNs appearing later in 
the same basin were considered to be higher-echelon nodes. SPECT/CT images were 
displayed in the operation room to guide laparoscopic detection during RALP.
Surgical technique
 Intraoperatively, the SLNs were visualized using a dedicated laparoscopic D-light 
NIR fluorescence camera (Karl Storz). Herein light, emitted by an internal light source (760 
nm) is guided through a special fluid light cable to a 30 degrees infrared-optimized rigid 
laparoscope containing an optical filter system. The image was recorded using a CCD-
camera. Intraoperative fluorescence imaging was performed through two 12 mm 
laparoscopy ports positioned 5 cm lateral to the umbilicus or 2 cm medial from the 
anterior iliac spine. The fluorescence signal was depicted in green on an additional screen 
attached to the laparoscope (Figure 1,3 I). During fluorescence imaging the laparoscopic 
image was projected into the surgeons goggles of the da Vinci S using the systems Tile/
Pro function (Figure 1,3 II; fluorescence in blue). After removal of the preoperatively 
localized SLNs, dissection was guided by a laparoscopic gamma probe (Europrobe) and 
the fluorescence laparoscope. 
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Figure 1. 1. Transrectal ultrasound guided intraprostatic injection of ICG-99mTc-nanocolloid. 2. Preoperative 
SPECT-CT showing the anatomical localization of the SLNs (arrows) and 3. intraoperative SLN detection using a 
laparoscopic near-infrared camera (fluorescence depicted in green). Surgical goggles were used to simultaneously 
depict the 3D surgical field and the intraoperative laparoscopic fluorescence image in blue (blue arrow; II). White 
circles highlight the fluorescent area.
Ex vivo specimen analysis
Ex vivo examination of the radioactive signal in the excised LNs was performed using 
a portable gamma camera (Figure 2A). The radioactive content of the excised tissue was 
evaluated by placing the head of the gamma camera at a standardized distance of 10 cm 
above each excised specimen. Radioactive counts were measured using an acquisition 
time of one min and were quantified using Sentinella Suite software (Oncovision). 
Fluorescence signal intensities were measured using a preclinical fluorescence scanner 
(IVIS 200; Xenogen Corp.; Figure 2A). Images were acquired with standard ICG (excitation: 
710 - 760 nm; emission: 810 - 875 nm) filter settings. Measured intensities (photons/s/cm2/
sr) were quantified using Living Imaging Acquisition and Analysis software (Xenogen 
Corp.). Trend line based linear regression correlations (Excel) were used to establish the 
correlation between the fluorescence intensities and the radioactive count rate findings 
(Table 1).16 Fluorescence imaging of paraffin-embedded material was used to visualize the 
location of the tracer injection and its distribution throughout the prostate (Figure 2B). 
Lymphoid tissue specimens were analyzed in a similar manner to evaluate their fluorescent 
content and the location of the imaging agent in the SLNs (Figure 2C). 
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Figure 2. Ex vivo analysis. A) Comparison of ICG-99mTc-nanocolloid signal in an excised tissue specimen containing 
SLNs. The radioactive signal was detected using a portable gamma camera and the fluorescence emission was 
detected using a preclinical fluorescence scanner. B) Fluorescence imaging of paraffin-embedded prostate 
samples (order I - IV) depicted the injection site and the distribution of ICG-99mTc-nanocolloid throughout the 
prostate. C) Fluorescence analysis also allowed detection of the imaging agent accumulation in embedded SLNs.
Interventional molecular imaging, a hybrid approach114
Results
In Chapters 3 and 4 it was shown that the lymphatic migration of ICG can be 
positively influenced by the carrier molecule 99mTc-nanocolloid after formation of the 
ICG-99mTc-nanocolloid complex.14-16 This hybrid complex provides gradual and specific 
migration of the imaging agent from the primary injection site into the SLNs (Figure 1). 
At 15 min post injection SLNs could be visualized in 55% of the patients. This visualization 
rate increased to 91% at two hrs post injection which is in agreement to previous reports 
by Jeschke et al.17 and Vermeeren et al.10 Preoperatively, 27 SLNs were detected (Table 1) 
with a median number of two SLNs per patient (range 0 - 4). 
During the surgical procedure SLNs were identified in real-time using a combination 
of a gamma probe and a NIR-optimized fluorescence laparoscope. The radioactive 
background signal coming form the injection site prevented accurate gamma probe 
guidance to some of the preoperatively defined SLNs. In these cases, SLNs could be 
identified with the fluorescence laparoscope. In areas where the radioactive background 
signal was less prominent, fluorescence imaging provided additional high resolution 
guidance during the last cm - mm of the SLN identification process. The fluorescence 
signal output of the NIR-optimized fluorescence laparoscope was presented in both blue 
and green (Figure 1). For proper detection of the fluorescence signal the white-light 
intensity of the da Vinci System was dimmed. Overlying tissue (e.g. fat, vessels etc.) had 
to be removed as it generally obscured the fluorescence image. One of the 27 
preoperatively detected SLNs was only detected on SPECT/CT and could not be identified 
during surgery using either the gamma probe or fluorescence laparoscope (Figure 3). 
Four of 27 SLNs (15%) could not be detected intraoperatively with the fluorescence 
laparoscope, but were found to contain fluorescence ex vivo (Table 1, Figure 3). In these 
cases the SLNs were completely embedded in tissue/fat, resulting in a significant 
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Figure 3. Schematic representation of the excised SLNs based on the preoperative SPECT/CT images, and the 
modalities with which they could be accurately identified during surgery. The red circles represent metastases 
containing SLNs. The blue dotted lines encompass the extended dissection field. Note: The inability to detect 
some of the SLNs in real-time using either the fluorescence laparoscope or the gamma probe is a technical 
limitation related to the emission type and the modality used as the correlation between fluorescence and 
radioactive content was high in all excised specimens (Table 1). 
Ex vivo gamma- and fluorescence imaging of the dissected specimens (Figure 2A) 
showed a high signal intensity correlation for all the individual patient samples (R2 > 0.71; 
total 112 LNs investigated; Table 1). This underlines that all radioactive nodes contained 
fluorescence and to a similar extend. Consequently, visualization difficulties encountered 
during the surgical procedure were not related to the hybrid imaging agent and its migration. 
As expected, the improved spatial resolution of fluorescence imaging allowed 
identification of the (superficial) SLNs within the resected tissue specimens (Figure 2A). Ex 
vivo fluorescence imaging can, therefore, also provide pathological guidance towards the 
SLNs embedded in the excised tissue specimens. The fluorescent signal could still be 
detected in the embedded samples up until twelve months after the decay of the 
radioactive signal (Figure 2B and C). 
Anatomical locations of the by preoperative and surgically identified SLNs were 
documented (Figure 3). In 36% of the patients SLNs outside of the extended dissection 




The integrated laparoscopic surgical guidance concept that was presented here is 
based on a hybrid imaging agent (ICG-99mTc-nanocolloid) that allows both surgical 
planning via lymphoscintigraphy and/or SPECT/CT and real-time fluorescence-based 
surgical guidance (Figure 1). Herein the radioactive antenna (99mTc) was used for 
preoperative imaging and intraoperative guidance to the region of interest. The fluorescent 
antenna (ICG) was used for improved intraoperative identification of the SLNs. 
We have previously shown that nanocolloid-based procedures were superior over 
those based on free ICG or ICG bound to (radiolabeled) human serum albumin.16 In the 
described procedure any free ICG present during injection will thus already have been 
cleared at the time of dissection.
The radioactive component in ICG-99mTc-nanocolloid enabled accurate preoperative 
assessment of the distribution of the hybrid imaging agent via lymphoscintigraphy and/
or SPECT/CT. The anatomical information provided by the CT component was previously 
shown to improve the SLN detection accuracy up to 98%.10 During the surgical procedure 
the SPECT/CT image provided guidance towards the area of the SLN. Still, the spatial 
orientation is often related to large anatomical structures such as vessels and bone. 
Movement of internal anatomy of the patient during the surgical procedure limits the 
accuracy of sole SPECT/CT-based navigation. Real-time gamma probe detection allows 
acoustic tracing of the SLN location. This technique, however, suffers from background 
signals coming from the injection site (e.g. prostatic fossa) and collimator issues that 
hamper depth perception. The use of ICG-99mTc-nanocolloid enabled us to integrate the 
advantages of optical fluorescence guidance into these procedures. We found that 
fluorescence imaging was especially valuable for the intraoperative identification of the 
SLNs in areas where acoustic gamma tracing was inefficient (Figure 3). In other areas 
fluorescence helped identifiy the location of the SLNs with a higher spatial resolution. 
One of the shortcomings of fluorescence imaging is the limited tissue penetration of 
the fluorescence signal. In the current study this prevented real-time surgical detection of 
the SLNs via fluorescence imaging alone in 15% of the cases; only fully exposed nodes 
could be accurately detected. This result underlines that fluorescence techniques benefit 
from additional guidance toward the areas of interest. The next challenge will be to 
investigate if SPECT/CT based image-navigation can help guide the laparoscope to the 
SLNs.20,21
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The majority of the clinically used intraoperative fluorescence cameras are 
designed for open surgery, e.g. Photodynamic Eye (Hamamatsu Photonics), the self-built 
fluorescence-assisted resection and exploration-system (FLARE) and the light-absorption 
corrected (multispectral) real-time surgical guidance-system (Surgoptics).22,23 Due to the 
less invasive character of laparoscopic surgery there is a clear need to also translate the 
fluorescence guidance technology into laparoscopic surgery. This translation was 
facilitated by the D-light fluorescence laparoscope. We found that integration of this 
laparoscope into the RALP procedures was feasible. The laparoscope could be inserted 
through one of the existing access ports and the read out of the fluorescence laparoscope 
could be integrated into the surgical da Vinci goggles. A limitation of the current setting is 
that the surgical assistant still has to manually guide the fluorescence laparoscope toward 
the lesions. Future developments that allow the surgeon to independently guide the 
laparoscope towards the lesion via integration in the robotic-system are expected to 
improve the accuracy even further. 
In our opinion, the widespread development of surgical fluorescence cameras and 
the development and clinical implementation of new imaging agents are all essential in 
improving the surgical efficacy. Additionally, integration of these developments into 
technical surgical procedures such as minimally invasive robot guided surgery will be 
crucial. The hybrid approach presented here can easily be expanded into other surgical 
guidance applications such as tumor bracketing24 and receptor targeted tumor 
imaging.25-27 Limiting for these extended applications, however, is obtaining approval for 
the clinical use of new imaging agents. ICG-99mTc-nanocolloid circumvents this problem as 
a cocktail of the in Europe clinically approved ICG and 99mTc-nanocolloid results in the 
formation of a hybrid complex without the requirement of any chemical modifications or 
altering the toxicological profile. As such, ICG-99mTc-nanocolloid facilitates the clinical 
introduction of the hybrid surgical guidance concept. 
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Conclusion
The hybrid radiocolloid ICG-99mTc-nanocolloid, which contains both a radioactive 
and fluorescent component, enabled us to link preoperative SPECT/CT guidance with 
intraoperative NIR-fluorescence laparoscopy. Initial data showed the feasibility of 
integrating surgical fluorescence guidance into the robot assisted laparoscopic 
prostatectomy. Real-time fluorescence guidance proved particularly valuable in areas 
where accurate gamma tracing was hindered by background signal. 
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Relation between intraprostatic 
tracer deposits and sentinel lymph node 
mapping in prostate cancer patients
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Abstract 
Intraprostatic injection of the hybrid tracer ICG-99mTc-nanocolloid has been shown to 
enable both preoperative sentinel lymph node (SLN) identification and intraoperative 
visualization of the SLN. By relating the fluorescence deposits in embedded prostate 
tissue specimens to the preoperatively detected SLNs, the relation between the site of 
deposition and the lymphatic drainage pattern can be studied. 19 patients with prostate 
carcinoma scheduled for robot assisted laparoscopic prostatectomy and lymph node (LN) 
dissection were included to study this effect. ICG-99mTc-nanocolloid was injected 
intraprostatically guided by ultrasound. SLN biopsy was performed using a combination 
of radio- and fluorescence-guidance. Tracer distribution was visualized in paraffin-
embedded prostate samples using ex vivo fluorescence imaging. Tracer distribution 
was correlated to the number and location of the (S)LNs identified on preoperative 
lymphoscintigraphy and SPECT/CT. Ex vivo fluorescence imaging revealed a large variation 
in the distribution of the intraprostatic tracer deposits among individual patients. Tracer 
deposition in the peripheral zone could be correlated to a higher amount of visualized 
LNs compared to tracer deposition in the central zone (on average 4.7 vs. 2.4 LNs per 
patient). Furthermore, tracer deposits in the mid gland could be correlated to more 
visualized LNs compared to deposits located near the base or apex of the prostate (on 
average 6 vs. 3.5 LNs per patient). In conclusion, the hybrid nature of the tracer does not 
only enable surgical guidance, but also provides the opportunity to study the correlation 
between the location of the tracer deposits within the prostate and the number and 
location of the preoperatively visualized LNs. The acquired data suggests that the location 
where a tracer deposit is placed is of influence on the lymphatic drainage pattern.
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Introduction
Lymph node (LN) metastases are often the initial step in the cascade of metastatic 
(prostate) cancer spread. Unfortunately, diagnostic imaging modalities such as CT, MRI 
and 18F-FDG PET lack sensitivity for identification of  metastases.1,2 Currently, laparoscopic 
sentinel lymph node (SLN) biopsy followed by histopathological examination of the 
excised tissue is used to assess the nodal status in prostate cancer patients.3,4 
The concept of SLN biopsy has been studied extensively in breast cancer and 
melanoma.5-7 For prostate cancer, the principle of SLN detection is based on the assumption 
that accurate SLN identification is possible after intraprostatic injection of a radioactive 
tracer guided by ultrasound.8,9 As the majority of adenocarcinomas arise in the peripheral 
zone of the prostate,10,11 placement of tracer deposits at this location in the prostate is 
considered favorable for the detection of the tumor draining SLNs. Accurate placement of 
the intraprostatic tracer deposits may increase the reliability of the entire SLN procedure. 
However, monitoring of the injection accuracy using the radioactive signature of the 
injected tracer is difficult. 
The extent of lymph node dissection in prostate cancer is a topic of debate.8,12 Where 
some have argued that sole excision of the SLN is a sensitive method to detect (micro)
metastases, others favor extensive nodal dissection. Since unexpected locations of SLNs 
outside the field of an extended pelvic lymphadenectomy are not rare, it is crucial that 
SLNs are accurately identified preoperatively as well as intraoperatively.9 
As radioguided intraoperative localization of SLNs based on the acoustic signal 
generated by a gamma probe has its drawbacks, the surgical guidance concept was 
previously expanded with the use of fluorescence imaging (Chapter 2 - 6). To achieve this, 
a hybrid radiocolloid that can be visualized with a gamma camera, single photon emission 
computed tomography/computed tomography (SPECT/CT) imaging and via near infrared 
(NIR) fluorescence imaging was developed.13,14 This hybrid radiocolloid enabled linking of 
preoperative SLN identification to intraoperative visualization of the SLNs in patients with 
prostate carcinoma.15 Ex vivo assessment of embedded tissue specimens revealed that 
the fluorescence signal could still be detected long after the radioactivity had decayed.15 
Reasoning that the fluorescent beacon could also be used to analyze intraprostatic tracer 
distribution in retrospect, we have analyzed the fluorescence signal in prostate specimens. 
Hereafter, the location of the tracer deposit in the prostate was correlated to the number 
and location of the (S)LNs identified by lymphoscintigraphy and SPECT/CT.
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Materials and Methods
Patients
The protocol (N09IGF, NL28143.031.09) was approved by the local ethics committee 
of the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital. Between June 
2010 and February 2011, 19 patients with prostate carcinoma of intermediate prognosis 
scheduled for robot-assisted laparoscopic prostatectomy (RALP) and retroperitoneal 
lymph node dissection (RPLND) were included after obtaining written informed consent 
Inclusion criteria were the presence of one or more of the following characteristics: clinical 
stage > T2b, prostate serum antigen level > 10.0 ng/mL, or Gleason sum score > 6. The 
complete patient characteristics are listed in Table 1. In the current study ex vivo analyses 
was performed on the prostate specimens obtained during the surgical intervention 
described below. 
Tracer preparation 
99mTc-nanocolloid was prepared by adding 1 mL pertechnetate (approximately 700 
MBq) in saline to a vial containing albumin nanocolloid (NanoColl; GE-Healthcare). ICG-
PULSION (Pulsion Medical Systems) was prepared by dissolving 25 mg of solid ICG in 5 mL 
demineralized water. The ICG-99mTc-Nanocolloid solution was prepared by adding 0.05 mL 
(0.25 mg ICG) of the ICG-PULSION solution to 1 mL 99mTc-nanocolloid solution (pH 6 - 7). 
ICG-99mTc-nanocolloid was formed via non-covalent interactions between ICG and albumin 
molecules.13-15 All procedures were performed under the Kern Energie Wet (Nuclear Energy 
Law) using Dutch guidelines for good manufacturing practice and with approval of the 
local pharmacist. 
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cT/pT cN/pN cM cG/pG cG1/pG1 cG2/pG2
1 60 41 cT2b/pT3a cN0/pN0 cMx 7/7 3/3 4/4
2 64 78 cT2c/pT2c cN0/pN0 cMx 7/6 3/3 4/3
3 67 46 cT2b/pT3a cN0/pN0 cMx 7/8 3/3 4/5
4 63 26 cT2b/pT2c cN0/pN0 cM0 7/9 3/4 4/5
5 50 40 cT2b/pT2c cNx/pN0 cMx 6/7 3/4 3/3
6 74 47 cT2a/pT3a cN0/pN0 cM0 7/7 3/3 4/4
7 63 40 cT2b/pT3a cN0/pN1 cM0 8/10 5/5 3/5
8 62 77 cT2c/pT3a cN0/pN0 cM0 6/6 3/3 3/3
9 63 35 cT2c/pT2c cN0/pN0 cM0 7/7 3/3 4/4
10 62 23 cT2c/pT2c cN0/pN0 cMx 7/7 3/3 4/3
11 63 27 cT2b/pT3b cN0/pN0 cM0 8/10 5/5 3/5
12 62 27 cT2a/pT2c cNx/pN0 cM0 6/6 3/3 3/3
13 63 35 cT3c/pT2c cN0/pN0 cM0 7/7 3/3 4/4
14 67 107 cT2a/pT2b cN0/pN0 cM0 8/9 5/4 3/5
15 61 37 cT3b/pT3c cN0/pN1 cM0 6/7 3/3 3/4
16 62 22 cT2c/pT2c cN0/pN0 cMx 7/7 3/3 4/4
17 56 39 cT2b/pT2c cNx/pN0 cMx 7/7 3/3 3/4
18 65 42 cT3a/pT2c cN0/pN0 cM0 7/7 3/3 4/4
19 49 19 cT3a/pT2c cN0/pN0 cM0 6/6 3/3 3/3
 
PSA = prostate-specific antigen (determined preoperatively); G = Gleason sum score; c = clinical values; p = 
pathologic values; T = tumor status; N = nodal status; M = distant metastatases.
Tracer administration and preoperative imaging 
Tracer was administered approximately three hrs prior to surgery (Figure 1). 
Transrectal positioning of the needle into the prostate was guided by ultrasound (Hitachi). 
Injections were performed by three different urologists. Subsequently, both lobes of the 
prostate were injected with two tracer deposits of 0.1 mL each (total volume 0.4 mL, 
average dose 280 MBq). The needle and tubing were flushed with approximately 0.7 mL 
of saline after placement of each tracer deposit. To assess the adequacy of delivery each 
tracer deposit, intraprostatic tracer retention was monitored using a portable gamma 
camera equipped with a pinhole collimator (Sentinella; Oncovision). 
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Planar lymphoscintigraphy (anterior and lateral 5 min images) was performed at the 
nuclear medicine department at 15 min and two hrs post injection using a hybrid dual-
head camera (Symbia T, Siemens). The first LN in each nodal basin appearing on early 
planar imaging was considered to be the SLN (SLN1), whereas LNs appearing later in the 
same basin were considered higher echelon nodes. For anatomical localization of the 
SLNs, SPECT/CT was performed directly after planar imaging at two hrs post injection 
using the same hybrid camera system. If SPECT/CT revealed additional hot spots in caudal 
areas or on a side without previous drainage, these hotspots were also considered to be 
SLNs. The amount of radioactivity in the SLNs was determined by measuring the counts/
cm2 per LN using Osirix software. The total activity on the left and right side of the body 
was determined by calculating the sum of the measured counts in all visualized LNs. Using 
these count rates, the total percentage of radioactivity (%RA) per patient and the mean 
percentage of radioactivity on each side were calculated. To determine the mean 
percentage of radioactivity in SLN1, only count rates in that SLN were used.
Figure 1. Intraprostatic injection procedure. A, B) Placement of the needle was conducted guided by ultrasound. 
C) ICG-99mTc-nanocolloid was injected into the prostate. D) A portable gamma camera was used to confirm 
adequate concentration of the tracer in the prostate using its radioactive 99mTc label.  
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Surgical procedure
SLNs were intraoperatively localized and excised after prostatectomy using a 
laparoscopic gamma probe (Europrobe, Euro Medical Instruments; Figure 2) and a 
fluorescence laparoscope (D-light system, Karl Storz Endoscopes, Germany). A RPLND was 
performed after SLN excision in all patients. When no SLNs were identified preoperatively, 
a LN dissection was performed comprising the internal/external iliac and obturator 
nodes.15 
Ex vivo specimen analysis 
Fluorescence imaging of paraffin-embedded prostate tissue was used to visualize 
the location of the tracer deposits. For each patient, 2 - 6 sections were analyzed. An 
overview of the tracer deposits throughout the prostate was created by combining of the 
sections of each patient. Figure 3 illustrates the different zones and the orientation of the 
prostate; the x-axis visualizes the difference between the left and right side of the prostate, 
the y-axis follows the path from the bottom (peripheral zone) to the top (central zone) and 
the z-axis follows the base to the apex of the prostate. No discrimination was made 
between the transition and central zone; both are specified as the central zone. 
Fluorescence signal intensities were measured using a preclinical fluorescence camera 
(IVIS 200 camera; Xenogen Corp.). Images were acquired with standard ICG filter settings 
(excitation 710 - 760 nm and emission 810 - 875 nm). Measured intensities (photons/s/
cm2/sr) were quantified using Living Imaging Acquisition and Analysis software (Xenogen 
Corp.). For analysis, the prostate was divided into four quadrants (Q1-Q4, Figure 1B); Q1 
and Q3 representing the left side of the prostate and Q2 and Q4 representing the right 
side. Q1 and Q2 were deemed to include the largest part of the central zone of the prostate, 
whereas Q3 and Q4 were deemed to mostly represent the peripheral zone. Per section, 
distribution of the fluorescence signal was evaluated and the (mean) percentage of 
fluorescence in each quadrant was calculated. 
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Figure 2. Robot-assisted intraoperative SLN biopsy. A) The SPECT/CT image was acquired  to preoperatively 
determine the exact location of the SLN and is displayed in the operation room. B) During the surgical procedure, 
a gamma probe and fluorescence laparoscope (arrow) were inserted through one of the access ports. C) The 
acoustic signal produced by the gamma probe (arrow) was used to roughly guide the surgeon towards the 
location of the SLN. D) The SLNs (depicted in green) were visualized using the fluorescence laparoscope.  
 
Figure 3. Schematic representation of the prostate. A) Within the prostate, discrimination can be made between 
the peripheral and central zone due to differences in tissue morphology. The base of the prostate is wider than 
the apex and is located next to the bladder. B) For quantificantion purposes, the embedded sections of the 
prostate samples were divided into four quadrants (Q1-4). Q1 and Q2 represent the central zone whereas Q3 and 
Q4 respresent the peripheral zone.
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Results
In Chapter 6 the use of ICG-99mTc-nanocolloid for combined preoperative detection 
and image guided dissection of SLNs in eleven patients with prostate carcinoma using 
radio- and fluorescence guidance was described.15 In the 19 patients reported here (eight 
additional patients included) the possibility to ex vivo assess the placement of the tracer 
deposit with fluorescence imaging was explored. The efficacy of the hybrid guidance 
procedure in this enlarged patient population remained similar to the previous report.
Pathological analysis of the embedded prostate samples showed that in all prostate 
samples tumor tissue was mainly present in Q3 and Q4 (84%), which corresponds with the 
peripheral zone of the prostate (Figure 3). Tumor spread was determined during pathologic 
analysis of the embedded prostate sections. In all patients tumor was found in the third 
quadrant (Q3; Figure 3, Table 2). In 16 patients tumor was also present in Q4. In three 
prostate samples tumor was present in Q1 or Q2 next to presence of tumor in Q3 and/or 
Q4 and in three patients tumor was present in all quadrants. 
 
Table 2. Tumor presence
Patient nr Q1 Q2 Q3 Q4
1 X
2 X X
3 X X X X
4 X X
5 X X
6 X X X
7 X X
8 X X X
9 X X X X
10 X X X
X= presence of tumor. Q1-4 depict the different quadrants in the prostate.
Ex vivo fluorescence imaging of the tracer deposits 
Within the paraffin-embedded sections of the prostate, fluorescence could still be 
detected more than twelve months after prostatectomy and embedding of the tissue. 
Overlay pictures wherein the fluorescence image was superimposed on a photograph of 
Patient nr Q1 Q2 Q3 Q4






17 X X X X
18 X X
19 X X
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that specific section of the prostate were used to determine the location of the tracer 
deposits. Figure 4 illustrates the variations that were found. Figure 4A depicts the 
fluorescence signal in the different sections of the prostate and the corresponding 
lymphoscintigraphy image in two representative patients; in patient 8 the tracer was 
injected into the peripheral zone, while in patient 6 the tracer was injected into the central 
zone of the prostate. The location of tracer deposits for all individual patients are 
graphically represented in Figure 4B. Clearly, deposits vary in size, intensity (light green 
deposits depict identical or low intensities, dark green deposits depict deposits with high 
fluorescent intensity) and location. 
Figure 4. Variations in tracer distribution throughout the prostate. A) Two representative patients examples 
wherein the tracer was injected evenly distributed over the left and right side of the peripheral zone (patient 
number 8), and mostly in the central zone on the right with a single deposit in the peripheral zone on the left 
(patient number 6). These images also illustrate the variation in the z-direction. B) A schematic overview of the 
tracer deposits per prostate sample. Fluorescence deposits are depicted in green (light green for deposits with 
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Table 4. Radioactivity based distribution in preoperatively defined (S)LN.
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Highest number of visualized LNs (L or R) are depicted in bold. † highest amount of counts in SLN1 (L or R). ‡ 
highest acitivity (total; L or R). § SLN visualized only on SPECT/CT. Ext. = external iliac; int. = internal iliac; obt. = 
obturator; comm. bif. = common iliac bifurcation; comm. = common iliac
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To provide a more quantitative readout, the mean percentage of fluorescence in each 
quadrant of the prostate (Q1-Q4; Figure 3) per patient is shown in Table 3. In most patients 
the sum of Q3 and Q4 was higher than the sum of Q1 and Q2. In 68% of the patients a clear 
difference in signal presence was observed between the left and right side. In 53% of 
patients, the tracer was injected into the peripheral zone of the prostate, in 31% in the 
peripheral and central zone and in 16% only in the central zone (Figure 4; y-axis). 
 Evaluation of the distribution from the base to the apex of the prostate (Table 3 and 
Figure 3; z-axis) revealed that in 47% of patients the fluorescence signal was evenly 
distributed over all sections. In 21% of patients a larger deposit near the base or the apex 
was detected. In 16% of patients the fluorescence signal was only present near the base 
and apex whereas in another 16% the fluorescence signal was only present in the mid 
gland of the prostate. 
Radioactivity based evaluation of lymphatic drainage
Immediately after injection a scan was made using a portable gamma-camera to 
evaluate possible loss of tracer during the injection, e.g. into the bladder or the bloodstream. 
In patient number 7 and 14 an upcoming signal in the bladder was observed. Loss of tracer 
could also be evaluated using the SPECT/CT images, which visualize loss of tracer via the 
bloodstream; in six patients (patient number 6, 9, 12, 13, 15 and 16) a signal in the liver could 
be detected at 15 min post injection. In one patient this resulted in non-visualization of the 
SLN (patient number 6). Overall the height of the signal in the SLN seems not to be influenced 
by the loss of tracer during the injection as the amount of counts/cm2 detected did not differ 
significantly between patients wherein loss of tracer to the bladder or liver was observed 
(see above) and patients wherein no loss of tracer occurred. 
Lymphoscintigraphy and subsequent SPECT/CT imaging were used to visualize the 
SLNs and second echelon LNs. Except for patient number 6, where no SLNs could be 
visualized, SLNs were predominantly found in the region of the obturator nerve and 
internal iliac/external iliac vessels. It must be noted that in patient number 15 the SLN 
could only be visualized with SPECT/CT at two hrs post injection whereas in all other 
patients a SLN was visualized with lymphoscintigraphy at 15 min post injection. In six 
patients (32%; patient number 2, 5, 7, 9, 14 and 17), SLNs situated further along the 
obturator- internal/external iliac drainage route were identified. 
As listed in Table 4, the lymphatic drainage was not equally distributed over both 
sides of the patients. In eleven patients more LNs were found on the left side (61%) 
whereas in three patients more LNs were found on the right side (17%). In four patients, 
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the same amount of LNs was found on both sides (22%). Besides the number of LNs 
visualized, the activity measured in the first SLN (SLN1) on each side was also slightly 
different. In Table 4 the side with the highest activity in SLN1 is noted as †. In twelve 
patients a higher signal was measured in SLN1 on the left side (67%), whereas in six 
patients a higher signal was measured in SLN1 on the right side (33%). This same trend 
was seen when the total activity per side was assessed (See ‡ in Table 4 for the highest 
activity); in 13 patients the total activity was higher on the left side compared to the right 
side (72%). 
Relation between tracer deposit location (fluorescence-based) and the lymphatic 
drainage pattern (radioactivity-based)
To evaluate the relation between the location of the tracer deposits and the drainage 
to the LNs, the fluorescence signals were directly correlated to the measured activity in 
the visualized LNs. Patient 6 was excluded from the comparison as preoperatively no 
drainage was observed in this patient. 
Comparison of the fluorescence detected on the left and right side of the prostate 
(Figure 3; x-axis) with the radioactivity intensities measured on each side of the body 
(Table 5) resulted in a positive trend in ten patients (56%). In these patients the highest 
percentage of fluorescence was found on the side where the highest count rates were 
detected. When the fluorescence and the radioactivity in SLN1 were compared, this 
percentage increased to 67%. This, and the fact that in patients wherein tracer was 
deposited mostly on one side of the prostate a larger number of LNs could be visualized 
on that side (Table 4) suggests that lymphatic drainage may be influenced by the site of 
injection (x-axis).
The influence of the injection site is underlined by the eight patients wherein no 
positive correlation between deposit distribution and the drainage pattern was found 
(Table 5). In two patients the lack of a correlation could not be explained, whereas in the 
remaining six patients a clear deposit in the central zone of the prostate (patient number 
1, 3, 7 and 12-14; Figure 4 and Table 3) was observed. The possible link between placement 
of deposits at different locations in the prostate (Fig. 3; y-axis) and the drainage pattern 
was further evaluated. The location of fluorescent deposits in the prostate (Table 3) was 
correlated to the amount of LNs detected on lymphoscintigraphy (Table 4). Presence of 
fluorescence in the central zone of all prostate sections resulted in visualization of a mean 
of 2.4 LNs per patient (patient number 15 - 19). However, when the fluorescence was 
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predominantly situated in the peripheral zone of all sections of the prostate the number 
of visualized LNs increased to an average of 4.7 per patient (patient number 3, 5, 7, 9, 10, 
12 and 14). Apparently, the drainage is reduced when the injection is placed partly or 
completely in the central zone. 
A difference in drainage was also observed after injection in different sections of the 
prostate (Figure 3; z-axis). When tracer deposits were unevenly distributed between the 
different sections, no positive correlation between the site of the fluorescent deposit and 
the radioactivity in the LNs was found (Table 5). Placement of tracer deposits in the 
peripheral zone near the base or apex resulted in visualization of on average 3.5 LNs per 
patient (patient number 1, 7, 11 and 14). When tracer deposits were placed in the 
peripheral zone in the mid gland of the prostate the number of visualized LNs per patient 
increased to an average of 6 (patient number 2, 4, 8 and 9). 
In addition to the number of visualized LNs, a clear correlation between the 
distribution of the tracer deposits (Table 3) and the location of the visualized SLN (Table 4) 
was observed. Injection into the peripheral zone near the base of the prostate resulted in 
visualization of a SLN in the common iliac area (patient number 7, 14 and 17), whereas in 
one patient the injection was localized near the apex of the prostate, yielding a paracaval 
SLN (patient number 9).
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1 47 ± 11 53 ± 11 71 29 No (inverted) 55 45 Yes (large 
variance FL)
2 59 ± 6 41 ± 6 73 27 Yes (larger difference RA) 52 48 Yes
3 49 ± 7 54 ± 4 79 21 No (inverted) 71 29 No (inverted)
4 46 ± 13 54 ± 13 58 42 Yes (larger difference RA) 35 65 Yes 
(difference 
RA larger)
5 39 ± 7 61 ± 7 37 63 Yes 37 63 Yes
6 38 ± 6 69 ± 9 - - No (no drainage) - - No (no 
drainage)
7 68 ± 8 32 ± 8 37 63 No (inverted) 60 40 Yes
8 56 ± 9 44 ± 9 71 29 Yes (larger difference RA) 58 42 Yes
9 55 ± 21 48 ± 24 54 46 Yes 58 42 Yes
10 45 ± 4 55 ± 4 71 29 No 66 34
11 65 ± 4 35 ± 4 39 61 No (inverted) 26 74 No (inverted)
12 38 ± 0 66 ± 0 71 29 No (inverted) 73 27 No (inverted)
13 57 ± 13 43 ± 13 31 69 No (inverted) 37 63 No
14 57 ± 18 43 ± 18 86 14 No 100 - Yes
15 38 ± 12 61 ± 12 48 52 Yes - - Yes§
16 68 ± 4 32 ± 4 77 23 Yes 82 18 Yes 
(difference 
RA larger)
17 84 ± 3 16 ± 3 73 27 Yes 100 - Yes
18 70 ± 11 30 ± 11 71 29 Yes 60 40 Yes
19 20 ± 5 87 ± 16 27 73 Yes - 100 Yes
In each patient the fluorescence within the different sections of the prostate was determined and the mean 
percentage of fluorescence (FL%) was calculated on both sides of the body (L/R). To evaluate the relation 
between the presence of fluorescence and radioactivity, the percentages on the L and R were compared. When 
the highest percentage of FL and RA was measured on one side of the body (L or R), this was noted as a positive 
correlation. § SLN visualized with SPECT/CT instead of lymphoscintigraphy.
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Discussion
Although a relatively small patient group was evaluated, the results obtained in this 
study underline the value of the hybrid surgical guidance technology. The present study 
shows that the position where a tracer deposit is placed in the prostate is of influence on 
the lymphatic drainage pattern and that large variations in placement do occur in 
practice. The first point is underlined by Wawroschek et al. who showed that in canines, 
the site of injection influences the drainage pattern from the prostate.16 
Overall, our data suggests that drainage from the peripheral zone seems to be 
higher than from the central zone; injection into the peripheral zone of the prostate 
resulted in visualization of more LNs per patient (Tables 3 and 4). This is in line with the 
hypothesis stated by Brössner et.al that different zones of the prostate follow a different 
lymphatic drainage pattern.11 Possibly this difference in lymphatic drainage can be 
explained by the fact that the structure of the peripheral zone is more densely packed.11 
As such, injection of the radiotracer may result in a local increase in the interstitial fluid 
pressure leading to an increase in lymphatic drainage. The relation between increased 
fluid pressure after injection and lymphatic drainage may also explain why deposits 
situated only on the left or right side of the prostate result in a greater number of 
visualized SLNs (Table 4). 
Placement of deposits in different regions (along the z-axis; Figure 3) of the prostate 
also resulted in visualization of LNs in different basins (Table 4). Deposits clearly situated 
near the base of the prostate led to the visualization of LNs in the common iliac region, 
whereas a deposit near the apex of the prostate resulted in visualization of a paracaval 
SLN. In all cases lymphatic drainage tended to occur via the standard drainage route of 
the prostate including the obturator, internal iliac, external iliac, common iliac and 
presacral nodes.17 These basins are also the most frequent sites of lymphatic metastatic 
spread.18 
Ideally, SLNs are identified during surgery as these nodes are most likely to harbor 
possible metastases. Unfortunately, actual visualization of prostate tumor tissue in vivo is 
difficult using current standard imaging methods. When taken into account that prostate 
cancer predominantly develops in the peripheral zone,9,10 which is in line with the results 
shown in Table 4, we suggest that distribution of tracer over the peripheral zone (Q3-Q4) 
yields the highest chance of visualizing the SLNs. To compensate for injection errors such 
as loss of tracer to the bladder resulting in less drainage to one side, it can be recommended 
to always perform a contralateral RPLND in case of unilateral SLN detection by preoperative 
imaging.
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In the current setting, the tracer was deposited into the prostate under ultrasound 
guidance, which has a poor sensitivity for tumor visualization. Zonal anatomy of the 
prostate can be visualized using T2-weighted MR images.19,20 Therefore, fusion of MR 
images with real-time transrectal ultrasound may provide a solution for more accurate 
injection procedures, without resulting in major adaptations to current patient logistics. 
Also, as MR guided biopsies and MR guided focal therapy allow real-time visualization of 
needle placement, methods for MR guided tracer injections could be explored.21,22  
The recently developed hybrid radiocolloid allowed us to accurately document 
tracer locations in archived prostate material. These findings may have implications for 




Besides the potential to improve surgical guidance during (robot-assisted) SLN 
biopsy, hybrid ICG-99mTc-nanocolloid provides a unique tool to postoperately monitor the 
location of tracer deposits in the prostates of individual patients. This study suggests that 
the location of intraprostatic tracer deposition may influence the preoperatively visualized 
lymphatic drainage patterns and as such, the SLN procedure in prostate cancer patients as 
a whole.
Interventional molecular imaging, a hybrid approach144
References
1   Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R. Sentinel lymph 
node dissection for prostate cancer: experience with more than 1,000 patients. J Urol. 
2007; 177: 916-920
2   Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi 
M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M. Combination of 
adjuvant hormonal and radiation therapy significantly prolongs survival of patients 
with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol. 2001; 59: 832-
840
3   Jeschke S, Beri A, Grüll M, Ziegerhofer J, Prammer P, Leeb K, Sega W, Janetschek G. 
Laparoscopic radioisotope-guided sentinel lymph node dissection in staging of 
prostate cancer. Eur Urol. 2008; 53: 126-132
4   Meinhardt W, Valdés-Olmos RA, van der Poel HG, Bex A, Horenblas S. Laparoscopic 
sentinel node dissection for prostate carcinoma: technical and anatomical 
observations. BJU Int. 2008; 102: 714-717
5   Valsecchi ME, Silbermins D, de Rosa N, Wong SL, Lyman GH. Lymphatic mapping and 
sentinel lymph node biopsy in patients with melanoma: A meta analysis. J Clin Oncol. 
2011; 29: 1479-1487
6   Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel 
lymphadenectomy for breast cancer. Ann Surg. 1994;220: 391-398; discussion 398-
401
7   Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran 
AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. 
Arch Surg. 1992; 127: 392-399
8   Meinhardt W. Sentinel node evaluation in prostate cancer. EAU-EBU update series 5. 
2007; 223-231
9   Holl G, Dorn R, Wengenmair H, Weckermann D, Sciuk J. Validation of sentinel lymph 
node dissection in prostate cancer: experience in more than 2,000 patients. Eur J Nucl 
Med Mol Imaging. 2009; 36: 1377-1382
10   Coackley F.V., Hrivak H. Radiologic anatomy of the prostate gland: a clinical approach. 
Radiol Clin North Am. 2000; 38: 15-30
11   Brössner C, Ringhofer H, Hernady T, Kuber W, Madersbacher S, Pycha A. Lymphatic 
drainage of prostatic transition and peripheral zones visualized on a three-dimensional 
workstation. Urology. 2001; 57: 389-393
145Chapter 7
12   Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, 
Studer UE. Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009; 55: 1251-
1265
13   Buckle T, van Leeuwen AC, Chin PT, Janssen H, Muller SH, Jonkers J, van Leeuwen FWB. 
A self-assembled multimodal complex for combined pre- and intra-operative imaging 
of the sentinel node. Nanotechnology. 2010; 21: 355101
14   van Leeuwen AC, Buckle T, Bendle G, Vermeeren L, Valdés Olmos R, van de Poel HG, 
van Leeuwen FWB. Tracer cocktail injections for combined pre- and intraoperative 
multimodal imaging of lymph nodes in a spontaneous mouse prostate model. J 
Biomed Opt. 2011; 16: 016004
15   van der Poel HG, Buckle T, Brouwer OR, Valdés Olmos RA, van Leeuwen FWB. 
Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in 
prostate cancer patients: Clinical proof of concept of an integrated functional imaging 
approach using a multimodal tracer. Eur Urol. 2011; 60: 826-833
16   Wawroschek F, Wengenmair H, Senekowitsch-Schmidtke R, Hamm M, Henke J, 
Schönberger T, Hauser A, Erhardt W, Harzmann R. Prostate lymphoscintigraphy for 
sentinel lymph node identification in canines: reproducibility, uptake, and biokinetics 
depending on different injection strategies. Urol Res. 2003; 31: 152-158
17   Park JM, Charnsangavej C, Yoshimitsu K, Herron D, Robinson TJ, Wallace S. Pathways of 
nodal metastasis from pelvic tumors. Radiographics. 1994; 14: 1309-1321
18   Yu KK, Hawkins RA. The prostate: diagnostic evaluation of metastatic disease. Radiol 
Clin North Am. 2000; 38: 139-157
19   Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MRI of the prostate: Clinical relevance 
and emerging applications. J Magn Reson Imaging. 2011; 33: 258-274
20   Verma S, Rajesh A. A clinically relevant approach to imaging prostate cancer: Review. 
AJR Am J Roentgenol. 2011; 196: S1-10
21   Haker SJ, Mulkern RV, Roebuck JR, Barnes AS, Dimaio S, Hata N, Tempany CM. Magnetic 
resonance-guided prostate interventions. Top Magn Reson Imaging. 2005; 16: 355-
368
22    Lundner U, Lawrentschuk N, Trachtenberg J. Image guidance for focal therapy of 














Kuil J, Buckle T, van Leeuwen FWB. 
Chem Soc Rev. 2012; 41(15): 5239-61
Imaging agents for 
the chemokine receptor 4 (CXCR4)
Interventional molecular imaging, a hybrid approach150
Abstract
The interaction between the chemokine receptor 4 (CXCR4) and stromal cell-derived 
factor 1 (SDF-1, also known as CXCL12) is a natural regulatory process in the human body. 
CXCR4 overexpression is found in diseases such as cancer, where it plays a role in, amongst 
others, metastatic spread. For this reason CXCR4 is an interesting biomarker for the field of 
diagnostic oncology, and is gaining increasing interest for applications in molecular 
imaging. In this Chapter small molecule imaging agents based on the CXCR4 targeting 
T140 peptide are discussed based on their receptor affinity/specificity and/or distribution. 
The level wherein CXCR4 is upregulated in cancer patients and its relation to the different 




The chemokine receptor 4 (CXCR4) is a 7-transmembrane G protein-coupled receptor 
consisting of 352 amino acids (40 kDa). The interaction between CXCR4 and its natural 
ligand stromal cell-derived factor-1 (SDF-1, also known as CXCL12, which is an extracellular 
chemokine consisting of 72 amino acids, 8 kDa) is considered important for directional 
cell migration (i.e. chemotaxis).1 
CXCR4 is expressed by adult CD34+ bone marrow progenitor cells, vascular smooth 
muscle cells, endothelial cells, retinal pigment epithelial cells, intestinal and alveolar 
endothelial cells, microglia, neurons and astrocytes, and several types of immune response 
related cells.2 On the other hand, SDF-1 is expressed/secreted by tissues/organs such as 
fibroblasts, liver and kidney cells and regions in the central nervous system.1 The cell 
migratory function of the SDF-1 - CXCR4 chemotacic axis is instrumental during the 
development of embryos and in the attraction of inflammatory cells.2 
Besides its expression in normal tissues, CXCR4 overexpression has also been related 
to a number of diseases. CXCR4 was first reported as a co-receptor for CD4+ T-cell infection 
of human immunodeficiency virus (HIV) type 1.3-4 More recently, a role for CXCR4 has been 
described in the pathogenesis of rheumatoid arthritis.5-7 Upregulation of CXCR4 has been 
reported in at least 23 different epithelial, mesenchymal and haemotopoietic types of 
cancer.8 However, not every cancerous lesion is CXCR4 positive and CXCR4 expression 
within a tumor is generally heterogeneous with clear positive and negative subpopulations.8 
In cancer, CXCR4-based chemotaxis acts directly on tumor cell migration and invasion 
towards an SDF-1 gradient. High expression levels of SDF-1 have been found at the most 
common sites of breast cancer metastasis: axillary lymph nodes, lungs, liver and bone 
marrow.1,8 CXCR4 overexpression in tumor tissue has been correlated to poor survival,9-14 
tumor aggressiveness,10,11,15,16 increased risk of metastasis11,16-18 and a higher probability of 
recurrence.19 Due to the important role of CXCR4 in oncology, CXCR4 is a candidate target 
for therapeutic purposes.8 For this reason a number of (small molecule-based) CXCR4 
inhibitors have been developed, which have been previously reviewed in several 
publications.20-25 A specific subset of antagonistic peptides is formed by the T140 family. 
Recently it was found that these CXCR4 targeting moieties also provide versatile platforms 
for the development of imaging agents (Figure 1).26 The underlying rational here is that 
(non-invasive) imaging of CXCR4 can potentially be used to detect tumors and/or highly 
aggressive subpopulations of tumor cells. 
Receptor-targeted27-31 and enzyme-targeted32,33 molecular imaging of cancer had 
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been reviewed extensively. Furthermore, targets such as somatostatin,34,35 ανβ3 integrin
36,37 
and bombesin38,39 have been published. To date, no comprehensive review involving 
the emerging target CXCR4 has been published; only a short overview was reported.26 In 
the following overview CXCR4 targeting imaging agents of the T140 family that are 
luminescent and/or radioactive are discussed with the parental compounds as a reference. 
Firstly the clinical situation and preclinical models are described to provide crucial back-
ground information. Secondly the potential of the different compounds for (pre)clinical 
use is assessed.
Figure 1. Schematic representation of the interaction between CXCR4 (protein data bank (PDB) code 3OE0) and 
SDF-1 (PDB code 2K05) and the use of CXCR4 as a target for therapy (inhibitor in yellow) and imaging.
CXCR4 expression levels in oncology: the clinical situation
Immunohistochemical analysis of patient samples, using a variety of different 
antibodies, revealed staining of CXCR4 in the cytoplasm, on the cell membrane and in the 
nucleus of the cell (Table 1). The percentage of CXCR4 positive samples ranged from 12% 
in early breast cancer to > 90% in ductal carcinoma in situ (DCIS), non small cell lung 
cancer (NSCLC), renal cell carcinoma, mesothelioma, gastric cancer and prostate cancer 
(Table 1). In metastatic lesions in breast cancer, NSCLC, gastric cancer and renal cell carcinoma 
the percentages of CXCR4 positive cells ranged between 63.3 and 100% (Table 1).   
Overexpression levels of CXCR4 determined with (quantitative) real-time PCR 
((Q-)RT-PCR), western blot, immunoblot or immunohistochemistry (IHC) revealed variance 
in expression between cancer types and stages of tumor progression (Table 2). With the 
exception of CXCR4 expression levels in renal cell carcinoma, the average expression of 
CXCR4 in tumor tissue samples was 4.5-fold (range between 2.5 - 6.6-fold; Table 2) higher 
compared to normal tissue or low CXCR4 expressing cells. 
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Preclinical models for the evaluation of imaging agents for CXCR4
In the development and evaluation of a new CXCR4 targeting imaging agent a few 
important challenges have to be met. Firstly, a compound has to bind to the CXCR4 
receptor with a high affinity.27 The receptor affinity of a compound is described by the 
dissociation constant (KD) or by the half maximum inhibitory concentration (IC50), the 
latter being more experiment dependent than the KD.
62 Both values have to be determined 
in vitro using cell lines with intrinsic CXCR4 expression or cell lines that overexpress the 
CXCR4 receptor after transfection with the (human) CXCR4 gene. Secondly, a high 
specificity is required for differentiation between CXCR4 positive and negative cells, which 
can also be determined in vitro.30 Especially possible binding to the closely related CXCR7 
receptor can cause non-CXCR4 mediated cell binding.63 Thirdly, for a clinical translation, 
the most ideal imaging agent should provide high tumor uptake, which can be evaluated 
in vivo in (mouse) tumor models.30,64 For toxicity reasons (nonspecific) retention in vital 
organs should be minimal. This may be especially important for imaging studies wherein 
high doses of potentially radiotoxic radionuclides are injected.31 Fourthly, as CXCR4 is also 
natively expressed in immune-related cells residing in tissues as the lymph nodes,65 
background staining in these tissues must be taken into consideration when evaluating 
both distribution and in vivo imaging results. 
Besides challenges during the development of the imaging agents, the preclinical 
evaluation set-up used can also have a large influence on the obtained data. The CXCR4 
expression level in the cells used for in vitro evaluation can be of influence on the 
determined affinity and even more on the specificity. Similarly, for in vivo evaluation, the 
(mouse) tumor model, in particular the CXCR4 expression level in the tumor, can influence 
the tumor accumulation of an imaging agent. All tumor models used for CXCR4 imaging 
agents are listed in Table 3. The cell line-based tumor models DU4475 and MDAMB231CXCR4+ 
and the transplantation-based MIN-O model show the closest resemblance to the clinical 
situation, since the level of upregulation is comparable to the average factor of 4.5 
measured in patient samples. For the other tumor models the CXCR4 expression level was 
not specified or higher, due to the use of transfected cell lines (Table 3). As the uptake of 
an imaging agent is also influenced by tumor morphology and vascular physiology, a 
transplantation-based model will generally provide a closer resemblance to the human 
situation than a cell line-based model. Tumor models based on transfected cell lines 
resemble the clinical situation to a lesser extent,31,66 but they are valuable in order to 
provide an indication whether an imaging agent can be used for tumor visualization at all. 
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T140 derivatives
In 1992 Fujii et al. reported on an 18 amino acid-containing peptide that possesses 
two disulfide bridges that was designed based on the antimicrobial peptides Tachyplesin 
and polyphemusin.78-80 The potent peptide analog, T140, consists of 14 amino acids and 
one disulfide bridge (Figure 2A).81 T140 is an inverse agonist of CXCR482  and its derivatives 
are one of the most widely studied classes of CXCR4 imaging agents. T140 derivatives 
have a low nanomolar affinity for CXCR4 and are proven to be specific; they solely bind to 
CXCR4 and not to CXCR7.68,81
Binding mode
The N- and C-terminus of T140 bind into the cavity of the seven transmembrane 
helices of CXCR4.83 The pharmacophore of T140 consists of residues Arg2, Nal3, Tyr5, and 
Arg14. Furthermore, residues 7 - 10 in the β-turn of T140 are located at more than 3.0 Å 
from the CXCR4 receptor.83 This CXCR4 binding model has been corroborated using a 
crystal structure of the T140 analog CXV15 (Figure 2B; protein data bank (PDB) structure 
ID: 3OE0).84 The crystal structure showed that the binding cavity of CXCR4 is larger, more 
open and located closer to the extracellular surface compared to other G protein-coupled 
receptors (GPCRs). Furthermore, it was shown that the peptide CXV15 fills most of the 
binding pocket: Arg1-Cys4 of CXV15 has interaction with Asp197-Tyr190 of CXCR4. Arg2 of the 
peptide also interacts with Thr117, Asp171 and His113 of CXCR4, Arg14 of the peptide makes a 
salt bridge with Asp262 and the C-terminus of the peptide interacts with Asp288.
Based on the location of the pharmacophore in T140, imaging labels can be attached 
to the N-terminus and the side chains of Lys7 and D-Lys8 (Figure 2B). During binding, the 
N-terminus is positioned in the binding cavity of CXCR4, limiting the space for label 
attachment at this position. Lys7 and D-Lys8 in the β-turn are directed away from the 
binding cavity, therefore these residues appear to be the most suited for functionalization. 
Inhibitors
T140 has been used as a starting point and reference compound during the 
development of many derivatives.85-95 One compound in particular, Ac-TZ14011, (Figure 
2A), showed a higher binding affinity for CXCR4 and a higher in vivo stability compared to 
T140. Furthermore, only one amine group is present (D-Lys8) in Ac-TZ14011, instead of 
three in T140, enabling controlled functionalization.68,71,96 
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Figure 2. A) T140, CVX15 and Ac-TZ14011. The pharmacophore of the T140 derivatives is indicated in red in T140. 
B) Model of T140 binding to CXCR4 based on the protein data bank (PDB) structure 3OE0.
Monomeric derivatives 
Three versions of imaging agents have been reported: fluorescent, radioactive and 
hybrid/multimodal (combined fluorescent and radioactive).
Ac-TZ14011 has been labeled on D-Lys8 with several fluorescent dyes,68,96-99 including 
FITC (λex = 495 nm, λem = 520 nm; Figure 3). The CXCR4 affinity of Ac-TZ14011-FITC is 24-
fold lower than that of Ac-TZ14011 (Table 4) despite the fact that molecular modeling 
demonstrated that D-Lys8 is the favored functionalization point. Nevertheless, the binding 
affinity remained in the nanomolar range and Ac-TZ14011-FITC could be used to 
discriminate MDAMB231CXCR4+ from MDAMB231 cells.75 In addition, Ac-TZ14011-FITC was 
able to identify CXCR4 positive tumor tissue in which the expression level was only 4.4-
fold upregulated.97
The receptor affinity of both Ac-TZ14011-Flu and Ac-TZ14011-Alexa488 (λex = 495 
nm, λem = 520 nm for both compounds) is slightly lower than unlabeled Ac-TZ14011 (factor 
3 and 1.5, respectively). Although these compounds are structurally very similar to Ac-
TZ14011-FITC (Figure 3, Table 4), their affinity for the CXCR4 receptor seems to be higher.68,96 
Moreover, Ac-TZ14011-Flu and Ac-TZ14011-Alexa488 possessed high specificity, since 
they did not bind to the closely related CXCR7 receptor, which was recently reported to 
also bind SDF-1.63 Ac-TZ14011-Ahx-Flu and Ac-TZ14011-Ahx-TAMRA (λex = 543 nm, λem = 
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575 nm), which both contain an additional aminohexanoic acid (Ahx) spacer between the 
peptide and the label, show a binding affinity that is similar to Ac-TZ14011-Flu and Ac-
TZ14011-Alexa488  (Table 4).68,96 Strangely, the binding affinity of Ac-TZ14011-Ahx-
Alexa488 was significantly lower.68,96 Ac-TZ14011-Flu, Ac-TZ14011-Alexa488, Ac-TZ14011-
Ahx-TAMRA and also Ac-TZ14011-Cy5 (λex = 650 nm, λem = 670 nm)
 could visualize cells 
with fluorescence microscopy and flow cytometry.98 Ac-TZ14011-Flu has also been 
successfully used in a bladder tumor model in mice.99
Ac-TZ14011 has also been functionalized with a relatively large luminescent iridium 
complex (Ir-(Ac-TZ14011)¸ Figure 3).76 The dissociation constant (KD) of this derivative is 
84.4 nM which is in line with other labeled Ac-TZ14011 peptides (Table 4). Uniquely, the 
iridium complex (λex = 383 - 410 nm, λem = 566 - 585 nm) was shown to have a luminescent 
lifetime of more than 200 ns; autofluorescence and organic fluorophores possess 
luminescence lifetimes shorter than 10 ns.76 Based on this long lifetime, fluorescence 
lifetime imaging microscopy (FLIM) of CXCR4 expression on cells was performed. 
For in vivo fluorescence imaging near-infrared (NIR) dyes are preferred, as lower 
background autofluorescence and better tissue penetration are observed using these 
dyes.100 Ac-TZ14011 has been labeled with NIR dye IR783 (λex = 783 nm, λem = 812 nm; 
Figure 3),62,98 which could be used for fluorescence guided surgery.62 Furthermore, Ac-
TZ14011-IR783 can bind non-covalently to human serum albumin via the NIR dye. This 
self-assembled complex could be used to change the distribution profile of the peptide 
using an albumin-carrier.98
Figure 3. Monomeric fluorescent and phosphorescent T140 derivatives.
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111In-DTPA-Ac-TZ14011 is the first reported radiolabeled Ac-TZ14011 derivative 
(Figure 4).71 The indium-bound DTPA chelate reduced the CXCR4 binding affinity in a 
similar manner as the fluorescent dyes (Table 4).101 For single photon emission computed 
tomography/ computed tomography (SPECT/CT) imaging relatively low specific activities 
(0.20 MBq/µg) were sufficient to visualize the tumor in a MIN-O transplantation model of 
ductal carcinoma in situ (DCIS) with only a four-fold overexpression of CXCR4 (Table 3).101 
At 24 hrs post injection (p.i.) an increase in tumor uptake could be correlated to an increase 
in CXCR4 expression, which was not the case at one hr post injection. Distribution studies 
in the MIN-O tumor model and in a pancreatic tumor model at 1, 6 and 24 hrs post injection 
revealed a rapid clearance from the blood and a noticeable uptake and retention in the 
liver, kidneys and spleen (Table 5).71,101 Despite low CXCR4 expression in the liver, the 
accumulation appeared to be partly specific, since co-injection of a large excess of Ac-
TZ14011 showed a marked decrease in uptake.71 Although the tumor accumulation was 
not very high, an adequate tumor-to-muscle (T/M) ratio was obtained at both 6 hrs post 
injection (4.43) and 24 hrs p.i. (7.17 ± 0.47) as the muscle uptake was low. 71,101 The tumor 
accumulation in the low CXCR4-expressing 4T1 tumor model was significantly lower 
compared to accumulation in the MIN-O tumor model at 24 hrs p.i. 101
An alternative radiotracer is 125I-IB-Ac-TZ14011 (Figure 4). For this compound a 
125I-labeling procedure was developed using an 3-iodobenzoyl group, which was coupled 
to D-Lys8 of Ac-TZ14011.102 The distribution, which was only determined for non-tumor-
bearing mice, showed a relatively fast clearance, mainly via the kidneys (Table 5). This 
large difference in the clearance profile is surprising given the relatively small difference in 
chemical structure with respect to 111In-DTPA-Ac-TZ14011. 
T140 has been labeled with 18F by coupling 4-18F-fluorobenzoic acid (4-18FBz) to the 
N-terminus of T140 (Figure 4).70 This functionalization did not result in a reduction of 
binding affinity compared to the parental compound (see IC50 values in Table 4).
89 An 
effect that can possibly be explained by the fact that 4-18FBz is small and can also provide 
additional hydrophobic interactions with the CXCR4 receptor. A potential disadvantage of 
18F labeling is that it is more laborious and time consuming than chelate-based labeling. 
Nonetheless, PET imaging was possible with 4-18FBz-T140 (two hrs post injection), enabling 
tumor visualization despite high background signals (tumor-to-muscle ratio = 2.94; Table 
5).70 The authors suggested that the remarkable high blood uptake (14.3 percentage 
injected dose per gram (% ID/g)) was caused by non-CXCR4-mediated binding of 
4-18FBz-T140 to red blood cells. When ten µg cold 4-FBz-T140 was co-injected, both the 
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uptake in blood and the spleen were greatly reduced, leading to a maximal tumor-to-
muscle (T/M) ratio of 21.6. A possible explanation for this behavior is that co-injection of 
unlabeled compound resulted in reduction of the specific activity in such a way that non-
specific binding was avoided. This is underlined by the fact that red blood cell binding was 
not observed in studies wherein a low specific activity was used.71,101 
In an alternative attempt to reduce the red blood cell binding, Jacobson et al. 
replaced the 4-18FBz group at the N-terminus with DOTA or NOTA (Figure 4).69 The use of 
these larger DOTA and NOTA chelates resulted in steric hindrance when binding to CXCR4 
and the chelates could not contribute to receptor binding via hydrophobic interactions. 
Accordingly, the affinity of DOTA-NFB and NOTA-NFB for CXCR4 was considerably reduced 
compared to 4-18FBz-T140 (27- and 55-fold, respectively; Table 4). Both the radiolabeled 
versions 64Cu-DOTA-NFB and 64Cu-NOTA-NFB displayed very low binding to red blood cells 
and could be used for PET imaging, despite of their high specific activity of 12.21 - 14.8 
MBq/µg. Regardless of the lower affinity, the tumor uptake of 64Cu-DOTA-NFB and 64Cu-
NOTA-NFB was reported to be comparable to that of  4-18FBz-T140 (Table 5). The blood and 
muscle uptake of 64Cu-DOTA-NFB and 64Cu-NOTA-NFB was lower than the uptake of 
4-18FBz-T140, yielding higher T/M ratios. Unfortunately, the uptake of 64Cu-DOTA-NFB  and 
64Cu-NOTA-NFB  was again high in liver and kidney. Similar to what was observed with 
4-18FBz-T140, co-injection with cold tracer (meaning reduction of the specific activity) can 
possibly further improve the distribution.
Modification of the N-terminus of T140 with the 4-FBz group has also been used to 
increase the CXCR4 affinity of 111In-DTPA-Ac-TZ14011. This radioactive indium-labeled 
compound, In-DTPA-4-FBz-T140, showed only a five-fold lower CXCR4 affinity than T140 
(Table 4).103 Unfortunately, no experiments with In-DTPA-4-FBz-T140 in mice have been 
reported up until now, making it difficult to estimate the effect of the 4-FBz modification 
in vivo.
Recently, a very similar agent, 64Ga-DOTA-4-FBz-TN14003, was described (Figure 3).104 
A relatively high CXCR4 affinity and a high specific activity of maximal 11.6 MBq/µg were 
obtained (Table 4). The stability in human plasma of 64Ga-DOTA-4-FBz-TN14003 is high; 
after 90 minutes 97% was still intact. In vivo experiments with this tracer have not yet 
been reported.
The T140 analog 64Cu-T140-2D also includes the 4-FBz modification at the N-terminus 
in addition to two DOTA chelates on Lys7 and D-Lys8 (Figure 4).72 The IC50 value of T140-2D 
was shown to be similar as that reported for T140 (Table 4). However, the IC50 value of 
T140-2D was determined in the presence of 64Cu-T140-2D and no IC50 value of a reference 
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compound such as T140 was measured using the same assay. Therefore, the binding affinity 
of 64Cu-T140-2D and T140 cannot be objectively compared. Based on previous results it 
seems likely that the two DOTA chelates will reduce the receptor affinity to some extend. 
Distribution studies with the 64Cu-labeled derivative revealed red blood cell binding similar 
to 4-18FBz-Ac-TZ14011 (Table 5). Again, co-injection of cold compound reduced the blood 
uptake, although less effectively than for 4-18FBz-T140. The distribution of 64Cu-T140-2D with 
co-injection of 5 mg of cold T140-2D still showed high liver, kidney and spleen uptake, 
similar to 111In-DTPA-Ac-TZ14011. Reducing the specific activity by co-injection of 5 mg of 
cold T140-2D was also required for tumor visualization during PET imaging.
Figure 4. Monomeric radiolabeled T140 derivatives. 
Ac-TZ14011 has also been labeled with a multifunctional single-attachment-point 
(MSAP) reagent,105,106 which consist out of a Cy5.5 like fluorophore and a DTPA chelate for 
indium binding (Figure 3).75 This hybrid derivative, Ac-TZ14011-MSAP, had a similar affinity 
as the FITC and DTPA derivatives, again demonstrating that a relative large label such as 
MSAP does not hamper CXCR4 binding more than smaller labels (Table 4). The obtained 
T/M ratio was also similar to the ratio found with 111In-DTPA-Ac-TZ14011 (4.55; Table 5). 
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Liver uptake was again high; nonetheless Ac-TZ14011-MSAP-111In provided the 
opportunity that it could be applied in vitro fluorescence imaging, as well as in vivo in 
both SPECT/CT imaging and fluorescence guided surgery.75
Figure 5. Monomeric hybrid T140 derivatives.
Multimeric derivatives 
In addition to the monomeric T140 derivatives discussed above, multimeric structures 
have also been described. The use of multimers allows for incorporation of the imaging 
label into the core of the molecule. The rationale behind this approach is that it may lead 
to shielding of the label from the environment and, subsequently, lower nonspecific 
binding. 
Multimers have been prepared using a core consisting of the iridium complex used 
in Ir-Ac-TZ14011 (Figure 3 and 6).76 A dimer and trimer were synthesized and evaluated in 
vitro. The dimer displayed a three-fold lower binding affinity than Ir-Ac-TZ14011, whereas 
the trimer had a slightly higher CXCR4 affinity (Table 4). 
We have also reported a dimeric and a tetrameric Ac-TZ14011 derivative, in which 
D-Lys8 was used to couple the peptide to a dendritic scaffold.77 Both unlabeled compounds 
had approximately a three-fold lower CXCR4 affinity than monomer Ac-TZ14011, which 
implies that additional peptide(s) hinder the binding to a certain extend. The dimer 
(Ac-TZ14011)2 and tetramer (Ac-TZ14011)4 have also been labeled with a hybrid 
MSAP label. The CXCR4 affinity of the dimer (Ac-TZ14011)2-MSAP and the tetramer 
(Ac-TZ14011)4-MSAP was approximately a two-fold higher than reference monomer 
Ac-TZ14011-MSAP (Table 4). Therefore it can be concluded that the additional peptides 
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reduce the negative’influence of the MSAP label, probably by shielding the MSAP label 
(Figure 7B).77 In distribution studies, the dimer and tetramer displayed significantly lower 
nonspecific muscle uptake compared to monomer, resulting in a higher T/M ratio for dimer 
(Ac-TZ14011)2-MSAP-
111In (7.41) (Table 5). The T/M ratio of tetramer (Ac-TZ14011)4-MSAP-
111In 
was lower than that of the dimer, due to lower tumor uptake. 
Figure 6. A) Multimeric T140 derivatives. B) Molecular models of the MSAP-labeled derivatives, illustrating the 
shielding of the MSAP label by the Ac-TZ14011 peptides. 
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Discussion 
For CXCR4 imaging luminescent and/or radioactive imaging labels have been used. 
Fluorescent labels are considered the best choice for in vitro evaluation, allowing e.g. 
microscopy and flow cytometric analysis. Additionally, fluorescence can be used for image 
guided surgery purposes. For in vivo imaging (SPECT, PET) and distribution studies radiolabels 
are the most desirable. Chelate-based radiolabeling is in general more convenient than e.g. 18F 
and 125I labeling, due to the shorter and more implementable labeling protocol.  Hybrid labels 
based on fluorescence and radioactivity can be used for all applications mentioned above, 
which facilitates integration of the results from the various imaging techniques.75
As described, a number of biological features of CXCR4 targeting are essential in the 
evaluation of a new imaging agent: the receptor affinity and specificity, high tumor and 
low background uptake and the cell line and tumor model. Based on these features, 
imaging agents of the T140 family were compared.
 
CXCR4 affinity and specificity
The receptor affinity and specificity of an imaging agent can be divided into two 
aspects: the potency of the parental compound and the (negative) influence of the 
imaging label. Both T140 and its derivative Ac-TZ14011 were shown to have a low 
nanomolar affinity for the CXCR4 receptor (Table 4). 
Chemical modifications of T140 derivatives for imaging purposes generally reduce 
the affinity and specificity. Steric hindrance can be reduced to an acceptable level and 
nonspecific binding can be restrained by avoiding hydrophobic labels. 
For labels attached to the D-Lys8 position there is no trend between the binding affinity 
and the size and hydrophobicity of the label (Table 4). Most likely this is due to the fact that the 
D-Lys8 functionalization yields a minimal amount of interactions between the label and the 
receptor (Figure 2). However, label-mediated nonspecific cell binding reduces the binding 
affinity to different degrees. Such nonspecific binding can partly be overcome by using 
multimerization approaches that shield the imaging label from the surrounding environment.77 
Variation in the experimental setup that is used in the different studies may be a major reason 
for the variation in the binding affinities reported for the different T140 derivatives. 
Tumor and background accumulation
High tumor uptake and low retention in other organs are important for good tumor 
visualization and low toxicity. To reduce retention in non-tumorous tissue and the 
associated possible side effects, rapid renal clearance is generally preferred over slower 
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hepatic clearance. Radioactively labeled variants of Ac-TZ14011 are primary cleared via 
the kidneys and in a lesser extent via the liver (Table 5). Rapid renal clearance of a 
compound decreases the (radioactivity-related) toxicity of a compound, as overall 
retention is reduced. Multimeric structures (Ac-TZ14011)2 and (Ac-TZ14011)4 are primarily 
cleared via the liver, which could be a result of the large size of the compounds.
Important to note is that CXCR4 is also present in the lymph nodes, spleen and bone 
marrow, which can result in background staining.101 A successful strategy to reduce the 
background staining of lymph nodes, spleen, bone marrow and red blood cells is the use 
of a low specific activity, whereby the excess of unlabeled compound is used to saturate 
CXCR4 in non-tumor tissue.71,101 With the addition of such background reductions, tumor 
accumulation of T140 derivatives has been proven to be CXCR4 specific. This was 
corroborated with low CXCR4-expressing tumors or blocking with high amounts of 
unlabeled compound. 
The distribution and pharmacokinetics of T140 derivatives can be worsened or 
improved by imaging labels. Hydrophobic fluorescent dyes tend to cause more nonspecific 
uptake and result in slow clearance via the liver, whereas hydrophilic chelates reduce 
nonspecific uptake and promote fast renal clearance.
Cell lines and tumor models
The cell lines and tumor models used in the preclinical evaluation process have a 
large influence on the obtained results. To eliminate the variation caused by the use of 
different cell lines/tumor models, derivatives are best compared in an identical set-up. 
Direct comparison of the reported tumor accumulation in vivo is nearly impossible, as 
high levels of tumor accumulation can be ascribed to the potency of the imaging agent and/ 
or to the tumor model used. Comparative results, where the same imaging agent was used 
in different tumor models showed that uptake levels and T/M ratios were highest in the 
tumor models with the highest CXCR4 expression levels. Expectedly T/M ratios obtained in 
e.g. the transplantation-based MIN-O tumor model with a more clinically relevant CXCR4 
expression level were clearly lower. This observation is in line with results reported by Cai 
et.al. who showed a linear correlation between tracer uptake and receptor expression.107
A combination of high and low expressing models during the evaluation may result 
in a more optimal selection procedure for new imaging compounds. Where transfected 
models can be used for a black-and-white evaluation of the specificity of an imaging 
agent, models that more accurately represent the modest five-fold overexpression found 
in the clinical situation can best be used for evaluation of its potential clinical utility.  
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Conclusion
The T140 peptide family provides a number of interesting candidates for the 
visualization of CXCR4 expression using fluorescent-, radio-, and hybrid- imaging labels. 
Hereby the label and its placement on the parental peptide have a large influence on the 
affinity, specificity and distribution of the imaging agents. Important in investigations 
regarding the imaging potential of CXCR4 targeted imaging agents is the clinical challenge 
that such compounds are meant to help solve. We found that only in a very limited number 
of studies the biological evaluation had taken place using representative tumor models.
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Abstract 
Pathology is fundamental in the evaluation of tumor grade and stage, and in 
treatment planning of malignancies. Direct fluorescent labeling of the peptide Ac-TZ14011 
with the fluorescent dye FITC, provides an alternative to conventional immuno-
histochemistry for the detection of CXCR4 in cells and tumor tissue. The use of 
Ac-TZ14011-FITC for staining of the chemokine receptor 4 (CXCR4) in human breast 
cancer cell lines MDAMB231 and MDAMB231CXCR4+ was evaluated during flow cytometric 
analysis. Staining specificity was validated via competition experiments and the efficacy 
of Ac-TZ14011-FITC was compared to commercially available antibodies. Confocal 
imaging revealed that CXCR4 staining was predominantly found on the cell membrane 
and/or in vesicles formed after endocytosis. Ac-TZ14011-FITC was able to differentiate 
MDAMB231 from MDAMB231CXCR4+ tumor cells and tumor tissue, proving its applicability 
in the detection of relatively small differences in levels of CXCR4 expression.
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Introduction 
Besides expression of the chemokine receptor 4 (CXCR4) in normal tissues, 
overexpression of CXCR4 has been reported for at least 23 types of cancer. A 5.5-fold 
upregulation of CXCR4 expression was found in breast cancer tissue1-3 Overexpression of 
CXCR4, and/or its natural ligand stromal-derived factor 1 (SDF-1), has been correlated to 
worsened prognosis and disease-free survival.4-6 Due to its important role in the malignancy/
metastasis of cancer, CXCR4 is considered a candidate biomarker for evaluating cancer 
progression and perhaps the selection/monitoring of treatment strategies. 
Recently, a lot of effort has been focused on the development of CXCR4 specific 
antagonistic peptides.7,8 Small peptides, such as T140 and its derivative Ac-TZ14011, were 
selected based on their antagonistic properties towards the CXCR4 receptor and their 
potential for treatment.10 These and several other peptide derivatives have been used to 
reduce cell proliferation and migration in vitro and to cause inhibition of primary tumor 
growth and tumor metastasis in vivo.8-14 A useful property of the Ac-TZ14011 peptide is 
that it has one free lysine group situated at a significant distance from the pharmacophore 
allowing functionalization with a single diagnostic antenna. For example, an 111Indium 
labeled DTPA-Ac-TZ14011 derivative has shown potential for use in non-invasive imaging 
of CXCR4 in vivo.14,15
As CXCR4 is part of a family of membrane bound G protein-coupled receptors, 
staining of the cell surface membrane could be considered most representative. However, 
immunohistochemistry (IHC) on breast cancer tissue using antibodies directed against 
CXCR4 has shown staining of the cell surface membrane, the cytoplasm, and the nucleus 
of the cell.4-6,8,16-18 Such differences in localization and the natural role of CXCR4 may 
present actual changes in the localization of the receptor or may be caused by the staining 
techniques used. Another downside of using antibodies for IHC is that the agent used for 
detection will differ from the peptides used in vivo. 
Ideally ex vivo validation is performed using an agent that accurately resembles the 
compound used for imaging. Nishizawa et al. have demonstrated the value of the 
fluorescein labeled T140 derivative TY14003 in the detection of high-grade bladder 
cancer.19 Hence we reasoned that a fluorescent derivative of Ac-TZ14011 (Ac-TZ14011-
FITC) can also potentially be used for fluorescent IHC (FIHC) of breast tumor tissue. 
In this Chapter Ac-TZ14011-FITC was used for FIHC to detect CXCR4 in MDAMB231 
and MDAMB231CXCR4+ cells and tumor tissue. The efficacy of Ac-TZ14011-FITC in staining 
CXCR4 was compared to that of commercially available anti-CXCR4 antibodies. 
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Materials and Methods
Cell culture   
Human breast cancer cell lines MDAMB231 and MDAMB231CXCR4+ were kindly 
provided by Olaf van Tellingen and Ed Roos (NKI-AvL, Amsterdam, The Netherlands), 
respectively. In the MDAMB231CXCR4+ cells CXCR4 expression was upregulated after culture 
under hypoxic conditions. Cells with high CXCR4 expression were selected using flow 
cytometry, resulting in the MDAMB231CXCR4+ cell line. MDAMB231 cells were used as control 
based on their basal CXCR4 expression. Both cell lines were maintained in Gibco’s 
minimum essential medium (MEM) enriched with 10% fetal bovine serum, Penicillin, 
Streptomycin, L-glutamine, non-essential amino acids, sodium pyruvate, and MEM 
vitamins solution (all Life Technologies Inc.). Cells were kept under standard culture 
conditions.
Flow cytometry
Cell staining: determination of the specificity of Ac-TZ14011-FITC for CXCR4
Freshly cultured MDAMB231 or MDAMB231CXCR4+ cells were trypsinized, washed with 
0.1% bovine serum albumin in phosphate buffered saline (0.1% BSA/PBS) and then 
incubated for one hr with monoclonal phycoerythrin (PE) labeled anti-CXCR4 antibody 
(12G5-PE (1:5) or 2B11-PE (1:100); BD Biosciences) or with Ac-TZ14011-FITC (1:200; for the 
preparation of Ac-TZ14011-FITC see the Annex of Chapter 9). Cells were labeled on ice or 
at room temperature (RT). Following incubation, cells were washed with 0.1% BSA/PBS 
and five min prior to analysis, propidium iodide (PI; 1:10,000; BD Biosciences) was added 
to distinguish live and dead cells.  
For fixed cell conditions, cells were trypsinized, washed with 0.1% BSA/PBS, and fixed 
with formalin overnight, again washed with 0.1% BSA/PBS and incubated for one hr with 
12G5-PE, 2B11-PE or Ac-TZ14011-FITC on ice, followed by washing with 0.1% BSA/PBS. 
Peptides and antibodies were diluted in 0.1% BSA/PBS in all flow cytometry 
experiments. Non-antibody/peptide incubated cells served as controls.
Cell-staining: SDF-1 and Ac-TZ14011 competition experiment 
One hr prior to the start of the experiment, MDAMB231 or MDAMB231CXCR4+ cells 
were given fresh culture medium. Following trypsinization, 6.0 x 106 cells/mL were 
incubated for one hr on ice with 12G5-PE and SDF-1 (Peprotech via Bio Connect; [8.87 
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nM]), Ac-TZ14011-FITC and SDF-1 ([0.67 µM]) or Ac-TZ12011-FITC and unlabeled Ac-
TZ14011 ([0.67 µM] and [6.70 µM], respectively). Cells were washed with 0.1% BSA/PBS. PI 
was added before cells were analyzed. 
Cell-staining: SDF-1 block experiment
One hr prior to the start of the experiment, MDAMB231 or MDAMB231CXCR4+ cells 
were given fresh culture medium. After trypsinization, 2.0 x 106 cells/mL were incubated 
for 90 min at 37°C with 1.5 µg SDF-1  in culture medium. SDF-1 was removed by 
centrifugation (five min, 1200 rpm, 4°C), and cells were resuspended at 6.0 x 106 cells/mL 
before incubation on ice for one hr with 12G5-PE or Ac-TZ14011-FITC. Hereafter, cells were 
washed with 0.1% BSA/PBS, PI was added and cells were analyzed. 
Flow cytometry settings
After staining, cells were analyzed using a Beckton Dickinson FACScalibur device (BD 
Biosciences) equipped with Cell Quest Pro software (BD Biosciences). FITC fluorescence 
was detected in the FL1 channel (excitation 488 nm; emission filter 585/42 nm). PE 
fluorescence was detected in the FL2 channel (excitation 488 nm; emission filter 530/30 
nm). PI was detected in the FL3 channel (excitation 488 nm; emission filter > 670 nm). 
Mean fluorescence signal intensity ratio’s (MFIRs) were calculated by dividing the 
mean fluorescent signal intensity of the antibody or peptide incubated condition by the 
mean fluorescent signal intensity of the control condition. To determine statistical 
significance between the different cell lines (Table 1) or the different incubation conditions 
(Table 2 and 3), a standard T-test was performed. All experiments were performed at least 
in triplicate. 
Generation mouse tumor models
Prior to injection in vivo, cells were washed three times with Hank’s buffered salt 
solution (HBSS; Life Technologies) and resuspended in HBSS to a final concentration of 
50.0 x 106 cells/mL and kept on ice.
Six to eight week old female Balb/c nude mice were anaesthetized with a mixture of 
hypnorm (Vetapharma), dormicum (Roche Diagnostics GmbH) and water suitable for 
injection (1:1:2; 5µL/gr intraperitoneal). 1.0 x 106 MDAMB231 or MDAMB231CXCR4+ cells 
were injected into the left inguinal mammary fat pad. As CXCR4 expression in the lymph 
nodes is intrinsically high, the left inguinal lymph node was cleared before injection of the 
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tumor cells, hereby creating a low background niche at the site of injection. Six to eight 
weeks following transplantation, mice were sacrificed and primary tumors (~ 4 cm3) were 
taken out (n = 20). Hereafter, fresh tumor tissue could be directly stained and analyzed or 
formalin-fixed and paraffin-embedded prior to staining (IHC and fluorescence IHC (FIHC)).
All animal experiments were performed in accordance with Dutch animal welfare 
regulations and approved by the local ethics committee.
Immunohistochemistry
Four micron formalin-fixed paraffin-embedded MDAMB231 or MDAMB231CXCR4+ 
tumor tissue sections were deparaffinized. Sections were heated for 30 min at 95˚C in 
citrate buffer (pH 6) to retrieve antigenic activity, followed by 30 min cooling at RT. For 
antigen retrieval, slides were incubated for 30 min with protein kinase or 20 min with 
trypsin at 37°C or heated for 30 min at 95°C in TRIS/EDTA (pH 9) followed by 30 min cooling 
at room temperature (RT). Slides were rinsed with PBS and incubated overnight at 4˚C 
with an monoclonal anti-CXCR4-antibody (clone 2B11 (1:100) (n= 5 - 10) or clone 12G5 
(1:100) (n = 3); BD Biosciences). After washing, slides were incubated for one hr at RT with 
the secondary antibody, goat-anti-rat (sc-2041; 1:100; Santa Cruz Technology) or with 
goat-anti-mouse (E0433; 1:500; DAKO) for clone 2B11 and 12G5, respectively. Negative 
controls were only incubated with the secondary antibody. Hereafter slides were washed, 
incubated for 30 min with horseradish-peroxidase-labeled StreptAvidin-Biotin Complex 
(HRP-sABC; 1:200; DAKO), developed with 3,3’-diamobenzidine tetrahydrochloride (DAB; 
Sigma-Aldrich) and slightly counterstained with haematoxylin (Sigma-Aldrich). Images 
were taken with a color CCD microscope system (Axiovert S100 with AxioCam HRc, Carl 
Zeiss) and analyzed using AxioVision (Carl Zeiss). 
Confocal imaging
Fluorescent immunohistochemistry of formalin-fixed paraffin-embedded tumor tissue
Following deparafinization, antigen retrieval incubation and three PBS washes (as 
described in the IHC section), slides were incubated for one hr at RT with Ac-TZ14011-FITC 
(1:200) (n = 3). Slides were washed with PBS, counterstained with 4’,6-diamidine-2’-
phenylindole dihydrochloride (DAPI; 1:1000; Roche Diagnostics GmbH) and washed 
thoroughly. Negative controls were only incubated with DAPI. Slides were mounted with 




24 - 48 Hrs prior to the start of the experiment, 1.0 x 105 MDAMB231 and 
MDAMB231CXCR4+ cells were seeded onto coverslips (Ø 24 mm; Karl Heicht GmbH&Co). 
When 80% confluency was reached, cells were washed with PBS and incubated with Ac-
TZ14011-FITC (1:200) for one hr on ice or at RT and washed again with ice cold PBS. Cells 
were kept on ice until analysis. For evaluation of internalization, images were taken at t = 
0, 15, 30 and 60 min.
For fixed cell conditions, cells were fixed with formalin overnight, washed with PBS 
and then incubated for one hr on ice with Ac-TZ14011-FITC. Confocal images were taken 
after washing with ice cold PBS. Non-peptide incubated slides served as negative control.
Ex vivo fluorescent tumor tissue imaging 
MDAMB231 or MDAMB231CXCR4+ tumor-bearing mice were sacrificed, and excised 
tumor tissue was formalin-fixed for 24 hrs (n = 3). Tissue slices were incubated for one hr 
with Ac-TZ14011-FITC (1:200) followed by washing with PBS and incubation with DAPI 
(1:1000) for 10 min and again thoroughly washed with ice cold PBS. 
Ex vivo detection after intravenous administration of Ac-TZ14011-FITC
MBAMB231 or MDAMB231CXCR4+ tumor-bearing mice were intravenously injected 
with 50 µg Ac-TZ14011-FITC (n = 3). 24 hrs after injection, mice were sacrificed, tumors 
were excised and kept on ice in PBS. Thin slices were cut, washed with ice-cold PBS and 
incubated for ten min with DAPI and again thoroughly washed before images were taken. 
Furthermore, excised tissue was formalin-fixed on ice for three hrs, cut into thin slices and 
washed with ice cold PBS and incubated with DAPI before imaging. Controls were only 
incubated with DAPI.
Confocal microscope properties
Confocal images were taken on a Leica TCS-SP2-AOBS Live confocal microscope 
(Leica Microsystems; magnification 400x / 630x) and a Leica TCS-NT confocal microscope 
(Leica Microsystems; magnification 630x). DAPI was excited at 405 nm and emission was 
detected between 409 - 468 nm. FITC was excited at 488 nm and emission was detected 
between 510 - 585 nm. Leica Confocal Software was used to analyze the images. 
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Results  
A FITC labeled antagonistic CXCR4 peptide, Ac-TZ14011-FITC, was investigated for 
use in the direct fluorescence-based visualization of CXCR4 expression levels in 
MDAMB231 and MDAMB231CXCR4+ cells and tumors derived thereof.
Determination of the specificity of Ac-TZ14011-FITC for CXCR4
The specificity of Ac-TZ14011-FITC for CXCR4 was validated using flow cytometric 
analysis. The MFIR of MDAMB231CXCR4+ (high level of CXCR4 expression) was 2.4-fold higher 
(p = 0.0003) compared to MDAMB231 cells (low level of CXCR4 expression) when live cells 
were incubated on ice with Ac-TZ14011-FITC (Table 1). However, after incubation at RT, 
only a 1.7-fold higher signal intensity could be detected (p = 0.04; Table 1). PE labeled anti-
CXCR4 antibody clones 12G5 or 2B11 (referred to as 12G5-PE or 2B11-PE, respectively) 
were used as a reference. After incubation with 12G5-PE a 4.4-fold higher MFIR could be 
detected in MDAMB231CXCR4+ cells compared to MDAMB231 cells (Table 1; P = 0.01). 
Incubation at RT resulted in a 7.5-fold higher MFIR (P = 0.0012). For 2B11-PE the measured 
difference in MFIR was only 1.3-fold (P = 0.003) and 1.2-fold (P = 0.0035) higher when 
incubated on ice or at RT.  
When formalin-fixed cells were stained with Ac-TZ14011-FITC, signal intensities and 
thereby the MFIRs increased for both MDAMB231 (MFIR = 25.788 ± 1.575) and 
MDAMB231CXCR4+ (MFIR = 62.357 ± 7.920) cells. However, the ratio between the two 
remained identical to that in live cells incubated on ice, namely 2.4 (P < 0.0001). Significant 
differences could no longer be detected when formalin-fixed MDAMB231 and 
MDAMB231CXCR4+ cells were incubated with 12G5-PE (MFIRs 7.380 ± 3.573 and 11.046 ± 
2.143; P = 0.22) or 2B11-PE (MFIRs 18.814 ± 6.636 and 13.378 ± 3.267; P = 0.29; Table 1). 
Ac-TZ14011 competition experiment
When cells were co-incubated with a 100-fold excessive amount of unlabeled Ac-
TZ14011 and Ac-TZ14011-FITC, the MFIR of MDAMB231CXCR4+ cells decreased with 57% (P 
= 0.0041; Table 2) indicating a higher affinity for Ac-TZ14011. The latter is in line with the 
slight decrease in affinity seen after functionalization of Ac-TZ14011 with other 
fluorophores.8
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Live cells; on ice 1.116 ± 0.054 4.920 ± 1.463 4.4*
Live cells; RT 1.160 ± 0.108 8.747 ± 1.245 7.5**
Fixed cells; on ice 7.380 ± 3.573 11.046 ± 2.143 1.5
2B11-PE
Live cells; on ice 1.179 ± 0.072 1.487 ± 0.051 1.3**
Live cells; RT 1.206 ± 0.047 1.435 ± 0.042 1.2**
Fixed cells; on ice 18.814 ± 6.636 13.378 ± 3.267 0.7
Ac-TZ14011-FITC
Live cells; on ice 2.337 ± 0.341 5.505 ± 0.900 2.4**
Live cells; RT 2.970 ± 0.289 4.941 ± 0.487 1.7*
Fixed cells; on ice 25.788 ± 1.575 62.357 ± 7.920 2.4**
For significance: MDAMB231 MFIRs were compared to MDAMB231CXCR4+ MFIRs; *P = < 0.05; **P = < 0.005; MFIR = 
mean fluorescent intensity ratio; SD = standard deviation; RT = room temperature; n = 3 - 6.
SDF-1 competition experiment
In further competition experiments a corresponding amount of SDF-1 was added to 
occupy the CXCR4 receptors, hereby preventing binding of Ac-TZ14011-FITC to the 
receptor. In the presence of Ac-TZ14011-FITC and SDF-1, a decrease of 33% was seen in 
the MFIR in MDAMB231CXCR4+ cells compared to cells who were incubated with Ac-TZ14011-
FITC alone (P = 0.002). Co-incubation of 12G5-PE and SDF-1 resulted in an 8% decrease in 
the MFIR in MDAMB231CXCR4+ cells (P = 0.13). No significant change in MFIR was seen in 
MDAMB231 cells (Table 2). 
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Table 2. Competition of antagonistic Ac-TZ14011-FITC with SDF-1 and Ac-TZ14011 for the CXCR4 receptor.
Cell type
MDAMB231 MDAMB231CXCR4+
MFIR ± SD % MFIR ± SD %
12G5-PE 1.134 ± 0.033 2.186 ± 0.048
SDF-1 + 12G5-PE 1.174 ± 0.009 + 3 2.015 ± 0.080 - 8
Ac-TZ14011-FITC 1.900 ± 0.049 6.905 ± 0.174
SDF-1 + Ac-TZ14011-FITC  2.010 ± 0.044 + 6 4.643 ± 0.339 - 33**
Ac-TZ14011 + Ac-TZ14011-FITC 2.266 ± 0.095 + 19* 2.985 ± 0.291 - 57**
For significance: 12G5-PE/Ac-TZ14011-FITC MFIRs were compared to MFIRs of SDF-1/unlabeled Ac-TZ14011 + 
12G5-PE/Ac-TZ14011-FITC incubated conditions; *P = < 0.05; **P = < 0.005; % = Percentage change in fluorescent 
signal intensity; MFIR = mean fluorescence intensity ratio; SD = standard deviation; n = 3.
SDF-1 block experiment
The CXCR4 receptor internalizes upon binding of SDF-1 resulting in clearance from 
the membrane.27,30 To study this effect, MDAMB231CXCR4+ cells were preincubated for 1.5 hrs 
with SDF-1 at 37°C. After removal of the excess SDF-1 in solution, cells were incubated 
with 12G5-PE or Ac-TZ14011-FITC for one hr on ice to determine the amount of available 
membranous CXCR4. As can be seen in Table 3, preincubation of MDAMB231CXCR4+ cells 
with SDF-1 followed by incubation with Ac-TZ14011-FITC resulted in a 29% decrease in 
MFIR compared to incubation with Ac-TZ14011-FITC alone (P = 0.0037). The MFIR 
decreased with 14% after preincubation with SDF-1 followed by 12G5-PE incubation (P = 
0.0043). Possibly this indicates that a significant number of the available CXCR4-receptors 
internalized after binding SDF-1, hereby preventing binding of Ac-TZ14011-FITC and 
12G5-PE.
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Table 3: blocking of CXCR4 with SDF-1  
Cell type
MDAMB231CXCR4+
MFIR ± SD %
12G5-PE 1.485 ± 0.018
SDF-1 + 12G5-PE 1.274 ± 0.033 - 14**
Ac-TZ14011-FITC 5.184 ± 0.144
SDF-1 + Ac-TZ14011-FITC  3.699 ± 0.034 - 29**
For significance: 12G5-PE/Ac-TZ14011-FITC MFIRs were compared to MFIRs of SDF-1 + 12G5-PE/Ac-TZ14011-
FITC incubated conditions; *P = < 0.05; **P = < 0.005; % = Percentage change in fluorescent signal intensity; MFIR 
= mean fluorescence intensity ratio; SD = standard deviation; n = 3.
Ac-TZ14011-FITC distribution in cultured tumor cells
Cellular localization of the CXCR4 receptor was evaluated using confocal imaging. As 
Figure 1A shows, only a faint membranous staining could be detected on MDAMB231 cells 
(i), whereas the degree of membranous staining in MDAMB231CXCR4+ cells was much higher 
(ii). Longitudinal imaging (t = 0 – 60 min; Figure 1C) revealed progressive internalization of 
the fluorescence signal into the cell. Here endocytosis resulted in internalization of Ac-
TZ14011-FITC in vesicle like structures visible in the cytoplasm. 
Incubation of formalin-fixed cells with Ac-TZ14011-FITC yielded an entirely different 
staining pattern. Ac-TZ14011-FITC, was found throughout the entire cell, in both MDAMB231 
(Figure 1Bi) and MDAMB231CXCR4+ (Figure 1Bii) cells. However, the staining of MDAMB231CXCR4+ 
cells was more intense than that of MDAMB231 cells, which is in line with the higher MFIR 
seen with flow cytometric analysis of cells under fixed conditions (Table 1). 
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Figure 1. Ac-TZ14011-FITC distribution in live and formalin-fixed MDAMB231 and MDAMB231CXCR4+ tumor cells. 
A) Live MDAMB231 and MDAMB231CXCR4+ cells were incubated with Ac-TZ12011-FITC for one hr on ice. B) 
Formalin-fixed cells were incubated for one hr with Ac-TZ12011-FITC on ice. C) MDAMB231CXCR4+ cells were 
incubated for one hr with Ac-TZ12011-FITC on ice, and confocal images were taken (t = 0 min). Over time, Ac-
TZ12011-FITC-CXCR4 receptor complexes internalized via vesicles (t = 15 - 60 min). Magnification 630x. 
(F)IHC
Standard IHC was performed on formaline-fixed paraffin-embedded tissue to 
determine the CXCR4 expression level in tumor tissue. Using the 12G5 antibody, only a 
minor degree of staining could be detected in the MDAMB231 tumor tissue. MDAMB231CXCR4 
tumor tissue however, stained brownish all over but no clear cytoplasmic or membranous 
staining could be discriminated. Control tumor tissue (only incubated with secondary 
antibody) showed a similar staining pattern (data not shown). Therefore these results 
were deemed non-specific. Use of different antigen retrieval methods did not result in 
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visualization of specific staining of the tissue (data not shown). Incubation of 
MDAMB231CXCR4 tissue with the 2B11 antibody resulted in strongly positively stained 
regions. In these regions, both membranous and cytoplasmic staining could be detected 
(Figure 2Bii). In comparison, little to no staining was detected on MDAMB231 tumor tissue 
(Figure 2Bi). The negative control slides showed no non-specific staining.
Incubation with Ac-TZ14011-FITC was initially also performed on formalin-fixed 
paraffin-embedded tumor tissue. MDAMB231 tumor tissue showed strong non-specific 
staining in the nuclear membrane, nucleoli and connective tissue (Figure 2Ci). 
MDAMB231CXCR4+ tumor tissue slides showed a somewhat different staining profile with 
predominantly cytoplasmic and membranous staining (Figure 2Cii). 
When tumor tissue was not paraffin embedded, but only formalin-fixed for 24 hrs, 
incubation with Ac-TZ14011-FITC resulted in more intense staining of MDAMB231CXCR4+ 
tumor tissue (Figure 2Dii) compared to MDAMB231 tumor tissue (Figure 2Di). This result is 
in line with the difference in staining observed with 2B11 (Figure 2Bi and ii). However, as 
can be seen in Figure 2Di and ii, staining was detected throughout the entire cell and 
staining was not confined to the membrane and cytoplasm. This staining pattern in fixed 
tissue was highly similar to that observed in fixed cells (Figure 1Bi and ii). 
FIHC of tumor tissue after intravenous administration of Ac-TZ14011-FITC in mice
Alternatively to ex vivo incubation of tissue, Ac-TZ14011-FITC can also be used for 
in vivo tumor staining (Figure 3). After intravenous administration, MDAMB231CXCR4+ 
tumor tissue slices showed positive staining for CXCR4 (Figure 3Bii). In MDAMB231 
tumor tissue (Figure 3Bi) hardly any CXCR4 staining was observed.
Formalin fixation of Ac-TZ14011-FITC preincubated tissue  predominantly revealed 
cytoplasmic staining for CXCR4 in MDAMB231CXCR4+ tumor tissue slices (Figure 3Cii) 
where MDAMB231 tumor tissue again stained weakly positive (Figure 3Ci). Importantly, 
the background signal found on formalin-fixed tumor tissue slices was relatively low 
(data not shown). 
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Figure 2. Predominant cytoplasmic CXCR4 expression on formalin-fixed paraffin-embedded and freshly isolated, 
formalin-fixed, breast cancer tissue. A) Formalin-fixed paraffin-embedded slides were incubated with the primary 
anti-CXCR4-antibody clone 12G5, B) primary anti-CXCR4-antibody clone 2B11 (Magnification 400x. n = 5 - 10); or 
C) incubated with Ac-TZ12011-FITC. Magnification 630x. n = 3 D) Freshly isolated, formalin-fixed tumor tissue 
incubated with Ac-TZ12011-FITC showed a different staining pattern. Magnification 630x. n = 3  
 
Figure 3. Predominantly cytoplasmic CXCR4 expression in in vivo Ac-TZ12011-FITC incubated MDAMB231CXCR4+ 
tumor tissue. A) Schematic overview of the principle of intravenously Ac-TZ14011-FITC incubation: 1. Mice were 
sacrificed and the tumor was isolated 24 hrs after 50 µg Ac-TZ14011-FITC was intravenously injected; 2. Tumors 
were cut into thin slices and placed on a coverslip. Hereafter confocal images were taken. B) Confocal images of 
live tumor tissue. Magnification 630x. Staining in controls was less profound (data not shown). C) Freshly isolated 
tumor tissue was formalin-fixed and imaged. Magnification 400x. Controls showed no staining (data not shown). 
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Discussion 
Pathology, or rather IHC, is considered the golden standard in the assessment of 
tumor tissue. In this Chapter the potential of the fluorescent peptide Ac-TZ14011-FITC for 
evaluation of CXCR4 expression was evaluated. Other than conventional antibody based 
IHC procedures, this fluorescent derivative of Ac-TZ14011 may in the future be used to 
visualize exactly the same features at FIHC as can be detected with non-invasive SPECT 
imaging using the radioactive derivative 111In-DTPA-Ac-TZ14011.
CXR4 overexpressing cell lines rather than CXCR4 transfected cell lines
The CXCR4 negative and positive cell lines used show a small (factor 2.4 - 7.5) 
difference in CXCR4 expression levels (Table 1). Clearly, this minor difference makes it 
more difficult to differentiate between these two cell lines using FIHC. This is especially so 
because the MDAM231 cell line cannot be considered completely CXCR4 negative, but 
has a low or basal CXCR4 expression. CXCR4 transfected and/or down regulated cell lines 
would make the differences much clearer. However, we reasoned that differences in 
clinical breast tumor samples would also be marginal, as an up regulation factor of 5.5 has 
been reported.1 
Due to this similarity in overexpression, we consider the difference between our 
MDAM231 cell lines more representative for the clinical situation and thus this experimental 
set-up may better predict the potential clinical value of the approach.
Selectivity of Ac-TZ14011-FITC for CXCR4
Ac-TZ14011-FITC was able to discriminate between MDAMB231 and MDAM231CXCR4+ 
cells (Table 1). Selectivity of Ac-TZ14011-FITC was further evaluated via competition with 
the natural ligand for CXCR4, SDF-1. Both competition and blocking experiments showed 
a reduction in binding of Ac-TZ14011-FITC (Table 2 and 3). From these results it can be 
concluded that SDF-1 has a higher affinity for CXCR4 than Ac-TZ14011-FITC, which is in 
accordance with results found by Nomura et al.20 For the antibody 12G5-PE, no significant 
reduction in uptake during a competition experiment with SDF-1 was seen, suggesting 
both can simultaneously interact with CXCR4. 
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Cellular localization of CXCR4
Using different antibodies, positive staining of the cell membrane, the cytoplasm 
and even the nucleus has been reported.4-6,16,17,21-23 However, as previously mentioned by 
Fischer et al.22 and Kryczek et al.,23 nuclear localization would not be compatible with 
CXCR4 being a membrane receptor and its function in cancer cell migration and homing. 
Hence membranous staining is considered most representative. Identical to results 
published by Nomura et al20 and Zhang et al.24 we found that Ac-TZ14011-FITC 
predominantly bound to CXCR4 on the cell membrane (Figure 1A) when live cells were 
incubated with Ac-TZ14011-FITC. Furthermore, membrane Ac-TZ14011-FITC-CXCR4 
complexes internalized into the cell in cytoplasmic vesicles over time (Figure 1C).20,25 
Distribution of Ac-TZ14011-FITC throughout the entire cell was only observed when 
fixed cells or tissues were incubated. These results suggest fixation may influence the 
distribution of the agent used for staining. 
Viable vs. fixed material
Confocal images helped resolve questions about the difference in signal intensity 
seen with flow cytometry between live and fixed cells (Figure 1 and Table 1). The 
distribution of Ac-TZ14011-FITC in fixed cells, wherein the whole cell was stained, was 
completely different from the distribution observed in viable cells. Formalin slightly 
permeabilizes the cell membranes, which might induce cellular and nuclear uptake of Ac-
TZ14011-FITC. Although the fixed cells were positively stained all over, the staining 
intensity of MDAMB231CXCR4+ cells was more intense than seen in MDAMB231 cells, which 
is in accordance with the results obtained with flow cytometry (Table 1). Fixation artifacts 
may also be of influence on the distribution patterns of Ac-TZ14011-FITC observed at IHC. 
The latter may thus not accurately represent the CXCR4 expresssion patterns in viable 
tissue.
In addition to fixation, paraffinization also had a negative influence on the peptide-
based staining (Figure 2). A clear differentiation could, however, be made on only formalin-
fixed tissue (Figure 2D).
 
Antibodies vs. peptides
Anti-CXCR4 antibody clones 12G5 and 2B11 were used as reference in both flow 
cytometric analysis and IHC. These antibodies differ in the type of CXCR4 that they 
recognize; where antibody 12G5 recognizes human origin CXCR4, antibody 2B11 is 
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directed against murine CXCR4. With flow cytometric analysis using viable cells, antibody 
12G5-PE was able to nicely distinguish MDAMB231 from MDAMB231CXCR4+ cells, while 
antibody 2B11-PE did not perform as well (Table 1). However, when the cells were fixed, 
the antibodies were unable to distinguish the two cell lines based on their CXCR4 
expression levels. Surprisingly, in IHC an opposite effect was observed; anti-murine 2B11 
antibody gave specific staining on the human-originated MDA tumors while anti-human 
12G5 antibody did not (Figure 2Ai and ii). This observation underlines that antibodies are 
not always interchangeable between different detection viz. flow cytometric analysis and 
IHC, whereas Ac-TZ14011-FITC peptide can be used in both cases.
To overcome the need to use different antibodies for different applications (e.g. flow 
cytometric analysis and IHC staining), Ac-TZ14011-FITC can be used. This peptide showed 
corresponding results in studies on cells and tumor tissue (Table 1 and Figures 1B and 2D). 
Clearly this will be most beneficial for evaluation of the more ‘experimental’ biomarkers 
such as CXCR4. Multispectral FIHC could even allow simultaneous detection of multiple 
biomarkers at once.
The main advantage of using peptides for IHC visualization of CXCR4 is that it makes 
it easier to directly correlate IHC stainings to imaging findings obtained with e.g. the 
111In-DTPA-Ac-TZ14011 analogue. Such a combination of differently labeled derivatives of 
the same peptide sequence would improve the integration of in vitro and in vivo 
diagnostics. A similar approach may be achieved using a combination of e.g. 125I-12G5 and 
12G5-PE.25 However, use of antibody takes away the advantages small molecules such as 
peptides have. 
Signal intensity differences obtained in flow cytometry varied between 12G5-PE and 
Ac-TZ14011-FITC (Table 1). While the latter showed significant differences under all 
the conditions studied, 12G5-PE showed larger differences between the live conditions 
studied in MDAMB231 and MDAMB231CXCR4+ cells. This result suggests that with 
Ac-TZ14011-FITC there is somewhat more nonspecific cellular uptake than with 12G5-PE.
Ex vivo visualization of CXCR4 expression in tumor tissue
During ex vivo (F)IHC, the peptide/antibody has access to the whole tumor tissue 
slide and, therefore, is able to stain all CXCR4 present. Intravenously administrated 
Ac-TZ14011-FITC (Figure 3) predominantly has access to the blood supplied areas of the 
tumor and will only provide a specific signal after binding to membranous CXCR4 (Figure 
1C and 3B), resulting in a more local staining. 
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Intravenous administration of Ac-TZ14011-FITC
To overcome the fixation artifacts seen in fixed cells and tumor tissue, and to study 
CXCR4 expression of the tumor tissue in its most natural environment, Ac-TZ14011-FITC 
was intravenously administrated to tumor-bearing mice (Figure 3A). Analysis of the freshly 
isolated tissue before or after fixation, revealed stronger staining of the cytoplasm of 
MDAMB231CXCR4+ tumor tissue as compared to MDAMB231 tumor tissue (Figure 3B and C). 
In line with the results obtained with viable tumor cells at RT (Figure 1C) the staining in the 
tumor cells was intracellularly localized after the incubation period. Furthermore, the 
intravenous administration of Ac-TZ14011-FITC visualized the staining efficacy that may 
be predictive for the molecular imaging agent 111In-DTPA-Ac-TZ14011. This illustrates how 
the Ac-TZ14011 peptide (and perhaps many others), in combination with different 
diagnostic antennae, can in the future be used to directly correlate in vivo findings with ex 
vivo staining.  
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Conclusion
The present study illustrates the value of Ac-TZ14011-FITC to identify tumor cells 
with slight levels of CXCR4 overexpression in both FIHC and flow cytometric applications. 
Where results with antibodies rely on employment of different antibodies for different 
applications, Ac-TZ14011-FITC is applicable in vitro, in vivo and even ex vivo, broadening 
the applicability of the peptide.
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The antagonistic CXCR4 peptide, Ac-TZ14011, was synthesized as described 
previously.1 Fluorescein isothiocyanate isomer I (FITC; 2.32 mg, 5.95 μmol) in 500 μL of 
dimethyl sulfoxide was added to the antagonistic CXCR4 peptide (11.1 mg, 3.96 μmol) in 
1 mL of 0.1 M NaHCO3 (Merck) and 2 mL of CH3CN (Acros, Belgium). The mixture was stirred 
overnight at room temperature (RT), solvents were evaporated and the product was 
purified by preparative HPLC using a Waters HPLC system with a UV detector operating at 
230 nm and a Waters Atlantis C18 10 μm column using a gradient of 0.05% trifluoroacetic 
acid (TFA; Sigma-Aldrich) in H2O/CH3CN 9:1 to 0.05% TFA in H2O/CH3CN 1:4 in 40 min. A 
yellow fluffy solid (4.3 mg, 35%) was obtained after lyophilization of the pooled fractions 
and characterized by MALDI-TOF-MS. 
The fluorescein labeled CXCR4 peptide antagonist will be reverted to as Ac-TZ14011-
FITC. All experiments were performed in the absence of light when fluorescent labels 
were used. 
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Non-invasive longitudinal imaging 
of tumor progression using an 111Indium 
labeled CXCR4 peptide antagonist
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Abstract 
CXCR4 targeted (molecular) imaging approaches may have diagnostic value in the 
detection of premalignant lesions such as ductal carcinoma in situ (DCIS). To this end, the 
indium labeled CXCR4 peptide antagonist, 111In-DTPA-Ac-TZ14011, was used to detect 
CXCR4 in a mammary intraepithelial neoplastic outgrowth (MIN-O) mouse tumor model 
that resembles human DCIS. MIN-O lesion development was longitudinally monitored 
using single photon emission tomography/computed tomography (SPET/CT). Tracer 
uptake was compared to uptake in low CXCR4 expressing 4T1 control lesions. Expression 
of CXCR4 was validated using immunohistochemistry (IHC) and flow cytometric analysis. 
The uptake of 111In-DTPA-Ac-TZ14011 was related to tumor angiogenesis using 111In-
c[RGDfK]-DTPA. Twenty-four hrs after tracer injection, MIN-O lesions could be discriminated 
from the low CXCR4 expressing control tumor lesions, while the degree of angiogenesis 
(based on the αvβ3 integrin expression) was similar in both tumor types. The uptake of 
111In-DTPA-Ac-TZ14011 in early stage MIN-O lesions was significantly lower than in larger 
intermediate and late stage lesions, 2.5-fold (P = 0.03) and 7-fold (P = 0.002), respectively. 
In concordance, intermediate and late stage lesions showed a higher degree of 
membranous CXCR4 staining at IHC and flow cytometric analysis. These results show that 




A possible clinical application of the chemokine receptor 4 (CXCR4) as an imaging 
target is the visualization of breast cancer lesions such as ductal carcinoma in situ (DCIS). 
Salvucci et al.reported that 69% of the DCIS lesions evaluated in their patient study was 
CXCR4 positive at immunohistochemistry (IHC),1 whereas Schmid et al. reported a 
92% positivity rate.2 Non-invasive visualization of DCIS is clinically challenging; X-ray 
mammography and contrast enhanced magnetic resonance imaging (MRI) does not 
always accurately detect DCIS lesions.3-5 Hence, CXCR4 targeting imaging agents are 
expected to help improve clinical diagnostics.
The well described mammary intraepithelial neoplastic outgrowth (MIN-O) model, a 
mouse tumor model resembling human DCIS6,7 has been previously used in imaging 
studies.8 In this model, preinvasive lesions progress to invasive lesions.9,10 Progression is 
consistent over time, and conveniently, lesions that have progressed to the invasive 
phenotype become palpable.  Differences in tumor cell differentiation, gene expression, 
and metabolism associated with progression have been reported and these features 
correspond to similar features in human DCIS progression.  
The preclinical MIN-O model and a low CXCR4 expressing 4T1 tumor model 
were used to evaluate the ability of the CXCR4 targeting peptide antagonist 111In-DTPA-
Ac-TZ14011. Here the challenge was to longitudinally monitor the progression of the 
tumor lesions via the level of CXCR4 expression. Imaging results were compared to 
immunohistochemical and flow cytometric analysis of the tumor tissue. Furthermore, 
111In-DTPA-c[RGDfK] was used to determine the influence of angiogenesis on the uptake 
of 111In-DTPA-Ac-TZ14011 in both tumor models. 
Materials and methods
In vivo mouse model
For generation of the MIN-O tumor lesions FVB mice (n = 20; 3 - 4 weeks of age) were 
used. Before transplantation (and imaging), mice were anaesthetized using a hypnorm 
(VetaPharma Ltd)/dormicum (Midazolam; Roche)/water solution (1:1:2; 5µL/g i.p.). Via a 
small incision, the inguinal lymph node was excised where after a piece of preinvasive 
MIN-O tissue (line 8w-B)10 was placed into the remaining tissue of the fourth mammary 
gland. Approximately three weeks after transplantation, lesions were deemed suitable for 
further experiments. 
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Control experiments were performed using orthotopic transplantation of 0.25 x 105 
4T1 tumor cells into the mammary tissue of Balb/c nude mice (n = 20; 6-8 weeks of age). 
4T1 cells were cultured under standard conditions in MEM medium containing MEM 
vitamins, L-glutamin, non-essential amino acids, natrium/pyruvate and penicillin/
streptomycin solution (all BD Biosciences). Before transplantation, cells were trypsinized 
and washed with HBSS (BD Biosciences). Transplantation of cells was carried out under 
identical conditions as placement of the MIN-O segments. All animal experiments were 
performed in accordance with Dutch welfare regulations and after approval was obtained 
by the local ethics committee.
Synthesis and radiolabeling 
DTPA-Ac-TZ14011 (Figure 1A) was synthesized as previously described by Hanaoka 
et al.8 Synthesis of DTPA-c[RGDfK] is described the Appendix of this Chapter. 
Imaging using single photon emission computed tomography/computed 
tomography (SPECT/CT)
Mice were injected intravenously with 50 µg 111In-DTPA-Ac-TZ14011 (10 MBq) or with 
25 µg 111In-DTPA-c[RGDfK] (10 MBq). SPECT/CT scans were conducted as described 
previously11 on a preclinical SPECT/CT scanner (Nanospect; Bioscan) at one hr and 24 hrs 
post injection. After acquisition, the CT data was reconstructed using a cone-beam filtered 
back projection. SPECT data was reconstructed using HiSPECT software (Scvis GmbH). In 
a region of interest including only the tumor, the percentage of the injected dose (%ID) 
was calculated using the following formula: ((MBq measured in tissue/injected dose) 
x100%). MIN-O and 4T1 tumor lesions within the same size range were compared. Signal 
intensities were analyzed using the InVivoScope postprocessing software (Bioscan, Inc.).11 
CT images were used to perform size measurements on the tumor. The formula for 
ellipsoid shapes: 3/4 π x (1/2a) x (1/2b) x (1/2c), was used to calculate tumor volume. 
Tumor stages were differentiated by size and histology. Size limits for the different 
stages were based on values reported by Abbey et al.7 and correlations between tumor 
volume and immunohistochemistry using our own data. Tumor lesions < 100 mm3 were 
deemed as early stage, lesions between 100 and 400 mm3 were deemed as intermediate 
stage, and > 400 mm3 as late stage lesions. In the mice that were longitudinally followed, 
only the %ID could be determined, as the weight of the tumor was unknown. Moreover, 
the density of the lesions differs between stages and tumor lesions. Corrections based on 
tumor volume were therefore considered inaccurate.
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Tracer distribution
After the final SPECT/CT scan mice were sacrificed. Organs and tumor lesions were 
excised and weighed to determine the percentage of the injected dose per gram (%ID/g). 
The amount of radioactivity present in the tissue was counted using a gamma counter 
(Wizard 3” 1480 automatic gamma counter, Perkin Elmer; 245 keV; 60 sec). The percentage 
of the injected dose (%ID/g) was calculated as follows: ((MBq measured in tissue/ injected 
dose) x100 %) / (weight of tissue). Statistics were conducted using a standard T-test.
Immunohistochemistry (IHC)
Formalin-fixed paraffin-embedded MIN-O or 4T1 tumor tissue sections were stained 
according to the protocol previously described with a monoclonal anti-CXCR4 antibody 
(Rat-anti-CXCR4 clone 2B11 1:100; BD Biosciences).12 Slides were assessed by a consultant 
breast pathologist and scored as positive or negative for membranous and cytoplasmic 
CXCR4 staining. Images were taken with a color CCD microscope system (Axiovert S100 
with AxiocamHRc, Carl Zeiss) at a 25x or 40x magnification. 
The percentage of cytoplasmic and/or membranous staining was determined per 
slide by dividing the amount of stained cells in a specific area by the total amount of cells 
in that area and multiplying this by 100%. Per tumor type/stage 5 different tumor slides 
were assessed. Per slide, 5 different areas were evaluated (magnification 40x). The ratio 
between staining in the MIN-O and 4T1 tumor lesions was determined by dividing the 
percentage of membranous staining in the MIN-O tumor lesions by the percentage of 
membranous staining in the 4T1 tumor lesions. Increase in membranous staining in the 
different MIN-O tumor stages was determined by dividing the percentage of staining in 
the intermediate or late stage MIN-O tumor lesions by the percentage of staining of the 
early stage MIN-O tumor lesions.
For the MIN-O model, early, intermediate, and late stage tumor lesions were assessed. 
For the 4T1 tumor model, only large tumor lesions (corresponding in size with late stage 
MIN-O lesions) were assessed as CXCR4 expression levels between different stages of 4T1 
lesions did not differ. Statistics were performed using a standard T-test. 
Flow cytometry
Tumor-bearing mice were sacrificed, tumor lesions were excised and  single cell 
suspensions were made. All stages of MIN-O lesions were assessed. Again, for the 4T1 
tumor model, only late stage tumor lesions were used. 
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500,000 cells per measuring condition were washed with 0.1% bovine serum albumin in 
phosphate buffered saline (0.1% BSA/PBS) and incubated for one hr on ice with monoclonal 
phycoerythrin (PE) labeled anti-CXCR4 antibody 2B11 (2B11-PE; 1:100; BD Biosciences) to 
determine their CXCR4 expression levels. After incubation, cells were washed with 0.1% BSA/
PBS and propidium iodide (PI; 1:10000; BD Biosciences) was added five min prior to analysis.
For evaluation of the amount of lymphocytes within the CXCR4 positive population in 
the tumor cell suspensions, cells were co-incubated for one hr with the 2B11-PE antibody 
and an Alexa-Fluor-700 (AF700) labeled anti-CD45 antibody (CD45-AF700 clone 30 F11; 
1:200; eBioscience). The percentage of CXCR4 positive lymphocytes was determined by 
dividing the CD45 positive population within the CXCR4 positive population by the total 
amount cells and multiplying this by 100%. 
Antibodies were diluted in 0.1% BSA/PBS in all flow cytometric experiments. Non-
antibody incubated cells served as controls. After staining, cells were analyzed using a 
Beckton Dickinson FACScalibur device equipped with Cell Quest Pro software (BD 
Biosciences). PE fluorescence was detected in the FL2 channel (excitation 488 nm; emission 
filter 530/30 nm). PI and AF700 were detected in the FL3 channel (excitation 488 nm; 
emission filter > 670 nm).
Mean fluorescence signal intensity ratio’s (MFIRs) were calculated as followed: (mean 
fluorescence signal intensity antibody incubated condition)/(mean fluorescence signal 
intensity control (no antibody)). Increase in signal in the different MIN-O tumor stages was 
determined by dividing the MFIR obtained in the intermediate or late stage MIN-O tumor 
lesions by the MFIR of the early stage MIN-O tumor lesions.
Results
To evaluate the potential of 111In-DTPA-Ac-TZ14011 to visualize tumor lesions 
via their CXCR4 expression, a group of animals was scanned longitudinally (Figure 1). 
SPECT/CT scans were made when tumor lesions were < 100 mm3 (early stage), 100 - 400 
mm3 (intermediate stage) and > 400 mm3 (late stage) in size.  
Figure 1. Longitudinal SPECT/CT imaging of 111In-DTPA-AC-TZ14011. A) Chemical structure of DTPA-Ac-TZ14011. 
Uptake of 111In-DTPA-Ac-TZ14011 in the tumor lesions measured at  B) one hr and C) 24 hrs after injection was 
set out against the tumor volume. D) Uptake in tumor lesions within the same size range was compared. 
E) SPECT/CT images (MIP) of MIN-O and 4T1 tumor lesions at 24 hrs after injection. F) Ex vivo tracer distribution 
in a 4T1 (i) and MIN-O (ii) tumor lesion after SPECT/CT imaging. Significance between uptake values was 
determined using a standard T-test. ns = not significant, P-values < 0.02 for comparison with late stage MIN-O 
lesions were noted as ** and P-values < 0.002 as ***. nd = not determined.
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%ID in tumor
MIN-O 1hr 4T1 1hr MIN-O 24hr 4T1 24hr
Early stage (< 100 mm3) 0.38 ± 0.20 ** n.d. 0.10 ± 0.003 *** 0.014 ± 0.004
Intermediate stage  (100 - 400 mm3) 0.62 ± 0.51 ** n.d. 0.25 ± 0.11 *** 0.030 ± 0.008
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As the time between injection of an imaging agent and time point of imaging can 
influence the imaging outcome, the optimal incubation time of 111In-DTPA-Ac-TZ14011 
was determined. This was done by comparing the tumor uptake at two different time 
points post injection. At one hr post injection MIN-O tumor lesions could be detected but 
differences between CXCR4 positive (MIN-O) and control (4T1) tumor lesions were not 
apparent (Figure 1B). Uptake in late stage MIN-O lesions seemed to be higher than the 
uptake (%ID) in 4T1 tumor lesions at one hr post injection, however, this difference was 
not significant (Figure 1D). At 24 hrs post injection uptake in the tumor lesions had overall 
decreased, but at this time point the differences between the MIN-O and 4T1 lesions were 
highly significant (Figure 1C and D). More importantly, uptake in 4T1 tumor lesions was 
low in tumor lesions of all sizes (between 0.014 ± 0.004 %ID to 0.030 ± 0.009 %ID), whereas 
the uptake in MIN-O lesions increased with lesion size (Figure 1D). Uptake increased from 
0.10 ± 0.03% of the injected dose in early stage lesions to 0.25 ± 0.11% in intermediate 
stage and 0.74 ± 0.21% in late stage MIN-O lesions. Uptake levels in MIN-O tumor lesions 
larger than 10 mm3 exceeded uptake levels found in 4T1 tumor lesions with a size range 
up to 1338 mm3. Figure 1E shows SPECT/CT images of the lesions during the different 
stages of tumor progression of both 4T1 and MIN-O tumor lesions. After the final SPECT/
CT scan in the longitudinal series, the distribution and quantitative tumor uptake (%ID/g) 
was determined. In late stage MIN-O tumor lesions (0.27 ± 0.06) uptake was higher 
compared to uptake in 4T1 lesions of comparable size (0.14 ± 0.02; P = 0.05). The tumor-
to-muscle ratio was 1.5-fold higher in the late stage MIN-O tumor lesions; 7.17 ± 0.47 
compared to 4.75 ± 0.90 in 4T1 tumor lesions (P = 0.01). Ex vivo SPECT/CT imaging shows 
the distribution throughout the tumor in the two tumor types (Figure 1F).
Distribution studies at 24 hrs post injection revealed that 111In-DTPA-Ac-TZ14011 was 
predominantly cleared via the kidneys, and to a lesser extent via the liver (Table 1). 
Hanaoka et al. previously reported on the distribution of 111In-DTPA-Ac-TZ14011 which 
also included a blocking study using unbound peptide.8 Here the distribution was 
evaluated using a different peptide dose but overall, we found that the distribution profile 
was comparable. 
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Table 1. Distribution of 111In-DTPA-Ac-TZ14011. 
Tissue 111In-DTPA-Ac-TZ14011 
%ID/g
Blood 0.02 ± 0.00
Brain 0.00 ± 0.00
Lungs 0.19 ± 0.01
Heart 0.08 ± 0.01
Liver 5.53 ± 0.51
Kidneys 24.82 ± 0.94
Spleen 1.03 ± 0.11
Stomach 0.08 ± 0.01
Intestines 0.16 ± 0.02
Muscle 0.03 ± 0.01
Mammary fatpad 0.05 ± 0.02
Axillary lymph nodes 1.33 ± 0.81
Mice were sacrificed 24 hrs after injection of 111In-DTPA-Ac-TZ14011. Tissues were excised and radioactivity in the 
tissues was determined using a gamma counter. %ID/g was calculated using the following formula: ((MBq 
measured in tissue/ injected dose)* 100%)/weight tissue.
To validate that the tumor uptake of 111In-DTPA-Ac-TZ14011 could be correlated to 
CXCR4 expression, the level of CXCR4 expression in the different tumor tissues was 
evaluated by IHC. Slices of MIN-O and 4T1 tumor tissue were stained using the 2B11 anti-
CXCR4 antibody and cytoplasmic and membranous CXCR4 staining was analyzed. In 
MIN-O lesions, staining patterns varied between different areas in the tumor, showing 
clear CXCR4 positive and negative areas (Figure 2A). Further evaluation demonstrated 
that in MIN-O lesions, CXCR4 staining was located in the cytoplasm and on the membrane 
of the tumor cells. 4T1 and early stage MIN-O lesions showed predominantly cytoplasmic 
staining and only sporadic membranous staining. Membranous staining was more evident 
in the larger intermediate stage MIN-O lesions and most apparent in the largest MIN-O 
lesions investigated (Figure 2). 
Interventional molecular imaging, a hybrid approach214
Figure 2. Immunohistochemistry: CXCR4 staining in 4T1 and MIN-O tumor tissue. A) Distribution pattern of the 
CXCR4 staining of the different MIN-O tumor stages. B) At a 25x magnification, in 4T1 tumor tissue only 
cytoplasmatic staining can be seen. In MIN-O tumor tissue, next to cytoplasmatic staining, an increasing level of 
membranous staining is observed. C) Membranous staining at 40x magnification. 
This visual observation was further underlined by quantitative analysis of the stained 
tissue slides. In Table 2, the percentage of CXCR4 staining determined by IHC in the 
different MIN-O stages and in the 4T1 control tumor lesions is shown. No significant 
difference in cytoplasmic staining was observed between the different tumor lesions, but 
differences in percentages of membranous staining were apparent. 
While membranous staining in 4T1 and early stage MIN-O lesions was almost 
identical (3.8 ± 1.9% and 4.1 ± 2.3%), the percentage of membranous staining increased 
3.3-fold in intermediate and 5.1-fold in late stage MIN-O lesions compared to the early 
stage MIN-O lesions. As only one representative slide per tumor was evaluated, this 
contributed to the relatively high SD in the quantitative analysis of the staining percentages 
(Table 2). 
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Table 2. Quantitative analysis of CXCR4 staining. 
Tumor type % Cytoplasmic staining % Membranous staining
MIN-O Early stage (< 100 mm3) 81.1 ± 10.6 4.1 ± 2.3 ***
MIN-O Intermediate stage (100 – 400 mm3) 84.8 ± 8.6 13.5 ± 5.8 **
MIN-O Late stage (> 400 mm3) 90.6 ± 3.3 21.0 ± 8.0
4T1 Late stage (> 400 mm3) 92.2 ± 3.0 3.8 ± 1.9 ***
Tumor cells were counted under 40x magnification (n = 5 per tumor type). Percentage cytoplasmic and 
membranous staining was calculated by dividing the amount of stained cells in an area by the total amount of 
cells counted in that area and multiplying this by 100%. P-values < 0.05 for comparison with late stage MIN-O 
lesions were noted as ** and P-values < 0.01 as ***.
 
Table 3. Flow cytometric analysis CXCR4 and the percentage of lymphocytes in 4T1 and MIN-O tumor cells. 
Tumor type MFIR CXCR4 % lymphocytes
MIN-O Early stage (< 100mm3) 2.25 ± 0.17 0.43  ± 0.002
MIN-O Intermediate stage (100 - 400mm3) 4.32 ± 0.02 2.07 ± 0.001
MIN-O Late stage (> 400mm3) 5.36 ± 1.80 3.48 ± 0.004
4T1 Late stage  (> 400mm3) 1.70 ± 1.07 3.39 ± 0.002
 
Tumor cell suspensions were incubated with 2B11-PE. The fluorescence signal in CXCR4 positive cells was 
measured (n = 3 per tumor type) and mean fluorescence intensity ratios (MFIR) were determined. The percentage 
of lymphocytes within the CXCR4 positive population was determined after co-incubation with 2B11-PE and an 
AF700 labeled anti-CD45 antibody. 
Further evaluation of the membranous CXCR4 expression in the tumor lesions was 
conducted using flow cytometric analysis. Viable tumor cells were incubated with a PE-
labeled version of the anti-CXCR4 antibody that was used for IHC. By performing the 
labeling on ice, the metabolic activity of the cells is slowed down preventing endocytosis, 
enabling visualization of only the cell-membrane-receptor-bound signal. Therefore, the 
level of fluorescence that could be detected in the tumor cell suspensions provided a 
measure of the membranous CXCR4 expression. Similar to results obtained with IHC 
(Table 2), a clear difference between the level of CXCR4 expression in the 4T1 and MIN-O 
tumor lesions was found (Table 3). MFIRs in the MIN-O tumor cells increased with 
progression of the lesions. The MFIR in intermediate and late stage MIN-O tumor cells was 
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respectively 1.9-fold and 2.4-fold higher than the MFIR in early stage MIN-O tumor cells. In 
all stages of MIN-O tumor progression, a higher level of fluorescence was detected than in 
the 4T1 tumor cells used in these experiments.
As can be seen in Table 1, tracer uptake was relatively high in the spleen and axillary 
lymph nodes. Both organs are part of the immune system and are known to harbor large 
amounts of CXCR4 positive lymphocytes.14 The presence of such CXCR4 positive 
lymphocytes in the tumor lesions can be of influence on uptake levels of 111In-DTPA-Ac-
TZ14011. For this reason, the level of lymphocytes present within the CXCR4 positive 
tumor cell population was evaluated. Flow cytometric analysis was done after co-
incubation of an AF700 labeled anti-CD45 antibody and the PE-labeled anti-CXCR4 
antibody (Table 3). The percentage of lymphocytes present in MIN-O tumor tissue 
increased with tumor stage; in early stage tumor cells only 0.43% of the cells in the tumor 
were CD45 positive, increasing to 2.07% in intermediate and 3.48% in late stage MIN-O 
tumor lesions. However, the presence of lymphocytes in late stage 4T1 tumor tissue 
(3.39%) was comparable to late stage MIN-O tumor tissue. Pathological analysis of tumor 
slices also revealed low amounts (≈ 2%) of lymphocytes in the tumor tissue. It is therefore 
not likely that uptake levels of 111In-DTPA-Ac-TZ14011 in the MIN-O and 4T1 tumor lesions 
were influenced by the presence of lymphocytes in the tumor.
To further specify that the uptake of 111In-DTPA-Ac-TZ14011 in the tumor lesions is 
related to the level of CXCR4 expression in the tumor cells, factors such as the effect of 
angiogenesis (based on αvβ3 integrin expression) had to be evaluated. Therefore, the 
uptake of 111In-c[RGDfK]-DTPA was studied in both tumor models. The RGD peptide 
c[RGDfK], binds to αvβ3 integrin, of which expression is linked to angiogenesis.
15 Uptake of 
111In-c[RGDfK]-DTPA in MIN-O and in 4T1 lesions increased with increasing lesion size, but 
no significant difference in uptake between the models was observed (Figure 3). Unlike 
SPECT/CT imaging with 111In-DTPA-Ac-TZ14011, lesions were only followed until they 
reached 400 mm3. The necrotic area’s in larger 4T1 tumor lesions resulted in unreliable 




MIN-O Early stage  (< 100 mm3) 0.12 ± 0.13
MIN-O Intermediate stage  (100 – 400 mm3) 0.34 ± 0.10
MIN-O Late stage  (> 400 mm3) 0.09 ± 0.09
4T1 Late stage (> 400 mm3) 0.30 ± 0.17
Figure 3. Longitudinal SPECT/CT imaging of 111In-c[RGDfK]-DTPA. A) Tumor uptake of 111In-c[RGDfK] was 
longitudinally monitored at 24 hrs after injection. B) Uptake in tumor lesions of tumor lesions within the same 
size range were compared.
Discussion
The potential of 111In-DTPA-Ac-TZ14011 to longitudinally monitor CXCR4 expression was 
studied in a MIN-O mouse tumor model resembling human DCIS. The present study has 
demonstrated that a CXCR4 targeting imaging approach can be used to monitor lesion 
progression from small early stage lesions to larger intermediate and late stage lesions via the 
CXCR4 expression of a lesion.
Rather than using subcutaneous xenograft based models wherein transfected (human) 
cell lines with extremely high CXCR4 expression rates,16 small early stage MIN-O mouse tumor 
segments were transplanted orthotopically into the mammary fatpad. This transplantation-
based model may resemble human lesion progression more accurately than that of a 
(CXCR4 transfected) xenograft model. Moreover, in the MIN-O model the CXCR4 expression 
is in line with the 5-fold overexpression reported in human tumor samples.1 The difference 
between lesions with high and low expression levels of CXCR4 will possibly be more black-
and-white when transfected cell lines are used, but the CXCR4 expression in these (mostly) 
homogeneous tumor lesions is likely to have less similarity with the human situation. In 
A
B
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the murine MIN-O model lesions with a modest CXCR4 expression level could be accurately 
detected; a 5.4-fold increase in uptake compared to surrounding mammary tissue was 
found. This allowed differentiation from the cell line based 4T1 control tumor tissues. Also 
important, CXCR4 expression in MIN-O lesions is heterogeneous. Ex vivo SPECT/CT 
imaging showed a patchy staining pattern in the tumor (Figure 1F) and IHC revealed clear 
positive and negative area’s (Figure 2A) in the MIN-O tumor tissue. This heterogeneous 
presence of CXCR4 is in line with what is seen in breast cancer patient biopsies.2 
Initial SPECT/CT measurements were performed using a lower dose of the imaging 
agent (10 µg; data not shown). Unfortunately, tumor lesions could not be visualized clearly. 
Increasing the dose to 50 µg lead to a lower specific activity but also to a better visualization 
of the tumor. This is in line with results reported by Jacobsen et al. who showed that tumor 
uptake increased after co-injection of 50 µg unlabeled peptide.13 In antibody-based imaging 
this phenomenon is well studied. Here an increase in dose was shown to improve tumor 
penetration and to decrease background staining.17-19 Imaging using SPECT/CT revealed 
that an 111In-DTPA-Ac-TZ14011 signal could already be detected in MIN-O lesions as small as 
10 mm3 and tumor uptake levels in lesions beyond 10 mm3 exceeded the uptake in 4T1 
control tumor lesions. These findings illustrate the potential of CXCR4 imaging for 
visualization of small tumor lesions. Obviously, ducts in the human mammary gland are not 
as closely packed as in the mouse model. Hence the value of these findings in a clinical 
setting still requires further investigation. Our preclinical findings, however, indicate that the 
signal detected in MIN-O lesions is 7.2-fold higher than the signal found in the muscle and 
5.4-fold as high as the signal found in the opposite mammary fat pad. 
Compared to human clinical trials the MIN-O mouse model of DCIS progression simplifies 
these experiments. Nevertheless, in our opinion, the imaging data combined with the reported 
detection of CXCR4 in human DCIS examples1,2 warrants further investigation towards using 
CXCR4 targeting imaging agents to detect DCIS via its CXCR4 expression levels. An important 
step herein will be the further ex vivo assessment of CXCR4 expression levels in existing human 
DCIS samples and their surrounding stroma and mammary gland tissue. 
In the MIN-O tumor model, uptake levels of 111In-DTPA-Ac-TZ14011 increased with 
progression of lesion size, which is identical to results shown with 18F-FDG PET.7 However, 
accumulation of the metabolic tracer 18F-FDG in the 4T1 control tumor lesions has also been 
reported.20 Clearly, the uptake of targeted imaging agents in the tumor needs to be directly 
related to the level of receptor expression. Unfortunately, such as perfusion may also 
influence the uptake of an imaging agent. An increase in the amount of new blood vessels 
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can increase perfusion of a tumor lesion resulting in higher uptake of an imaging agent. 
Evidently this can obscure the interpretation of the imaging data. Evidence that the uptake 
of 111In-DTPA-Ac-TZ14011 is not governed by the degree of tumor angiogenesis is provided 
by the SPECT/CT experiments, as data obtained with 111In-DTPA-c[RGDfK] shows a 
comparable uptake in both tumor types. This result, combined with the absence of 
membranous staining in the control tumor lesions and the increase in membranous staining 
in intermediate and late stage MIN-O tumor lesions seen with IHC and flow cytometry 
(Figure 2, Table 2 and 3), underlines that the uptake of the 111In-DTPA-Ac-TZ14011 in the 
MIN-O lesions is driven by the presence of the CXCR4 receptor on the membrane of the cell.
Next to presence of the target, we found that the specificity of the signal in the tumor 
lesions (Figure 2) was greatly influenced by the time between injection and the SPECT 
measurements. Other than the data reported by De Silva et al.21 and Nimmagadda et. al,22 
who showed that the best results were obtained at 90 min after injection of [64Cu]AMD3465 
and [64Cu]AMD3100, with 111In-DTPA-Ac-TZ14011 no discrimination could be made 
between MIN-O and control tumor lesions at one hr after injection (Figure 1). A 
differentiation could only be clearly made at 24 hrs after injection. This suggests a high 
level of non-specific uptake of 111In-DTPA-Ac-TZ14011 at earlier time points. Hanaoka et al. 
previously evaluated the distribution of 111In-DTPA-Ac-TZ14011 in a CXCR4 positive tumor 
model for pancreatic cancer at various time points.8 They showed that tumor uptake was 
highest at one hr post injection, but that non-specific background was significantly 
decreased after 24 hrs. Reasoning that at earlier time points (e.g. one hr and six hrs) the 
possibility of presence of unbound compound in the tumor exists, which could decrease 
the overall visibility of the tumor. The best imaging time point for this specific tracer was 
considered to be 24 hrs post injection. This time span is still significantly shorter than the 
reported antibody based CXCR4 imaging approaches, which require a 48 hrs incubation 
time.16 A 24 hrs incubation time, however, limits imaging studies to the use of longer living 
isotopes such as 111In and 89Zr. 
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Conclusion
IHC and flow cytometry validate that 111In-DTPA-Ac-TZ14011 based imaging of CXCR4 
receptor expression enabled longitudinal monitoring of the tumor lesion progression in a 
mouse model resembling human DCIS. Presence of CXCR4 positive lymphocytes and 
tumor-angiogenesis were shown to have little effect on the uptake of 111In-DTPA-Ac-
TZ14011 in the tumor.
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Ac-TZ14011 was synthesized according to previously described procedures.1
DTPA-Ac-TZ14011
DTPA-Ac-TZ14011 was synthesized according to previously described procedures.1  
For imaging of one mouse, 50 µg of the DTPA- Ac-TZ14011 peptide antagonist was 
dissolved in 80 mL 0.1 M acetic acid after which 20 µL 111In Cl3 (10 MBq; Covidien-Mallinkrodt) 
was added. After 30 min incubation, labeling was validated using thin layer chromatography. 
In all cases, labeling efficacy was > 99%. Before injection, 1 mL of saline was added.
Synthesis and radiolabeling DTPA-c[RGDfK]
The RGD peptide, c[RGDfK], binds to the αvβ3 integrin receptor, of which expression 
has been linked to angiogenesis.2 c[RGDfK] was synthesized by Fmoc/tBu-SPPS on a trityl 
resin. The protected peptide was cleaved from the resin and cyclized head-to-tail with 
BOP/HOBt. After purification by silica column chromatography, the remaining protecting 
groups were removed and the product was purified by RP-HPLC.
DTPA-c[RGDfK] was synthesized by reacting the in situ formed succinimidyl ester of 
DTPA(tBu)4 with c[RGDfK]. The protecting groups were removed with TFA/TIS/water and 
the product was purified by RP-HPLC. For imaging of one mouse, 25 mg of DTPA-c[RGDfK] 
was dissolved in 50 mL 0.1M acetic acid and 25 mL InCl3 (10 MBq) was added. After 30 min 
incubation, labeling was validated using thin layer chromatography. In all cases, labeling 
efficacy was > 99%. Before injection, 100 mL of saline was added.
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Abstract
Conjugation of a hybrid imaging label to the CXCR4 targeting Ac-TZ14011 peptide 
results in an imaging agent that can be detected using multiple imaging modalities. To 
examine the influence of such a hybrid label on the CXCR4 specificity and targeting 
affinity, Ac-TZ14011 was labeled with a multifunctional single attachment point (MSAP) 
reagent containing a DTPA chelate and a fluorescent dye. Although the affinity of Ac-
TZ14011-MSAP was slightly lower than that of the unlabeled peptide, flow cytometry and 
confocal microscopy showed that the hybrid peptide was specifically bound to the 
receptor. Furthermore, Ac-TZ14011-MSAP was able to discriminate between MDAMB231 
and MDAMB231CXCR4+ cells. Here the CXCR4 targeting antibody 12G5-PE, was used as a 
reference. In vivo, Ac-TZ14011-MSAP could be used for pre- and intraoperative tumor 
visualization using SPECT and fluorescence imaging.
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Introduction
For molecular imaging of cancer-related biomarkers several modalities are in use, 
including single photon emission computed tomography  (SPECT), positron emission 
tomography (PET), magnetic resonance imaging (MRI) and fluorescence imaging.1 Each 
modality has its own strengths and weaknesses and therefore often a combination of 
modalities is needed during the clinical trajectory.2-5 To ensure detectability using  multiple 
modalities an imaging agent needs to contain at least two different diagnostic labels. The 
combination of radiolabels for SPECT or PET and fluorescent labels in particular has 
potential in peptide-based molecular imaging.4 This combination benefits from the high 
sensitivity of nuclear imaging and the high spatial resolution of fluorescence imaging.5 
Hybrid imaging agents were shown to be of added value in surgical guidance by 
combining pre- and intraoperative imaging. 6-8 In this setting surgical planning is based on 
the radioactive signal and optical surgical guidance is achieved via the fluorescent 
component. This application can be expanded to tumor targeting peptides for visualization 
of tumor tissue.4
For evaluation of chemokine receptor 4 (CXCR4) expression levels, several CXCR4 
antagonistic peptides have been developed.9,10 The binding of dye- and chelate-labeled 
Ac-TZ14011 peptides to CXCR4 has already been validated in vitro and in vivo;4,11-13 the 
specificity of Ac-TZ14011 for CXCR4 has been underlined by the fact that a scrambled 
peptide and a peptide with inversed stereocenters could not label CXCR4 expressing 
cells.14 However, a hybrid derivative of this CXCR4-targeting peptide has not yet been 
reported. 
In this Chapter, the conjugation of a hybrid multifunctional single attachment point 
(MSAP) reagent15,16 to Ac-TZ14011 is described.  Using the hybrid imaging agent Ac-
TZ14011-MSAP in vitro validation studies were performed to examine the influence of the 




All chemicals were obtained from commercial sources and used without further 
purification. Preparation of compounds, recording of absorption and emission spectra 
and radiolabeling of the peptides are described in the Appendix of this Chapter. 
Interventional molecular imaging, a hybrid approach228
In vitro experiments
Cell culture
Human breast cancer cell lines MDAMB231 and MDAMB231CXCR4+ were kindly 
provided by Olaf van Tellingen and Ed Roos (both NKI-AvL, Amsterdam, The Netherlands), 
respectively. In the MDAMB231CXCR4+ cells CXCR4 expression was upregulated after culture 
under hypoxic conditions. Cells with high CXCR4 expression were selected using flow 
cytometry, resulting in the MDAMB231CXCR4+ cell line. MDAMB231 cells were used as control 
based on their basal CXCR4 expression. Both cell lines were maintained in Gibco’s 
minimum essential medium (MEM) enriched with 10% fetal bovine serum, Penicillin/
Streptomycin, L-glutamine, non-essential amino acids, sodium pyruvate and MEM 
vitamins solution (all Life Technologies Inc.). Cells were kept under standard culture 
conditions.
Flow cytometry analysis of MDAMB231 and MDAMB231CXCR4+ cell binding 
Freshly cultured MDAMB231 or MDAMB231CXCR4+ cells were trypsinized, aliquoted in 
portions of 300.000 cells, centrifuged (1200 rpm, five min, 4°C) and decanted. 6.4 nM of 
monoclonal phycoerythrin (PE) labeled anti-CXCR4 antibody (CD184 12G5-PE (12.5 μg/
mL), BD Biosciences) or 1 μM of Ac-TZ14011-MSAP or Ac-TZ14011-MSAP-In in 50 μL of 
0.1% bovine serum albumin (BSA) in phosphate buffered saline (PBS) was added to the 
cells. After one hr of incubation at 4°C, the cells were washed (twice) with 300 μL of 0.1% 
BSA in PBS, resuspended in 300 μL of 0.1% BSA in PBS and fluorescence was measured 
using a CyAn ADP flow cytometer (DakoCytomation) at APC-Cy7 settings (635 nm laser 
and 750 nm long pass filter). Live cells were gated on Forward Scatter, Side Scatter and 
Pulse Width and approximately 20.000 viable cells were analyzed. All experiments were 
performed in triplicate.    
Determination of dissociation constants 
MDAMB231CXCR4+ cells were trypsinized and aliquoted in portions of 300.000 cells. For 
saturation binding experiments different concentrations of Ac-TZ14011-MSAP or Ac-
TZ14011-MSAP-In, in a range of 0 – 1000 nM, were added. For competition experiments 
different concentrations (0 – 10,000 nM) of Ac-TZ14011, Ac-TZ14011-DTPA or Ac-TZ14011-
FITC in the presence of 250 nM of Ac-TZ14011-MSAP were added. Cells were incubated for 
one hr at 4°C. The cells were washed twice with 300 μL of 0.1% BSA in PBS, resuspended in 
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300 μL of 0.1% BSA in PBS and fluorescence was measured using a CyAn ADP flow 
cytometer (DakoCytomation) at APC-Cy7 settings. Live cells were gated on Forward 
Scatter, Side Scatter and Pulse Width and approximately 20,000 viable cells were analyzed. 
All experiments were performed in duplicate. 
The normalized geometric means were fitted with equations in the GraphPad Prism 
5 software. The KD values of Ac-TZ14011-MSAP and Ac-TZ14011-MSAP-In were calculated 
using the ‘Binding – Saturation, One site – Total’ nonlinear regression equation (Eq.1). The 
KD values of Ac-TZ14011, Ac-TZ14011-DTPA and Ac-TZ14011-FITC were calculated using 
the ‘Binding – Competitive, One site – Fit Ki’ nonlinear regression equation (Eq. 2 and 3).  
             (Eq. 1)
y  = normalized fluorescence
Bmax  = maximum specific binding in the units of the y axis 
x  =  concentration of Ac-TZ14011-MSAP or Ac-TZ14011-MSAP-In 
in nM
KD  =  equilibrium dissociation constant of Ac-TZ14011-MSAP or Ac-
TZ14011-MSAP-In in nM
NS  = slope of nonspecific binding
Background  = amount of normalized fluorescence with no added compound
                (Eq. 2)
     (Eq. 3)
IC50  =  concentration of competitor that results in binding half-way 
between Bottom and Top
KD  = equilibrium dissociation constant of the competitor in nM
[Ac-TZ14011-MSAP]  = concentration of Ac-TZ14011-MSAP (250 nM)
KD,Ac-TZ14011-MSAP  = dissociation constant of Ac-TZ14011-MSAP (186.9 nM)
y  = normalized fluorescence
Bottom and Top  = plateaus in the units of the y-axis
y = Bmax ∗ x
KD + x
+ NS ∗ x + Background
log IC50 = log(10
logKD ∗ (1 + [Ac−TZ14011−MSAP]
DK ,Ac−TZ14011−MSAP
))
y = Bottom + Top − Bottom
1+10(x − log IC50 )
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Confocal microscopy 
MDAMB231CXCR4+ cells were seeded onto coverslips (Ø 24mm; Karl Hecht GmbH & Co) 
and incubated overnight. The cells were washed with PBS and incubated with 1 μM of Ac-
TZ14011-MSAP for one hr at 4°C and washed again with ice cold PBS. Confocal microscopy 
images were taken at 37°C on a Leica TCS-SP2-AOBS Live confocal microscope (Leica 
Microsystems Heidelberg GmbH). 
In vivo experiments
In vivo model
For generation of the CXCR4 positive mouse tumor lesions, FVB mice (n = 3; 3 - 4 
weeks of age) were used. Before transplantation (and imaging), mice were anaesthetized 
using a hypnorm (VetaPharma Ltd)/dormicum (Midazolam; Roche)/water solution (1:1:2; 
5 µL/g i.p.). Via a small incision, the inguinal lymph node was excised where after a piece 
of preinvasive 8w-B MIN-O tissue was placed into the remaining tissue of the fourth 
mammary gland.6-8 Approximately six weeks after transplantation, lesions were deemed 
suitable for further experiments. Control experiments were performed using orthotopic 
transplantation of 0.25 x 105 4T1 mouse tumor cells into the mammary tissue of Balb/c 
nude mice (n = 3; 6 - 8 weeks of age). Cells were cultured under standard conditions in 
MEM medium containing MEM vitamins, L-glutamine, non-essential amino acids, natrium 
pyruvate and Penicillin/Streptomycin solution (all BD Biosciences). Before transplantation, 
cells were trypsinized and washed with HBSS (BD Biosciences). Transplantation of cells 
was carried out under identical conditions as placement of the MIN-O segments. All 
animal experiments were performed in accordance with Dutch welfare regulations and 
approved by the local ethics committee.
Single photon emission computed tomography/ computed tomography (SPECT/CT)
24 Hrs after intravenously injection of 50 μg of 111In-labeled Ac-TZ14011-MSAP (10 
MBq), the mice were placed in a temperature controlled (37 °C) animal holder (Equipment 
Veterinaire MINERVE) before performing a SPECT/CT scan on the nanoSPECT/CT (Bioscan 
Inc.) The region of interest incorporating the whole mouse was selected, based on a 
(sagital) tomographic planning X-ray image followed by a helical 3D CT. Hereafter, a 
sequential total body SPECT scan of the same field of view was performed. Following 
231Chapter 11
acquisition, the data was reconstructed with HiSPECT software (Scivis GmbH). The SPECT 
and CT data sets were automatically co-registered. The images were analyzed using the 
InVivoScope post processing software (Bioscan Inc.).
Fluorescence imaging 
After SPECT/CT, the mice were sacrificed. In vivo fluorescence imaging was conducted 
on a preclinical fluorescence scanner (IVIS 200; Xenogen Corp.) using Living Imaging 
Acquisition and Analysis software (Xenogen Corp.). Images were acquired with standard 
Cy5.5 (excitation 615 - 665 nm and emission 695 - 770 nm) settings.
 
Distribution studies 
After fluorescence imaging, tissues were excised. Tissues were weighed and the 
amount of radioactivity present in the tissues was counted using a Perkin Elmer 1480 
Wizard 3’’ automatic gamma counter (245 keV; 60 sec). Counts per minute were converted 
into MBq and corrected for decay. The percentage of the injected dose per gram of tissue 
(%ID/g) was calculated as followed: ((MBq measured in tissue/ injected dose) *100%) / 
weight of tissue.
Results
The hybrid peptide derivative was generated using a MSAP reagent, which contains 
a DTPA and a CyAL-5.5b fluorochrome reporter and a reactive NHS ester.
15-17 Via the active 
NHS ester the MSAP reagent was selectively coupled to the D-Lys8 amine functionality on 
Ac-TZ14011 (Figure 3C, Appendix Scheme A1). To study the possible influence of chelation 
of a metal ion in the DTPA moiety, a portion of Ac-TZ14011-MSAP was coordinated to 
(non-radioactive) indium, yielding Ac-TZ14011-MSAP-In (Appendix Scheme A1).
The absorption spectra of Ac-TZ14011-MSAP and Ac-TZ14011-MSAP-In were shown 
to be analogous and the emission spectra were also very similar (Figure 1). For both 
compounds the absorption maximum was found at 680 nm and the emission maximum 
at 704 nm. Moreover, binding of indium in the DTPA chelate did not reduce the fluorescent 
intensity. 
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Figure 1. Absorption and emission spectra of compounds A) Ac-TZ14011-MSAP and B) Ac-TZ14011-MSAP-In.
The ability of Ac-TZ14011-MSAP and Ac-TZ14011-MSAP-In to discriminate between 
basal and CXCR4 overexpressing tumor cells was quantitatively examined with flow 
cytometry. As a reference the commercially available phycoerythrin (PE) labeled anti-
CXCR4 antibody CD184, clone 12G5 (12G5-PE), was used. Incubation with the antibody 
revealed a 4.4-fold upregulation of CXCR4 in the higher CXCR4 expressing cells, 
MDAMB231CXCR4+, compared to the basal cell line MDAMB231 (Table 1). The ratio between 
the fluorescence signals found for Ac-TZ14011-MSAP was a factor 4.1, which nicely 
corresponds to the ratio obtained with the antibody (Figure 1, Table 1). This indicates that 
the antibody and the peptide are both suited to detect CXCR4. 
Where the ratio between the fluorescence signals was similar to that of the antibody, 
the mean fluorescence intensity ratios (MFIRs) obtained with Ac-TZ14011-MSAP were 
approximately 10 times higher  (Table 1). This difference might be caused by the fact that 
the concentration used for the antibody was significantly lower than that of the peptides, 
6.4 nM and 1 μM, respectively. Moreover, due to the lower autofluorescence at the flow 
cytometer settings used for the MSAP peptides, the voltage of the photomultiplier 
detector could be set higher when the MSAP peptides were measured, compared to the 
PE-labeled antibody.
Table 1. Quantitative analysis of cellular uptake of MDAMB231 and MDAMB231CXCR4+ cells using a CXCR4 
antibody, Ac-TZ14011-MSAP and Ac-TZ14011-MSAP-In.
compound MFIR ± SD MDAMB231 MFIR ± SD MDAMB231CXCR4+ MFIR ratio
12G5-PE antibody 1.116 ± 0.054 4.920 ± 1.46 4.4
Ac-TZ14011-MSAP 10.94 ± 1.62 45.27 ± 2.19 4.1
Ac-TZ14011-MSAP-In 18.24 ± 1.93 56.67 ± 2.84 3.1
MFIR = mean fluorescence intensity ratio
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Figure 2. Flow cytometry analysis of the peptides Ac-TZ14011-MSAP and Ac-TZ14011-MSAP-In using A) 
MDAMB231 cells or B) MDAMB231CXCR4+ cells. Both graphs show untreated cells (trace filled with grey), 1 μM of 
Ac-TZ14011-MSAP (black trace) and 1 μM of Ac-TZ14011-MSAP-In (grey trace). 
Incubation of the cells with Ac-TZ14011-MSAP-In resulted in a slightly lower ratio 
between fluorescence intensities in high and low CXCR4 expressing cells, namely 3.1 
compared to 4.1 for Ac-TZ14011-MSAP (Table 1). Since the MFIR in the MDAMB231 cells 
was increased after incubation with Ac-TZ14011-MSAP-In compared to Ac-TZ14011-MSAP 
and the antibody (Table 1), it is plausible that incubation with Ac-TZ14011-MSAP-In results 
in increased nonspecific binding (Figure 2). 
Incubation of MDAMB231CXCR4+ cells with different concentrations of Ac-TZ14011-
MSAP yielded a binding curve that appears to exist out of two components (Figure 3A). 
The nonlinear component of the binding curve can be ascribed to specific receptor 
binding and the linear component to nonspecific cell binding. By using this binding 
model, direct determination of the nonspecific binding was not required. The similarity in 
the CXCR4-receptor affinities of Ac-TZ14011-MSAP and Ac-TZ14011-MSAP-In (Table 2) 
indicates that indium binding does not affect the interaction between the peptide and 
CXCR4. 
Table 2. Dissociations constants (KD) of the constructs.   
Construct KD (nM)
Ac-TZ14011-unlabeled 8.61 ± 1.42
Ac-TZ14011-MSAP 186.9 ± 52.4
Ac-TZ14011-MSAP-In 177.1 ± 37.2
Ac-TZ14011-DTPA 124.4 ± 23.9
Ac-TZ14011-FITC 203.5 ± 67.1
TR14010 (scambled pepide) > 5000
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Figure 3. A) Determination of affinity of constructs Ac-TZ14011-MSAP and Ac-TZ14011-MSAP-In with saturation 
binding experiments. B) Competition experiments with three other Ac-TZ14011 peptides in the presence of 250 
nM of Ac-TZ14011-MSAP. C) Structures of the peptides used for competition experiments.
To compare the receptor affinity of Ac-TZ14011-MSAP and Ac-TZ14011-MSAP-In 
with the other peptide derivatives, different amounts of Ac-TZ14011, Ac-TZ14011-DTPA or 
Ac-TZ14011-FITC were added in the presence of 250 nM of Ac-TZ14011-MSAP (Figure 3B 
and 3C). All three peptide derivatives could compete with Ac-TZ14011-MSAP for CXCR4 
binding, confirming the specificity of Ac-TZ14011-MSAP. The KD values, obtained by fitting 
the inhibition curves with a competition model, of the monolabeled peptides Ac-TZ14011-
DTPA and Ac-TZ14011-FITC were in the order of the KD values of Ac-TZ14011-MSAP and 
Ac-TZ14011-MSAP-In (Table 1). In line with previous reports, the scrambled peptide 
TR14010 did not show significant binding; KD > 5000 nM (Table 2).
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The cellular distribution of Ac-TZ14011-MSAP was evaluated to see if binding to 
CXCR4 on the cell membrane did occur. Confocal microscopy imaging performed at 4°C 
revealed clear staining of the cell membrane of MDAMB231CXCR4+ cells after incubation 
with Ac-TZ14011-MSAP (Figure 4). During imaging at 37°C minor staining in vesicular 
structures was detected, which is common for internalizing membrane receptors.  
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Figure 4. Confocal microscopy of Ac-TZ14011-MSAP using MDAMB231CXCR4+ cells.
As the CXCR4 expression in MDAMB231CXCR4+ cells decreases to basal levels in vivo, 
mice with CXCR4 positive ‘spontaneous’ MIN-O tumors were used. Low CXCR4 expressing 
4T1 tumor lesions served as control. Tumor-bearing mice were injected with 111In-labeled 
Ac-TZ14011-MSAP 24 hrs prior to the SPECT/CT and fluorescence imaging (Figure 5). 
MIN-O tumor lesions could be accurately detected with both modalities. The obtained 
tumor-to-muscle ratio was significantly higher in MIN-O tumor lesions compared to 4T1 
tumor lesions; 4.55 ± 0.68 vs. 1.20 ± 0.12 (P < 0.01). This indicates that Ac-TZ14011-MSAP 
can be used to discriminate CXCR4 positive from CXCR4 negative tumors in vivo. 
Figure 5. A) SPECT/CT (axial) of a MIN-O tumor-bearing mouse. B) Fluorescence image of an intersected MIN-O 
tumor-bearing mouse.
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Discussion
Conjugation of a hybrid imaging label to a peptide results in an imaging agent that 
can be detected using multiple imaging modalities. Unfortunately, conjugation of such 
a label can have a negative influence on the affinity of the targeting moiety.4 This was 
also seen after conjugation of the MSAP reagent to Ac-TZ14011 as the receptor affinity 
of the unlabeled peptide was approximately 20-fold higher than for the labeled 
derivatives (Table 2). Since the affinity of Ac-TZ14011-MSAP-In remains in the nanomolar 
range, this decrease is not likely to be an obstruction for using Ac-TZ4011-MSAP-In in 
molecular imaging applications.20 Furthermore, comparison between the receptor 
affinities of differently labeled derivatives of Ac-TZ14011 illustrated that the hybrid 
MSAP label does not hamper receptor binding more than the smaller FITC and DTPA 
labels do.
The uptake ratio obtained with Ac-TZ14011-MSAP-In in the MDAMB231CXCR4+ and 
MDAMB231 cells was somewhat lower compared to Ac-TZ14011-MSAP, namely 3.1 
and 4.1, respectively (Table 1). This effect can be caused by an increase in nonspecific 
binding of Ac-TZ14011-MSAP-In (Figure 2). Such an increase in nonspecific binding 
is most likely a charge related effect; the DTPA chelate in Ac-TZ14011-MSAP is mainly 
-2 charged and indium bound DTPA in Ac-TZ14011-MSAP has a charge of -1, 21,22 
increasing hydrophobicity of the label. In general, labels with increased hydrophobicity 
drive (nonspecific) cellular uptake.4
Molecular modeling studies showed that D-Lys8 in T140 (the parental compound 
of Ac-TZ14011) does not interact with CXCR4.23 Furthermore, the crystal structure of 
CVX15, which is similar to T140, bound to CXCR4 also showed no crucial interactions in 
this area.24 However, we found that D-Lys8 functionalization in Ac-TZ14011 still influenced 
the binding affinity. This influence might be explained by evaluation of the possible 
different effects of peptide modification on (CXCR4) receptor binding. A modification on 
the peptide: i) can directly change a receptor interaction (e.g. a hydrogen bond), ii) can 
change the 3D structure of the peptide, and/or iii) can hinder the phamacophore to 
bind properly to the receptor via steric hindrance.25 Here, the third effect is most likely 
the cause of the decrease in affinity. 
A logical chemical modification to reduce the steric hindrance would be the 
incorporation of a larger spacer between the imaging label and the pharmacophore. 
Although it has been shown that incorporation of a 6-aminocaproic acid spacer does 
not yield a higher affinity,26 it is possible that longer spacers will be more effective. 
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Conclusion
In this Chapter, the first hybrid CXCR4 antagonistic peptide, containing a Cy5.5-like 
dye and a DTPA chelate is described. Despite functionalization with a relatively large 
hybrid label Ac-TZ14011-MSAP retained its specificity and nanomolar CXCR4-affinity in 
vitro. Moreover, indium binding to the chelate did not affect the fluorescence properties. 
The initial in vivo studies showed that Ac-TZ14011-MSAP was able to discriminate between 
CXCR4 positive and negative tumors.  
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All chemicals were obtained from commercial sources and used without further 
purification. The reactions were monitored by thin layer chromatography (TLC).
Scheme A1. Conjugation of the MSAP label to Ac-TZ14011 and subsequent indium labeling. 
Ac-TZ14011 
Ac-TZ14011 was synthesized according to described procedures.1 
CyAL-5.5b
CyAL-5.5b (Figure A1) was synthesized according to previously described procedures.
2
Figure A1. Chemical structure of CyAL-5.5b.
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MSAP reagent 
The multifunctional single attachment point (MSAP) reagent was synthesized based 
on previously described procedures.3,4
Ac-TZ14011 (8.4 mg, 3.0 μmol) and the MSAP reagent (3.4 mg, 2.0 μmol) were 
dissolved in 2 mL of DMSO. DiPEA (7.0 μL, 40 μmol) was added and the mixture was stirred 
overnight at room temperature, after which the mixture was purified by preparative HPLC 
using a Waters HPLC system with a UV detector operating at 230 nm and a Waters Atlantis 
C18 10 μm (250 ´ 19 mm) column. A gradient of 0.05% TFA in H2O/CH3CN 9:1 to 0.05% TFA 
in H2O/CH3CN 1:4 40 minutes was used. The product was obtained as a blue fluffy solid (3.9 
mg, 45%) after pooling of the appropriate fractions and lyophilization. MS (MALDI-TOF): 
[M+H]+ calculated 3676.677, found 3676.256.
For the chemical structure of Ac-TZ14011-MSAP, see Scheme A1
Radiolabeling of Ac-TZ14011-MSAP 
Ac-TZ14011-MSAP was dissolved in 0.1 M of acetic acid (50 μg/100 μL) and InCl3 
(10 MBq/50 ug of Ac-TZ14011-MSAP; Covidien-Mallinkrodt) was added. After 30 min 
of incubation, labeling was validated with thin layer chromatography (TLC) using 74 mM 
of sodium citrate (pH 5) as an eluent and a VCS-201 TLC scanner (Veenstra Instruments). In 
all cases, labeling efficacy was >99%. Before injection, saline (1:1) was added. 
Ac-TZ14011-MSAP-In 
A solution of Ac-TZ14011-MSAP with a concentration of 160 μM in 0.1 M AcOH was 
prepared. Half of this solution was diluted (1:1 v/v) with 0.1 M of AcOH to yield a stock 
solution of 80 μM of Ac-TZ14011-MSAP. The other half was added to the same amount of 
160 μM of InCl3 in AcOH, incubated for 30 min, yielding a stock solution of 80 μM of 
Ac-TZ14011-MSAP-In. 
Ac-TZ14011-DTPA 
Ac-TZ14011-DTPA was synthesized according to previously described procedures.1
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Ac-TZ14011-FITC 
Fluorescein isothiocyanate isomer I (FITC; 2.32 mg, 5.95 μmol) in 500 μL of DMSO was 
added to Ac-TZ14011 (11.1 mg, 3.96 μmol) in 1 mL of 0.1 M NaHCO3 and 2 ml of CH3CN. 
The mixture was stirred overnight at room temperature, the solution was concentrated 
and the product was purified by preparative HPLC using a Waters HPLC system with a UV 
detector operating at 230 nm and a Waters Atlantis C18 10 μm (250 × 19 mm) column 
using a gradient of 0.05% TFA in H2O/CH3CN 9:1 to 0.05% TFA in H2O/CH3CN 1:4 in 40 min. 
The product was obtained as a yellow fluffy solid (4.3 mg, 35%) after pooling of the 
appropriate fractions and lyophilization. MS (MALDI-TOF): [M+H]+ calculated 2496.118, 
found 2495.168.
Scrambled peptide TR14010 
TR14010 (Figure A2) was synthesized according to previously described procedures.5
Figure A2. Structure of TR14010.
Spectroscopy
For the recording of absorption and emission spectra 0.25 mL of Ac-TZ14011-MSAP 
or Ac-TZ14011-MSAP-In stock solution was added to 1 mL of EtOH and 2.25 mL of PBS. 
Absorption spectroscopy was performed on a Lambda Bio 20 spectrometer (Perkin Elmer). 
Emission spectra were recorded using a 627 nm LED lamp (Luxeon III Star, Lambt, red, 
Farnell) and a VS140-VISNIR-CCD spectrometer (Horiba Jobin Yvon). Absorption and 
emission spectra of Ac-TZ14011-MSAP and Ac-TZ14011-MSAP-In are shown in Figure 1 of 
the main text.
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Abstract
Conjugation of a hybrid MSAP label was shown to have a negative influence on the 
affinity of the CXCR4 targeting peptide Ac-TZ14011. To investigate if multimerization, e.g. 
increasing the amount of targeting peptides per molecule, could be used to minimize the 
influence of the MSAP label on the binding affinity of Ac-TZ14011, mono-, di- and 
tetrameric Ac-TZ14011-containing dendrimers were prepared and functionalized with a 
MSAP label. Confocal microscopy revealed membranous staining of MDAMB231CXCR4+ cells 
after incubation with the dendrimers at 4°C, consistent with the localization of CXCR4. 
Unlabeled, the CXCR4 affinity of the dimer and tetramer was somewhat lower than the 
affinity of the monomer. However, when labeled with the hybrid label the CXCR4 affinity 
of the dimer and tetramer increased compared to the monomer. Distribution studies 
revealed that the presence of additional peptides in the dimer and tetramer reduced 
nonspecific muscle uptake. Thus, multimerization of the Ac-TZ14011 peptide reduced the 
negative influence of the hybrid label on the receptor affinity and the biodistribution. 
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Introduction
The development of hybrid imaging agents is attaining a significant interest in the 
field of molecular imaging as hybrid imaging agents can be used in more than one 
imaging modality.1-6 Each modality has its own strengths and weaknesses, and therefore, 
a combination of modalities is often used in the clinic. In principle, hybrid imaging agents 
can also be used for postoperative pathology and assessment for the effectiveness of 
chemo- and/or immunotherapy.
Several receptor targeting peptides (e.g. RGD, octreotate, bombesin and Ac-TZ14011) 
have been functionalized with labels that combine radioactivity and fluorescence.1,7 Such 
labels are often as large as the tumor targeting peptide. Therefore, this hybrid labeling 
technology can have a significant (negative) influence on the receptor binding and the 
biodistribution. Especially the dye-driven, nonspecific uptake by organs and tissues is a 
substantial concern.1 We reasoned that use of multimeric peptide dendrimers, consisting 
of multiple peptides (e.g. 4) and one hybrid label, can possibly reduce the influence of the 
label.1 Multimerization is a well known strategy in order to enhance the receptor affinity 
and specificity for a targeting moiety.8-14 By increasing the amount of peptides with respect 
to the label,  the label can be shielded from the biological environment.1 
The strategy of peptide multimerization has already been successfully applied with 
radiolabels and fluorescent labels.15-19 However, only nano-sized multimeric peptides have 
been prepared with both a radiolabel and a fluorescent label.20,21 Despite the fact that 
nanoparticles can generally benefit from the enhanced permeability and retention (EPR) 
effect,22 these specific ‘large’ nanoparticles suffer from high nonspecific (liver) uptake and 
are not able to extravasate from blood vessels into the tumor.20,21 Surprisingly, small hybrid 
peptide dendrimers, which generally have a better biodistribution, have never been 
reported. Here, the first hybrid Ac-TZ14011-containing dimeric and tetrameric dendrimers 
for targeting the chemokine receptor 4 (CXCR4) are described. 
Materials and Methods
Cell culture
The human breast cancer cell line MDAMB231CXCR4+ was kindly provided by Ed Roos 
(NKI-AvL, Amsterdam, The Netherlands). In the MDAMB231CXCR4+ cells CXCR4 expression 
was upregulated after culture under hypoxic conditions. Cells with high CXCR4 expression 
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were selected using flow cytometry, resulting in the MDAMB231CXCR4+ cell line. Cells were 
maintained in Gibco’s minimum essential medium (MEM) enriched with 10% fetal bovine 
serum, Penicillin/Streptomycin, L-glutamine, non-essential amino acids, sodium pyruvate 
and MEM vitamins solution (all Life Technologies Inc.). Cells were kept under standard 
culture conditions.
Confocal microscopy 
MDAMB231CXCR4+ cells were seeded onto coverslips (Ø 24mm; Karl Hecht GmbH & Co) 
and incubated overnight. The cells were washed with medium and incubated with 1 μM 
of compound in medium for one hr at 4°C and washed again with ice cold phosphate 
buffered saline (PBS). Confocal microscopy images were taken at 37°C on a Leica TCS-SP2-
AOBS Live confocal microscope (Leica Microsystems Heidelberg GmbH). 
Determination of dissociation constants by flow cytometry
MDAMB231CXCR4+ cells were trypsinized and aliquoted in portions of 300000 cells. 
For saturation binding experiments different concentrations of (Ac-TZ14011)2-MSAP or 
(Ac-TZ14011)4-MSAP ranging between 0 - 1000 nM in 50 μL of 0.1% bovine serum albumin 
(BSA) in PBS were added. For competition experiments different concentrations 
(0 -100,000 nM) of (Ac-TZ14011)2 or (Ac-TZ14011)4 in the presence of 250 nM of 
Ac-TZ14011-MSAP in 50 μL of 0.1% BSA in PBS were added. Cells were incubated for 
one hr at 4°C. The cells were washed (two times) with 300 μL of 0.1% BSA in PBS, 
resuspended in 300 μL of 0.1% BSA in PBS and fluorescence was measured using a CyAn 
ADP flow cytometer (DakoCytomation) with APC-Cy7 settings (635 nm laser and 750 nm 
long pass filter). Live cells were gated on Forward Scatter, Side Scatter and Pulse Width 
and 20000 viable cells were analyzed. All experiments were performed in duplicate. 
The normalized geometric means were fitted with equations in the GraphPad Prism 
5 software. The KD values of (Ac-TZ14011)2-MSAP and (Ac-TZ14011)4-MSAP were calculated 
using the ‘Binding – Saturation, One site – Total’ nonlinear regression equation (Eq. 1). 
The KD values of (Ac-TZ14011)2 and (Ac-TZ14011)4 were calculated using the ‘Binding - 
Competitive, One site – Fit Ki’ nonlinear regression equation (Eq. 2 and 3). The KD values of 
Ac-TZ14011-MSAP (186.9 nM) and Ac-TZ14011 (8.61 nM) have previously been reported.10 
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Cell viability analysis
Cell viability, based on the percentage of gated cells, was assessed using the flow 
cytometry data obtained from the saturation binding and competition experiments. For 
compounds Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP and (Ac-TZ14011)4-MSAP the 
percentage of gated cells when no compound was added was defined as 100% and the 
percentage of gated cells for the different concentrations of Ac-TZ14011-MSAP, (Ac-
TZ14011)2-MSAP and (Ac-TZ14011)4-MSAP was calculated with respect to this. For 
compounds Ac-TZ14011, (Ac-TZ14011)2 and (Ac-TZ14011)4 the percentage of gated cells 
when only 250 nM of Ac-TZ14011-MSAP was added was defined as 100% and the 
percentage of gated cells for the different concentrations of Ac-TZ14011, (Ac-TZ14011)2, 
(Ac-TZ14011)4 was calculated in accordance.
             (Eq. 1)
y  = normalized fluorescence
Bmax  = maximum specific binding in the units of the y axis 
x  =  concentration of Ac-TZ14011-MSAP or Ac-TZ14011-MSAP-In 
in nM
KD  =  equilibrium dissociation constant of Ac-TZ14011-MSAP or Ac-
TZ14011-MSAP-In in nM
NS  = slope of nonspecific binding
Background  = amount of normalized fluorescence with no added compound
                (Eq. 2)
     (Eq. 3)
IC50  =  concentration of competitor that results in binding half-way 
between Bottom and Top
KD  = equilibrium dissociation constant of the competitor in nM
[Ac-TZ14011-MSAP]  = concentration of Ac-TZ14011-MSAP (250 nM)
KD,Ac-TZ14011-MSAP  = dissociation constant of Ac-TZ14011-MSAP (186.9 nM)
y  = normalized fluorescence
Bottom and Top  = plateaus in the units of the y-axis
y = Bmax ∗ x
KD + x
+ NS ∗ x + Background
log IC50 = log(10
logKD ∗ (1 + [Ac−TZ14011−MSAP]
DK ,Ac−TZ14011−MSAP
))
y = Bottom + Top − Bottom
1+10(x − log IC50 )
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In vivo model
For generation of the CXCR4-positive mouse tumor lesions, FVB mice (n = 3 for each 
compound; 3 - 4 weeks of age) were used. Before MIN-O lesion segment transplantation 
(and imaging), mice were anaesthetized using a hypnorm (VetaPharma Ltd)/dormicum 
(Midazolam; Roche)/water solution (1:1:2; 5 µL/g i.p.). Via a small incision, the inguinal 
lymph node was excised, whereafter a piece of preinvasive 8w-B MIN-O tissue was placed 
into the remaining tissue of the 4th mammary gland.23-25 Approximately 6-8 weeks after 
transplantation, lesions were deemed suitable for further experiments (0.8 - 1 cm in 
diameter). All animal experiments were performed in accordance with Dutch welfare 
regulations and approved by the local ethics committee.
Radiolabeling
Compounds Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP and (Ac-TZ14011)4-MSAP were 
dissolved in 0.1 M of acetic acid (50 μg/100 μL) and InCl3 (10 MBq/50 μg of compound; 
Covidien-Mallinkrodt) was added. After 30 min of incubation, the labeling was validated 
with TLC using 74 mM of sodium citrate (pH 5) as an eluent and a VCS-201 TLC scanner 
(Veenstra Instruments). In all cases, labeling efficacy was >99%. Before injection, the 
solution was diluted (1:1) with saline (0.90% w/v of NaCl in water).  
Single photon emission computed tomography/computed tomography (SPECT/CT)
24 Hrs after intravenously injection of 50 μg of 111In-labeled compound (10 MBq), the 
mice were placed in a temperature controlled (37°C) animal holder (Equipment Veterinaire 
MINERVE) before performing a SPECT/CT scan on the nanoSPECT/CT (Bioscan Inc.). The 
region of interest (ROI) incorporating the whole body was selected based on a (sagital) 
tomographic planning X-ray image followed by a helical 3D CT. After ROI selection, a 
sequential total body SPECT scan of the same field of view was performed. After acquisition, 
the data was reconstructed with HiSPECT software (Scivis GmbH). The SPECT and CT data 
sets were automatically co-registered. The images were analyzed using the InVivoScope 
post processing software (Bioscan Inc.).
Distribution
After SPECT/CT imaging, tissues were excised and weighed. The amount of 
radioactivity present in the tissues was counted using a Perkin Elmer 1480 Wizard 3’’ 
automatic gamma counter (245 keV; 60 sec). Counts per minute were converted into MBq 
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and corrected for decay. The percentage of the injected dose per gram of tissue (%ID/g) 
was calculated as followed: ((MBq measured in tissue/ injected dose) *100%)/weight of 
tissue. P values were calculated using an unpaired t test (GraphPad).
Results
Design and synthesis
In order to minimize the negative influence of the hybrid MSAP label on the receptor 
affinity of the CXCR4 targeting peptide Ac-TZ14011, dimeric and tetrameric dendrimers 
were prepared, where the MSAP label was placed in the core of the dendrimer (Figure 1). 
Additional β-alanine spacers were incorporated to ensure that the peptide epitopes 
would not hinder the CXCR4 binding of the other peptides. The design of the multimeric 
compounds was verified by inserting the respective models of Figure 1 into the crystal 
structure of CXCR4 using the modeling program Yasara.26 The modeling data suggested 
that the spacers were long enough to avoid steric hindrance (see the Appendix of this 
Chapter). The synthesis of the dendrimers is outlined in the Appendix of this Chapter 
(Scheme A1).
Figure 1. Molecular models of the mono-, di- and tetrameric Ac-TZ14011 dendrimers with the MSAP label. For 
clarity, the MSAP label is not colored by element: the CyAL-5.5b fluorophore is displayed in red, the indium-
bound DTPA chelate in blue and the spacer in grey. In the dimer and, especially, in the tetramer a smaller 
percentage of the whole molecule comprises the MSAP label.  
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In vitro evaluation
The CXCR4 receptor affinity of the unlabeled constructs was determined using a 
previously reported cell-based competition assay, where the unlabeled peptides 
compete with monomer Ac-TZ14011-MSAP for binding to the CXCR4 receptor on 
MDAMB231CXCR4+ cells (Figure 2A).7 The dissociation constant (KD) of the monomer 
Ac-TZ14011 has previously been reported to be 8.61 nM (Table 1).7 The receptor affinity 
of both dimer (Ac-TZ14011)2 and tetramer (Ac-TZ14011)4 was found to be somewhat 
lower; 23.5 nM and 30.6 nM, respectively. A multivalency effect based on e.g. bivalent 
binding or statistical rebinding was not observed, but rather a slight decrease in affinity 
(Table 1). 
Table 1. Dissociation constants (KD) of the Ac-TZ14011 derivatives.   
Unlabeled derivatives MSAP-labeled derivatives
compound KD (nM) compound KD (nM)
monomers Ac-TZ14011 8.61 ± 1.42 Ac-TZ14011-MSAP 186.9 ± 52.4
dimers (Ac-TZ14011)2 23.5 ± 2.43 (Ac-TZ14011)2-MSAP 93.1 ± 10.1
tetramers (Ac-TZ14011)4 30.6 ± 4.84 (Ac-TZ14011)4-MSAP 80.5 ± 11.6
The receptor affinity of the MSAP-labeled constructs Ac-TZ14011-MSAP, 
(Ac-TZ14011)2-MSAP and (Ac-TZ14011)4-MSAP was determined using saturation binding 
experiments (Figure 2B). The affinity of the monomer Ac-TZ14011-MSAP amounts to 
186.9 nM.7 Interestingly, the dimer (Ac-TZ14011)2-MSAP had a two-fold higher affinity 
(93.1 nM). This clear effect is in contrast with the trend found for the unlabeled peptide 
derivatives; the unlabeled dimer (Ac-TZ14011)2 had an almost three-fold decrease in 
affinity compared to the monomer Ac-TZ14011 (Table 1). For the tetramer (Ac-TZ14011)4-
MSAP (KD = 80.5 nM) the improvement with respect to dimer (Ac-TZ14011)2-MSAP was 
minimal. However, the saturation binding curve showed that the nonspecific cell 
binding was considerably reduced for the tetramer (Ac-TZ14011)4-MSAP, i.e. the linear 
part of the curve is less steep than that Ac-TZ14011-MSAP (Figure 2B and Eq 1). This 
suggests that the peptides in the tetramer indeed shield the MSAP label from nonspecific 
cell membrane binding, as was designed. 
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Figure 2. A) Competition experiments of Ac-TZ14011, (Ac-TZ14011)2 and (Ac-TZ14011)4 in the presence of 250 
nM of Ac-TZ14011-MSAP. B) Saturation binding experiments of Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP and (Ac-
TZ14011)4-MSAP. C and D) Cell viability of MDAMB231
CXCR4+ cells in the presence of different concentrations of 
Ac-TZ14011, (Ac-TZ14011)2 and (Ac-TZ14011)4 C) and Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP and D) (Ac-
TZ14011)4-MSAP. For all graphs the bars represent average ± SD.
Next to the CXCR4 affinity studies with flow cytometry, the cellular distribution of 
Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP and (Ac-TZ14011)4-MSAP was evaluated using 
confocal microscopy. MDAMB231CXCR4+ cells were incubated with 1 μM of compound for 
one hr at 4°C, to minimize active internalization. All three peptide conjugates displayed 
membranous staining (Figure 3), which is in accordance with the location of the CXCR4 
receptor.7,27-29 Also a small amount of internalization Ac-TZ14011-MSAP, (Ac-TZ14011)2-
MSAP and (Ac-TZ14011)4-MSAP observed. This internalization was most likely caused by 
the fact that the confocal imaging was performed at 37°C, resulting in some receptor 
mediated endocytosis during the image acquisition. As a negative control, cells were 
incubated with the MSAP label alone, as the latter showed almost no staining (Figure 
3D). Hence the cell membrane staining pattern of compounds Ac-TZ14011-MSAP, (Ac-
TZ14011)2-MSAP and (Ac-TZ14011)4-MSAP is driven by the targeting peptide moieties 
and is not caused by nonspecific binding of the MSAP label. 
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Figure 3. Confocal microscopy and transmission images of the hybrid peptide conjugates on MDAMB231CXCR4+ 
cells. A) 1 μM of monomer Ac-TZ14011-MSAP; B) 1 μM of dimer (Ac-TZ14011)2-MSAP; C) 1 μM of tetramer 
(Ac-TZ14011)4-MSAP; D) 1 μM of MSAP label.
The effect of the monomers Ac-TZ14011 and Ac-TZ1401-MSAP, dimers (Ac-TZ14011)2 
and (Ac-TZ14011)2-MSAP and tetramers (Ac-TZ14011)4 and (Ac-TZ14011)4-MSAP on the 
cell viability during the KD determination was measured (Figure 2C-D); reduced cell 
viability may increase nonspecific binding and/or uptake. None of the six compounds 
influenced cell viability up to concentrations of 1 μM. The tetramer (Ac-TZ14011)4 displayed 
toxic effects (IC50 = 13.0 μM ± 0.29) at lower concentrations compared to the dimer (Ac-
TZ14011)2 (IC50 = 88.9 μM ± 8.77) and the monomer Ac-TZ14011 (IC50 = 1912 μM ± 285) 
(Figure 2C). 
In vivo evaluation
In vivo imaging studies were performed to evaluate the tumor targeting ability of 
Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP and (Ac-TZ14011)4-MSAP at 24 hrs after injection 
of 111In-labeled compounds (Figure 4). 
All three compounds enabled visualization of the tumor lesions. Biodistribution of 
the dendrimers was compared to the distribution of Ac-TZ14011-DTPA, containing only a 
DTPA chelate as an imaging label.30 As a negative control, the MSAP label was used without 
further functionalization (reactive group was neutralized). 
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Figure 4. SPECT/CT of A) monomer Ac-TZ14011-MSAP, B) dimer (Ac-TZ14011)2-MSAP and C) tetramer 
(Ac-TZ14011)4-MSAP. 
Table 2. Distribution of 111In-labeled Ac-TZ14011-DTPA , MSAP label, monomer Ac-TZ14011-MSAP, dimer 
(Ac-TZ14011)2-MSAP and tetramer (Ac-TZ14011)4-MSAP  in MIN-O tumor bearing mice at 24 hrs post injecting.
Uptake (%ID/g)






Blood 0.01 ± 0.00 0.32 ± 0.09** 0.14 ± 0.02*** 0.14 ± 0.03** 0.11 ± 0.01***
Brain 0.00 ± 0.00 0.03 ± 0.01 0.02 ± 0.00 0.03 ± 0.01 0.02 ± 0.00
Lungs 0.13 ± 0.02 0.65 ± 0.18** 1.02 ± 0.13*** 2.13 ± 0.60** 1.68 ± 0.31**
Heart 0.05 ± 0.00     0.64 ± 0.12** 0.89 ± 0.22** 0.60 ± 0.12** 0.43 ± 0.06***
Liver 5.08 ± 0.52 5.76 ± 1.11 22.46 ± 5.46** 30.59 ± 5.45** 22.43 ± 0.67***
Kidneys 27.07 ± 0.74 6.49 ± 2.99*** 7.50 ± 1.39*** 6.46 ± 1.36*** 4.37 ± 0.52***
Spleen 1.14 ± 0.32 0.93 ± 0.13 4.76 ±1.23** 7.01 ± 1.45** 4.66 ± 0.46***
Stomach 0.06 ± 0.01 0.81 ± 0.45* 0.81 ± 0.16** 0.97 ± 0.52* 1.09 ± 0.52*
Intestines 0.10 ± 0.01 1.02 ± 0.31** 1.85 ± 0.08*** 2.06 ± 0.26*** 1.56 ± 0.46**
Tumor 0.19 ± 0.03 n.d. 1.10 ± 0.60 0.57 ± 0.19* 0.42 ± 0.10*
Muscle 
(paw)
0.03 ± 0.00 0.22 ± 0.06** 0.31 ± 0.01*** 0.07 ± 0.03 0.08 ± 0.02*
The significance with respect to 111In-labeled Ac-TZ14011-DTPA is indicated by the asterisks (* = P < 0.05, ** = P < 
0.01, *** = P < 0.001). N.d. = not determined.
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Figure 5. Distribution of 111In-labeled Ac-TZ14011-DTPA, MSAP label, monomer Ac-TZ14011-MSAP, dimer 
(Ac-TZ14011)2-MSAP and tetramer (Ac-TZ14011)4-MSAP in MIN-O tumor-bearing mice at 24 hrs post injection. 
Significant differences (P < 0.05) with respect to 111In-labeled Ac-TZ14011-DTPA are indicated by the asterisks. (* = P 
< 0.05). 
 
Injection of the monomer Ac-TZ14011-MSAP resulted in an increase in liver and 
intestinal uptake and a reduction in kidney uptake compared to the reference Ac-TZ14011-
DTPA, suggesting a change in the clearance route (Table 2, Figure 5). Tumor uptake of the 
monomer Ac-TZ14011-MSAP was more than five times higher than for Ac-TZ14011-DTPA. 
However, this increase was accompanied with higher nonspecific uptake in the lungs, 
heart, spleen, stomach, intestines and muscles, most likely caused by interactions with the 
relative hydrophobic CyAL-5.5b fluorophore. Overall, this resulted in a lower tumor-to-
muscle ratio compared to Ac-TZ14011-DTPA, 4.55 vs. 6.67, respectively (Table 3). The 
dimer (Ac-TZ14011)2-MSAP had a similar uptake profile as the monomer (Table 2, Figure 
5). However, the muscle uptake was significantly lower than that of the monomeric MSAP 
peptide (P < 0.0001). The tumor and heart uptake was lower than that of monomer Ac-
TZ14011-MSAP, although this different was not significant. The decrease of the uptake in 
the muscle and heart was larger than in the tumor, resulting in an improved tumor-to-
muscle ratio of 7.41 (Table 3). This improvement was again not significant, as the standard 
deviation found for (Ac-TZ14011)2-MSAP was rather high.
The same trend was seen for the tetramer (Ac-TZ14011)4-MSAP (Table 2, Figure 5). 
The uptake in the tumor and in the heart was slightly lower than that of dimer 
(Ac-TZ14011)2-MSAP, while uptake in muscle was not reduced further for the tetramer 
(Ac-TZ14011)4-MSAP. As a consequence, the tumor-to-muscle ratio of the tetramer was 
lower than that of the dimer (5.47 vs. 7.41, respectively; Table 3). 
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Table 3. Tumor-to-muscle ratios derived from the biodistribution studies.   
Compound Tumor-to-muscle ratio Relative ratio compared to 
compound Ac-TZ14011-DTPA
Ac-TZ14011-DTPA 6.67 ± 0.66 1
monomer Ac-TZ14011-MSAP 4.55 ± 0.68* 0.68
dimer (Ac-TZ14011)2-MSAP 7.41 ± 1.87 1.11
tetramer (Ac-TZ14011)4-MSAP 5.47 ± 0.50 0.82
* P < 0.05 for the comparison of compound Ac-TZ14011-MSAP with Ac-TZ14011-DTPA. 
Discussion
The main goal of this study was to minimize the negative influence of the hybrid 
MSAP label on receptor binding and nonspecific binding in vivo by using multimeric 
structures. 
It is challenging to design relatively small dendrimers that can position peptide-
binding epitopes correctly for simultaneous binding to multiple G-protein coupled 
receptors (GPCRs). Previously reported iridium complexes outfitted with one, two or three 
Ac-TZ14011 peptides did not display a considerable multivalency effect.27 Moreover, 
Tanaka et al. have shown that bivalent pentapeptidic CXCR4 ligands with spacers larger 
than 4.5 nm (15 proline residues) only display a modest increase in affinity of maximal 3.2-
fold due to multivalent interactions.31 These findings are not uncommon for peptides 
binding to GPCRs, as multimeric octreotides also do not bind in a multivalent manner to 
the somatostatin GPCR.49,50 
However, the relatively short spacers that were used during the synthesis of the 
dimer (Ac-TZ14011)2-MSAP and the tetramer (Ac-TZ14011)4-MSAP did enable the shielding 
of the MSAP label from the biological environment by the peptides (Figure 1). As a 
consequence, the different peptide moieties on the dendrimers will not be able to bind 
multiple CXCR4 receptors simultaneously. Most likely this requires larger spacers of 5.5 – 
6.5 nm.31 However, our design can increase the binding affinity via statistical rebinding,8-10 
which is caused by an overall slower off-rate of the multimeric compound due to the close 
proximity of other CXCR4-binding peptide epitopes. As such, the bound peptide can be 
replaced by another peptide when released from the binding site.
The affinity of (Ac-TZ14011)2-MSAP and (Ac-TZ14011)4-MSAP was approximately 
two-fold higher compared to the affinity of the monomer. The increase in affinity of the 
Interventional molecular imaging, a hybrid approach260
tetramer with respect to the dimer was minimal, but the saturation binding curve showed 
that the nonspecific cell binding was considerably reduced for the tetramer, i.e. the linear 
part of the curve was less steep than that of the monomer (Figure 2B). Combined this 
suggests that addition of a peptide moiety reduces the negative influence of the MSAP 
label on the receptor affinity and that the peptides in the tetramer indeed increase the 
shielding of the MSAP label. 
The increasing multimeric character of the Ac-TZ14011 peptide seemed to lead to 
more cytotoxicity. Increasing the positive charge from +6 in the monomeric Ac-TZ14011-
MSAP, to +11 in the dimeric  (Ac-TZ14011)2-MSAP and +21 in the tetrameric (Ac-TZ14011)4-
MSAP may result in charge-driven (nonspecific) membranous binding and cause 
cytotoxicity, similar to that reported for positively charged PAMAM dendrimers.27,34
In vivo, an increase in nonspecific binding and a reduction in tumor-to-muscle ratio 
is a common effect when using monomeric hybrid labeled peptides.1 This is most likely 
caused by the relative large size of the (hybrid) imaging label. Addition of a peptide moiety 
in (Ac-TZ14011)2-MSAP clearly reduced nonspecific muscle uptake of monomer Ac-
TZ14011-MSAP compared to Ac-TZ14011-DTPA. While the uptake profile of both the 
monomer Ac-TZ14011-MSAP and the dimer (Ac-TZ14011)2-MSAP were similar (Table 2 
and Figure 5), the muscle uptake was significantly lower than that of the monomeric 
MSAP peptide (P < 0.001). Lower uptake levels in the muscle and heart resulted in an 
improved tumor-to-muscle ratio for the dimer (Ac-TZ14011)2-MSAP (Table 3). 
Unfortunately, this improvement was not significant, as the standard deviation was rather 
high (Table 3).
Nonspecific uptake of tetramer (Ac-TZ14011)4-MSAP in organs such as the lungs, 
heart and liver was slightly lower compared to the dimer (Ac-TZ14011)2-MSAP. The two 
additional peptides decreased the MSAP label driven nonspecific uptake even further and 
increased overall clearance from the body. Faster clearance is generally accompanied with 
reduced blood concentrations, and therefore, reduced the amount of compound available 
for receptor binding in the tumor. This effect appeared to have overruled the higher 
CXCR4 affinity of tetramer (Ac-TZ14011)4-MSAP compared to dimer (Ac-TZ14011)2-MSAP 
resulting in a slightly reduced uptake in the tumor.
Based on the in vitro experiments the dimer (Ac-TZ14011)2-MSAP provides the most 
promising imaging agent as it practically has the same high affinity for CXCR4 as the 
tetramer (Ac-TZ14011)4-MSAP, has considerable less influence on the cell viability and is 
easier to prepare than the tetravalent derivative (Ac-TZ14011)4-MSAP. 
From the results of the in vivo studies a comparable conclusion can be drawn as the 
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additional peptide in dimer (Ac-TZ14011)2-MSAP reduced the negative influence of the 
hybrid MSAP label in monomer (Ac-TZ14011)-MSAP, yielding a tumor-to-muscle ratio 
higher than that of monomer (Ac-TZ14011)-MSAP,  and even than Ac-TZ14011-DTPA. The 
addition of two more peptides, as in tetramer (Ac-TZ14011)4-MSAP, however, did not result 
in a further improvement of the tumor-to-muscle ratio. 
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Conclusion
Multimerization resulted in reduction of the nonspecific binding caused by the 
hybrid label. The dimer, however, has less influence on the cell viability and the tumor-to-
muscle ratio of the dimer is higher. Thus, dimer (Ac-TZ14011)2-MSAP is the most promising 
CXCR4 imaging probe. 
The concept of multimerization of hybrid peptides can also be applied to other 
targeting peptides. It seems that the use of highly positively charged peptides and highly 
hydrophobic peptides should be avoided to suppress the cytotoxicity and the nonspecific 
cell and tissue binding. 
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Appendix Chapter 12
General
All chemicals were obtained from commercial sources and used without further 
purification. The reactions were monitored by thin layer chromatography (TLC). NMR 
spectra were taken using a Bruker Ultrashield 300 spectrometer (300 MHz 1H NMR, 75 MHz 
13C NMR) and the chemical shifts are given in ppm (δ) relative to tetramethylsilane (TMS). 
Abbreviations used include singlet (s), doublet (d), doublet of doublets (dd) and unresolved 
multiplet (m). MS (ESI) spectra were measured on a Waters LCTTM Orthogonal Acceleration 
Time of Flight Mass Spectrometer equipped with a Waters 2795 Seperation Module 
(Alliance HT) and a Waters 2996 Photodiode Array Detector (190 - 750 nm). HPLC was 
performed on a Waters HPLC system using a 1525EF pump and a 2489 UV detector. For 
preparative HPLC a Dr. Maisch GmbH Reprosil-Pur 120 C18-AQ 10 μm (250 x 20 mm) 
column was used and a gradient of 0.1% TFA in H2O/CH3CN 9:1 to 0.1% TFA in H2O/CH3CN 
1:9 in 40 min (12 mL/min) was employed. For analytical HPLC a Dr. Maisch GmbH Reprosil-
Pur C18-AQ 5 μm (250 x 4.6 mm) column was used and a gradient of 0.1% TFA in H2O/
CH3CN 95:5 to 0.1% TFA in H2O/CH3CN 5:95 in 20 min (1 mL/min) was employed.
MSAP reagent 
The multifunctional single attachment point (MSAP) reagent was synthesized based 
on previously described procedures.1
Ac-TZ14011 was synthesized according to previously described procedures.2 
Ac-TZ14011-MSAP 
Ac-TZ14011-MSAP was synthesized according to previously described procedures.1 
For use in confocal imaging, the active NHS ester of the MSAP label was hydrolyzed prior 
to the incubation:  150 μg of MSAP was dissolved in 29 μL of EtOH, 262 μL of H2O and 
2.5 μL of 4 M NaOH. After one hr stirring at 20°C, 3 μL of AcOH was added to neutralize the 
solution. This stock solution was further diluted in medium. 
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Ac-TZ14011-DTPA
Ac-TZ14011-DTPA (Figure A1) was synthesized according to previously described 
procedures.2
Figure A1. Structure of Ac-TZ14011-DTPA
Boc-Glu(β-Ala-OH)-β-Ala-OH
Boc-Glu-OH (9.10 g, 36.8 mmol), β-alanine methyl ester hydrochloride (14.0 g, 100 
mmol) and N-hydroxysuccinimide (8.60 g, 75 mmol) were dissolved in 500 mL of DMF. 
DiPEA (17.4 mL, 100 mmol) was added and the solution was cooled to 0°C. DCC (15.5 g, 75 
mmol) was added and the mixture was stirred overnight at 20°C. DMF was evaporated 
and H2O was added. The aqueous phase was extracted with EtOAc (three times). The 
combined organic phases were washed with 0.1 M Na2CO3 (three times), 5% citric acid 
(three times) and brine, dried with MgSO4, filtered and concentrated affording 9.8 g (23.5 
mmol, 64%) of Boc-Glu(β-Ala-OMe)-β-Ala-OMe. The product was used without further 
purification.
Boc-Glu(β-Ala-OMe)-β-Ala-OMe (1.47 g, 10 mmol) was dissolved in 105 mL of dioxane 
and 37.5 mL of MeOH. 7.5 mL of 4 M NaOH (30 mmol) was added and the solution was 
stirred for one hr at 20°C. The volatiles were evaporated and H2O was added. The aqueous 
phase was washed with EtOAc (two times), acidified with citric acid and extracted with 
EtOAc (five times). The combined organic phases were washed with 5% citric acid and 
brine, dried with MgSO4, filtered and concentrated. The product was purified by silica gel 
column chromatography (1% AcOH in CH2Cl2/MeOH 93:7) yielding 2.79 g (72%) of a Boc-
Glu(β-Ala-OH)-β-Ala-OH  as a white solid. 1H NMR (DMSO-d6, 300 MHz) δ = 1.37 (s, 9H, 3 
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CH3), 2.03-2.07 (m, 2H, Glu β CH2), 2.33-2.39 (m, 4H, Glu δ CH2 and CH2COOH), 2.62 (d, 2H, 
CH2COOH), 3.18-3.28 (m, 4H, 2 CH2CH2COOH), 3.82 (dd, 1H, Glu α CH), 6.79 (d, 1H, NH Boc), 
7.79-7.86 (m, 2H, 2 β-Ala NH). 13C NMR (DMSO-d6, 75 MHz) δ = 28.0 (Glu β CH2), 28.1 (3 CH3), 
31.2 (Glu δ CH2), 33.8, 33.9, 34.7, 34.7 (4 β-Ala CH2), 71.8 (Glu α CH), 78.0 (Boc C), 155.1 (Boc 
CO), 171.2, 171.6 (2 amide CONH), 172.8 (2 COOH).
Boc-protected dimer (Ac-TZ14011)2 
Boc-Glu(β-Ala-OH)-β-Ala-OH (1.95 mg, 5 μmol), Ac-TZ14011 (35 mg, 12.5 μmol) and 
BOP (5.53 mg, 12.5 μmol) were dissolved in 2 mL of DMSO. DiPEA (17 μL, 100 μmol) was 
added and the mixture was stirred overnight at 20°C, after which the mixture was purified 
by preparative HPLC. The product was obtained as a white fluffy solid (16.5 mg, 58%) after 
pooling of the appropriate fractions and lyophilization. MS (ESI): [M+3H]3+ calculated 
1522.78, found 1522.45; [M+4H]4+ calculated 1142.34, found 1142.06; [M+5H]5+ calculated 
914.07, found 914.08; [M+6H]6+ calculated 761.89, found 761.71.
Dimer (Ac-TZ14011)2 
Boc-protected dimer (Ac-TZ14011)2 (4.68 mg, 0.844 μmol) was dissolved in H2O 
(100 μL) and TFA (2 mL) and the solution was stirred for three hrs at 20°C. TFA was 
evaporated and the product was lyophilized from CH3CN/H2O yielding the product in 
quantitative yield as a white fluffy solid. MS (ESI): [M+4H]4+ calculated 1117.32, found 
1117.56; [M+5H]5+ calculated 894.06, found 894.25; [M+6H]6+ calculated 745.22, found 
745.39; [M+7H]7+ calculated 638.90, found 639.06.
Dimer (Ac-TZ14011)2-MSAP 
Dimer (Ac-TZ14011)2 (2.27 mg, 0.397 μmol) and MSAP (1.34 mg, 0.793 μmol) were 
dissolved in 800 μL of DMSO. DiPEA (2.6 μL, 15 μmol) was added and the solution was 
stirred overnight at 20°C, after which the mixture was purified by preparative HPLC. The 
product was obtained as a blue fluffy solid (1.97 mg, 69%) after pooling of the appropriate 
fractions and lyophilization. MS (ESI): [M+6H]6+ calculated 1006.82, found 1006.67; 
[M+7H]7+ calculated 863.13, found 863.19; [M+8H]8+ calculated 755.36, found 755.30.
Boc-protected tetramer (Ac-TZ14011)4
Boc-protected dimer (Ac-TZ14011)2 (11.42 mg, 1.46 μmol) was dissolved in H2O (200 
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μL) and TFA (2.8 mL) and the solution was stirred for 3 hrs at 20 °C. TFA was evaporated and 
the residue was dissolved in 1 mL of DMSO. DiPEA (5 μL, 29 μmol), Boc-Glu(β-Ala-OH)-β-Ala-
OH (0.19 mg, 0.50 μmol) and BOP (0.66 mg, 1.5 μmol) were added and the solution was 
stirred overnight at 20°C, after which the mixture was purified by preparative HPLC. The 
product was obtained as a white fluffy solid (2.61 mg, 45%) after pooling of the appropriate 
fractions and lyophilization. MS (ESI): [M+8H]8+ calculated 1161.47, found 1161.76; [M+9H]9+ 
calculated 1032.53, found 1032.73; [M+10H]10+ calculated 929.37, found 929.87; [M+11H]11+ 
calculated 844.98, found 845.05; [M+12H]12+ calculated 774.65, found 774.64.
Tetramer (Ac-TZ14011)2
Boc-protected tetramer (Ac-TZ14011)4 (2.61 mg, 0.23 μmol) was dissolved in H2O (100 
μL) and TFA (2 mL) and the solution was stirred for three hrs at 20°C. TFA was evaporated and 
the product was lyophilized from CH3CN/H2O yielding the product in quantitative yield as a 
white fluffy solid. MS (ESI): [M+9H]9+ calculated 1021.41, found 1021.63; [M+10H]10+ 
calculated 919.37, found 919.50; [M+11H]11+ calculated 835.88, found 836.00.
Tetramer (Ac-TZ14011)4-MSAP 
Tetramer (Ac-TZ14011)4 (2.08 mg, 0.18 μmol) and MSAP (0.51 mg, 0.30 μmol) were 
dissolved in 1 mL of DMSO. DiPEA (10 μL, 57 μmol) was added and the solution was stirred 
overnight at 20°C, after which the mixture was purified by preparative HPLC. The product 
was obtained as a blue fluffy solid (0.97 mg, 50%) after pooling of the appropriate fractions 
and lyophilization. MS (ESI): [M+19H]19+ calculated 567.40, found 568.95; [M+33H]33+ 
calculated 327.08, found 327.86; [M+34H]34+ calculated 317.49, found 316.91.
Molecular modeling
The structures of  MSAP label (the succinimidyl group was omitted), dimer Glu(β-Ala-
OH)-β-Ala-OH and tetramer Glu(β-Ala-Glu(β-Ala-OH)-β-Ala-OH)-β-Ala-Glu(β-Ala-OH)-β-
Ala-OH were minimized in Chem3D Pro 12.0 using the MM2 force field (minimum RMS 
gradient = 0.100) and PDB files of these minimized structures were made. The PDB file of 
CXCR4 complexed with the Ac-TZ14011 analog CVX15 (PDB entry code 3OE0) was loaded 
in YASARA (http://www.yasara.org).3 CXCR4 was deleted and the CVX15 peptide was 
modified to Ac-TZ14011 (Gln6 " Cit6; Lys7 " Arg7; D-Pro8 " D-Lys8; Gly15 and D-Pro16 " 
deleted). Ac-TZ14011 was minimized in YASARA: a simulation cell, in which each axis was 
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extended 5.0 Å from the molecule, was defined. The Amber99 forcefield was used and the 
temperature control was step-10 annealing, starting from 298 K and at every 10 simulation 
steps the velocity of all atoms was reduced to 90%. The simulation was stopped after 
10 000 fs, when the atoms almost did not move anymore. A PDB file was made of the 
minimized Ac-TZ14011 peptide.
For the monomer Ac-TZ14011-MSAP the PDB files of the minimized Ac-TZ14011 and 
MSAP label were loaded and the MSAP label was properly placed with respect to the 
amine of D-Lys8 and a peptide bond was created, yielding a model of monomer 
Ac-TZ14011-MSAP.
For the dimer (Ac-TZ14011)2-MSAP the PDB files of the minimized Ac-TZ14011 
(four times), dimer Glu(β-Ala-OH)-β-Ala-OH and MSAP label were loaded and the 
molecules were properly placed with respect to each other and peptide bonds were 
created, yielding a model of dimer (Ac-TZ14011)2-MSAP.
For the tetramer (Ac-TZ14011)4-MSAP the PDB files of the minimized Ac-TZ14011 
(four times), tetramer Glu(β-Ala-Glu(β-Ala-OH)-β-Ala-OH)-β-Ala-Glu(β-Ala-OH)-β-Ala-OH 
and MSAP label were loaded and the molecules were properly placed with respect to each 
other and peptide bonds were created, yielding a model of tetramer (Ac-TZ14011)4-MSAP.
 For the models of Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP and (Ac-TZ14011)4-
MSAP binding to CXCR4 (see Figure A2), the PDB files of CXCR4 with the CVX15 peptide 
(PDB entry code 3OE0) and of Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP or (Ac-TZ14011)4-
MSAP were loaded. An Ac-TZ14011 peptide in Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP or 
(Ac-TZ14011)4-MSAP was overlaid onto CVX15 and CVX15 was deleted, yielding models of 
Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP and (Ac-TZ14011)4-MSAP binding to CXCR4.
 To estimate the size of Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP and (Ac-TZ14011)4-
MSAP, the largest distances between two atoms in the models were established. The sizes 
were 27.5 Å, 48.5 Å and 71.2 Å for Ac-TZ14011-MSAP, (Ac-TZ14011)2-MSAP and 
(Ac-TZ14011)4-MSAP, respectively.
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Scheme A1. Synthesis of dimer (Ac-TZ14011)2, dimer (Ac-TZ14011)2-MSAP, tetramer (Ac-TZ14011)4 and tetramer 
(Ac-TZ14011)4-MSAP and the structures of MSAP reagent, Ac-TZ14011 and monomer Ac-TZ14011-MSAP.
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Figure A2. Molecular models of the Ac-TZ14011-MSAP derivatives binding to CXCR4. A) CXCR4 is shown in ribbon 
representation and monomer Ac-TZ14011-MSAP, B) dimer (Ac-TZ14011)2-MSAP and C) tetramer (Ac-TZ14011)4-
MSAP as stick models, which is colored by element. For clarity, the MSAP label is not colored by element: the CyAL-
5.5b fluorophore is displayed in red, the indium-bound DTPA chelate in blue and the spacer in grey.
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Integrating target validation with in vivo 
and ex vivo imaging of mouse tumor 
lesions resembling human DCIS using 
a single hybrid imaging agent
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Abstract
Screening of biomarker expression levels in tumor biopsy samples provides not only 
an assessment of prognostic and predictive factors, but may also be used for the selection 
of biomarker specific imaging strategies. To assess the feasibility of using a biopsy 
specimen for a personalized selection of an imaging approach, the chemokine receptor 4 
(CXCR4) was used as a reference biomarker. A hybrid CXCR4 targeting peptide (MSAP-Ac-
TZ14011) containing a fluorescent dye and a chelate for radioactive labeling, was used to 
directly compare initial flow cytometry based target validation in fresh tumor tissue to in 
vivo single photon emission computed tomography (SPECT) imaging and in vivo and ex 
vivo fluorescence imaging. Flow cytometric analysis of mouse tumor derived cell 
suspensions enabled discrimination between 4T1 control tumor lesions with low CXCR4 
expression levels and CXCR4 positive early, intermediate and late stage MIN-O lesions; 
CXCR4basal, CXCR4+ and CXCR4++ cell populations could be accurately discriminated. Mean 
fluorescent intensity ratios between MIN-O and 4T1 tissue found with flow cytometry 
were comparable to ratios obtained with in vivo SPECT/CT and fluorescence imaging, ex 
vivo fluorescence evaluation and standard immunohistochemistry. This Chapter 
demonstrates that the hybrid nature of a targeting imaging agent like MSAP-Ac-TZ14011 
enables integration of target selection, in vivo imaging and ex vivo validation using a 
single imaging agent. The use of biopsy tissue for biomarker screening can readily be 
expanded to other targeting hybrid imaging agents and can possibly help increase the 
clinical applicability of tumor specific imaging approaches.
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Introduction
Screening of biomarker expression levels in breast cancer biopsy samples using 
immunohistochemistry (IHC) is a routine procedure that provides an assessment of 
prognostic and predictive factors such as histological grade, subtype and hormone 
receptor and human epidermal growth factor receptor 2 (Her2/neu) status.1,2 The 
molecular insights derived from these biopsy samples can be used for decision-making in 
(personalized) treatment planning. For example, estrogen receptor (ER) and/or the Her2/
neu status in biopsy samples predicts a response to trastuzumab when added to standard 
adjuvant chemotherapy.3-5 Additionally, staining of biopsy tissue for less established 
biomarkers such as the chemokine receptor 4 (CXCR4) has been shown to correlate with 
aggressiveness/invasiveness and metastatic potential in breast cancer.6-8
The current standard of care in (preoperative) non-invasive imaging of breast cancer 
is implementation of contrast enhanced MRI and 18F-FDG PET. Both modalities are widely 
implemented in the detection of cancer and many other diseases as they rely on differences 
in perfusion/vascular leakiness (MRI) and metabolism/glucose uptake (PET) between 
diseased and normal tissue. For more specific visualization of e.g. tumor tissue, at present, 
numerous alternative imaging agents are being developed for direct targeting of all kinds 
of biomarkers expressed on the cell membrane. 
Expression patterns of such biomarkers tend to be heterogeneous and vary between 
patients and tumor subtypes, which could also imply the need for more than one targeting 
compound for accurate imaging-based assessment of a specific tumor lesion. However, 
realistically, one cannot perform consecutive biomarker screening studies in a single 
patient. Similar to their use in treatment selection, individual biomarker expression 
patterns may also be exploited for specific imaging strategies, as was shown by Dijkers et 
al. who performed non-invasive positron emission tomography (PET) imaging of Her2/
neu positive lesions in patients with metastatic breast cancer.9 
Identification of a biomarker or rather a diagnostic target during the different 
logistical steps in clinical management viz. IHC of biopsy tissue, (preoperative) imaging, 
intraoperative surgical guidance and pathological evaluation of excision margins, are all 
commonly performed using different methods and different (targeting) compounds. This 
variation may lead to a discrepancy in findings; in an ideal situation, target selection and 
further follow-up are conducted using one and the same imaging agent. This should yield 
more interchangeable and complementary results during the whole logistical process of 
cancer management (Figure 1). As such a smart screening method for an imaging 
approach or a combination thereof is required.
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A tailored selection process that identifies the best diagnostic target will be 
instrumental for the successful application of biomarker specific imaging agents. With this 
in mind we reasoned that a biopsy specimen can potentially be used for the selection of a 
specific imaging approach. 
To demonstrate the feasibility of the integrating biopsy in fresh breast tumor tissue 
with in vivo imaging, the chemokine receptor 4 (CXCR4) was used as a reference biomarker. 
In a recent critical review, in which we evaluated CXCR4 targeting imaging agents based 
on their affinity, specificity and biodistribution, the T140 peptide derivative Ac-TZ14011 
was shown to be one of the best targeting moieties for fluorescence imaging of CXCR4 
expression levels.10 Different imaging labels on the peptide Ac-TZ14011 can aid the 
specific visualization of CXCR4 expressing tumor cells with: i) fluorescence IHC (FITC 
labeled version), ii) flow cytometric analysis (FITC labeled version), iii) SPECT/CT (111In-
DTPA labeled version) and iv) in vivo fluorescence imaging (near-infrared labeled 
version).11-13 The synthetic development of a hybrid version of this targeting peptide 
(MSAP-Ac-TZ14011), which contains both a fluorescent label and a chelate for radioactive 
labeling, enabled integration of in vitro affinity evaluations and in vivo imaging 
methods.14,15 
In this study the concept of using a biopsy specimen for a personalized selection of 
the most optimal targeting imaging approach was evaluated using MSAP-Ac-TZ14011. 
The fluorescent label was used to assess the membranous CXCR4 expression pattern in 
fresh tumor segments obtained from tumor-bearing mice, while after radioactive labeling 
with 111indium, the imaging agent was suitable for in vivo SPECT/CT imaging. The initial 
screening results obtained with flow cytometry (Figure 1A) were directly correlated to in 
vivo imaging results (SPECT/CT and fluorescence imaging; Figure 1B), and microscopic ex 
vivo analysis (fluorescence confocal microscopy; Figure 1C); hereby comprising all steps in 
clinical cancer management. 
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Figure 1. Schematic representation of the integrated logistics made possible by using a targeting hybrid 
imaging agent. A) Analysis of tumor biopsy samples using the fluorescent beacon of the imaging agent using 
flow cytometry. B) Non-invasive tumor visualization using SPECT/CT after radiolabeling of the hybrid agent. 
Fluorescence imaging enables intraoperative surgical guidance. C) Ex vivo evaluation of tracer distribution using 
fluorescence imaging and –microscopy after excision of the tumor.
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Materials and Methods
Synthesis and radiolabeling of MSAP-Ac-TZ14011 
MSAP-Ac-TZ14011 (Figure 2) was synthesized and radiolabeled according to 
previously described procedures.15
Figure 2. Structure of MSAP-Ac-TZ14011
   
In vivo model
As a CXCR4 positive tumor model, the orthotopic MIN-O transplantation model 
resembling human ductal carcinoma in situ was used.16,17 In this model, preinvasive lesions 
progress into invasive lesions with increasing membranous CXCR4 expression.12 Tumor 
lesions were staged according to previously reported criteria; based on CT-based size 
measurements and discrimination was made between early stage (< 100 mm3), 
intermediate stage (100 - 400 mm3), and late stage (> 400 mm3) lesions.12
Cell line based 4T1 tumor lesion served as control. In these control tumors, CXCR4 
expression is constantly low during tumor progression and therefore no discrimination 
between stages was applied.12  4T1 cells (from American Type Culture Collection, ATCC) 
were a kind gift of dr. O. van Tellingen (NKI-AvL, Amsterdam, The Netherlands). 
All tumor lesions were generated as reported previously.12 Animal experiments were 
performed in accordance with Dutch welfare regulations and were approved by the ethics 
committee of the Netherlands Cancer Institute under references 08021 B19 and 08021 B21. 
Implantation of tumor tissue or cells and in vivo imaging were performed under hypnorm/
dormicum/water (1:1:2; 5 μL/g i.p.) anesthesia. All efforts were made to minimize suffering.
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Fresh tumor tissue analysis
From fresh tumor specimens (MIN-O: n = 6 per stage; 4T1: n = 6) single cell suspensions 
were made by cutting the tumor into small pieces with a scalpel and suspending them 
using a 18G, 21G and a 25G needle, respectively. The cell suspension was incubated for 
five min with an ER-lysis buffer (0.31 M NH4Cl, 0.02 M KHCO3, 0.5 M EDTA in 2 L H2O; pH 7.4) 
to remove red blood cells. 300,000 cells per measuring condition were washed with 0.1% 
bovine serum albumin in phosphate buffered saline (0.1% BSA/PBS) and incubated for 
one hr at 4oC under dark conditions with MSAP-Ac-TZ14011 (1:200 from a stock of 
1 mg/mL) or with the monoclonal phycoerythrin (PE) labeled anti-CXCR4 antibody 2B11 
(2B11-PE; 1:100; BD Biosciences). For evaluation of the overlap in staining between MSAP-
Ac-TZ14011 and 2B11-PE, cells were co-incubated with MSAP-Ac-TZ14011 and 2B11-PE. 
Following incubation cells were washed with 0.1% BSA/PBS and propidium iodide (PI; 
1:10.000; BD Biosciences) was added to allow the selection of viable cells. Antibodies were 
diluted in 0.1% BSA/PBS in all flow cytometric experiments. Non-peptide/antibody incubated 
cells served as controls. Cells were analyzed (approximately 20,000 events per sample) using a 
CyAn ADP flowcytometer (DakoCytomation) equipped with Summit v4.3 sorftware 
(DakoCytomation). PE fluorescence was detected after excitation at 488 nm. Emission was 
collected at 575/25 nm. PI was detected after excitation at 488 nm and emission was collected 
at 613/20 nm. The CyAL-5.5b dye on the MSAP label was exited at 635 nm and emission was 
collected at 665/20 nm. Cell viability was comparable between samples.
For evaluation of CXCR4 staining, stained populations were divided into CXCR4- 
(CXCR4 negative cells), CXCR4basal (basal/low expression of CXCR4), CXCR4+ and CXCR4++, 
based on the measured cell surface associated fluorescence; populations were 
discriminated based on differences in the mean fluorescence of that specific population. 
Mean fluorescence intensity ratios (MFIRs) were calculated by dividing the mean 
fluorescent intensity of all cells stained by MSAP-Ac-TZ14011 by the mean fluorescence 
intensity of the non-incubated control. The ratio between the MIN-O and 4T1 tumor lesion 
was determined by dividing the MFIR of the various MIN-O tumor lesions by MFIR of the 
4T1 tumor lesion. The ratio between the CXCR4basal and the CXCR4+ and CXCR4++ 
populations was determined by calculating the MFIR between the CXCR4+ or CXCR4++ and 
the CXCR4basal population. This resulted in a semi quantitative evaluation of the level of 
overexpression. 
To evaluate the amount of lymphocytes in the CXCR4 positive population in the 
tumor cell suspension, cells were co-incubated with MSAP-Ac-TZ14011 and the PE-labeled 
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anti-CD45 antibody (CD45-PE; 1:200; eBioscience). The percentage of CXCR4 positive 
lymphocytes was determined by dividing the CD45 positive (CD45+) population within 
the whole CXCR4 positive population by the total amount of counted cells and multiplied 
by 100%. Statistics were performed using a standard T-test. 
Confocal imaging of fresh tumor slices 
For direct ex vivo evaluation of CXCR4 staining, 4T1 (n = 3) and late stage MIN-O (n = 
3) tumor-bearing mice were sacrificed and the tumor was removed. Next, the tumor was 
cut into thin tissue slices which were then incubated with MSAP-Ac-TZ14011 (1:200 in 
MEM medium) for one hr at 4°C under dark conditions. 
For comparison, 4T1 (n = 3) and late stage MIN-O (n = 3) tumor-bearing mice were 
intravenously injected with 50 μg MSAP-Ac-TZ14011. 24 Hrs after injection, mice were 
sacrificed where after the tumor was removed and cut into thin slices. 
Before analysis using the Leica TCS SPII AOBS confocal microscope (Leica 
Microsystems), slices were incubated with DAPI, washed thoroughly with PBS and placed 
on 24 mm ø glass coverslips. Non-incubated tumor slices were used as negative control. 
Images were acquired at 37oC following excitation at 633 nm at 10x and 63x magnification. 
Emission was collected from 650 - 725 nm. DAPI was excited at 405 nm and emission was 
collected from 409 - 468 nm. Images were analysed using Leica Confocal Software (Leica 
Microsystems). 
Immunohistochemistry (IHC)
Formalin-fixed paraffin-embedded MIN-O or 4T1 tumor tissue sections were stained 
according to the protocol previously reported by van den Berg et al.11 with a monoclonal 
anti-CXCR4 antibody (rat-anti-CXCR4 clone 2B11 1:100; BD Biosciences). Images were 
obtained at 40x magnification. Membranous staining was assessed as previously 
reported.12 The ratio between the MIN-O and 4T1 tumor lesions was determined by 
dividing the percentage of membranous staining in the MIN-O tumor lesions by the 
percentage of membranous staining in the 4T1 tumor lesions. Statistics were performed 
using a standard T-test. 
In vivo imaging
Mice (n = 5 for intermediate stage MIN-O (100 - 400 mm3) lesions and n = 5 for late 
stage 4T1 tumor lesion (< 400 mm3)) were injected intravenously with 50 µg 111In-MSAP-
Ac-TZ14011 (10 MBq). SPECT/CT scans were conducted on a preclinical SPECT/CT scanner 
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(Nanospect; Bioscan) 24 hrs post injection. After acquisition, the CT data was reconstructed 
using a cone-beam filtered back projection and SPECT data were reconstructed iteratively 
with HiSPECT software (Scvis GmbH). Signal intensities were analyzed using the 
InVivoScope post-processing software (Bioscan Inc.). For further details, see van Leeuwen 
et al.18 After SPECT/CT imaging, mice were sacrificed. Tumor-to-muscle ratios (T/M) were 
determined after measurement of radioactivity as previously reported.12
In vivo fluorescence imaging was conducted on the IVIS 200 camera (Xenogen Corp.) 
using Living Imaging Acquisition and Analysis software (Xenogen Corp.). Images were 
acquired with standard Cy5.5 (excitation 615 - 665 nm and emission 695 - 770 nm) settings. 
Fluorescent content was measured in photons/sec/cm2.
Results 
To set up an analytical method that can be applied for screening of fresh biopsy 
specimens, cell suspensions of freshly obtained tumor segments were prepared. After 
incubation of the tumor derived cell suspensions with MSAP-Ac-TZ14011, flow cytometric 
analysis revealed differences in fluorescent intensity levels between the samples. 
Table 1. Evaluation of CXCR4 expression with flow cytometric analysis and IHC.
MFIR CXCR4+ and 
CXCR4++ population
Ratio MFIR MIN-O/4T1 Ratio membranous 
staining MIN-O/4T1
MIN-O early stage 165.5 ± 13.8 1.8 1.1
MIN-O intermediate stage 329.6 ± 33.6 3.6 3.5
MIN-O Late stage 367.9 ± 22.4 4.0 5.5
4T1 91.5 ± 14.4 - -
For MIN-O tumor tissue, six biopsy samples per stage were evaluated. Also, six 4T1 biopsy samples were assessed. 
All samples were evaluated in triplicate. MFIR: mean fluorescence intensity ratio. Ratio of membranous staining 
calculated from data reported in 15 .
CXCR4 expression levels in MIN-O and 4T1 tumor lesions
In the MIN-O tumor lesions MFIR of all stained cells increased from 165.5 ± 13.8 in 
early stage to 367.9 ± 22.4 in late stage MIN-O lesions (for MFIR values see Table 1). Overall, 
the MFIR found in the MIN-O lesions was 3-fold (range 1.8 - 4) higher than in the 4T1 tumor 
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lesions (MFIR 91.5 ± 14.4; P < 0.001; Table 1). This result is comparable to the ratios found 
between MIN-O and 4T1 control tumor lesions after flow cytometric assessment using the 
anti-CXCR4 antibody 2B11-PE.12 Comparable ratios were also found when comparing 
ratios found with MSAP-Ac-TZ14011 based flow cytometry (Table 1) to quantified 
membranous staining (IHC) in MIN-O and 4T1 tumor lesions. 
Figure 3. CXCR4 staining using immunohistochemistry. Membranous staining of fixed tumor tissue slices after 
incubation with the anti-CXCR4 antibody 2B11 in A) early, B) intermediate, C) late stage MIN-O tumor lesions and 
D) 4T1 control tumors (40x magnification). 
Identification of individual cell populations
IHC revealed increasing but heterogeneous membranous staining for CXCR4 in the 
MIN-O lesions (Table 1, Figure 3). Flow cytometric analysis enabled identification of 
different CXCR4 expressing cell populations after incubation with MSAP-AcTZ14011.
(Figure 4). As incubation occurred at 4oC, these populations were differentiated based on 
the cell membrane associated binding of the imaging agent. Figure 4A shows that besides 
a low percentage of CXCR4 negative cells (CXCR4- mean 13.2 ± 2.6), three distinct 
populations were evident; CXCR4basal (mean 58.9 ± 3.7), CXCR4+ (mean  367.3 ± 47.0) and 
CXCR4++ (mean 2197.4 ± 413.3). 
The different cell populations were found in the MIN-O lesions as well as in the 4T1 
tumor specimens. The increase in fluorescence intensity between the different populations 
was determined by calculating the MFIR between the CXCR4basal and the CXCR4+ or 
CXCR4++ population. This resulted in a 7.8 ± 1.2-fold higher ratio in the CXCR4+ and a 
47.0 ± 10.4-fold higher ratio in the CXCR4++ population compared to the CXCR4basal 
population. Carlisle et al. reported comparable differences in fluorescent intensities when 
comparing several cell lines with different levels of CXCR4 expression. 19 As such it appears 
that different CXCR4 positive cell populations exist within a tumor. 
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Figure 4. Fluorescence based fresh tumor biopsy analysis after incubation with MSAP-Ac-TZ14011. A) CXCR4 
staining pattern in early (black), intermediate (red) and late stage (blue) MIN-O biopsy samples. B) CXCR4 staining 
pattern in 4T1 biopsy samples. Non-incubated control samples are depicted in grey. C - F) Analysis of CD45 
expression in CXCR4 positive cells in early, intermediate and late stage MIN-O tumor lesions and 4T1 tumor lesions.
Further analysis of the results obtained with flow cytometry revealed that the 
percentage of CXCR4basal cells was highest in the 4T1 tumor samples and that in the MIN-O 
lesions this percentage of cells decreased during lesion progression (Table 2). The 
percentage of strongly CXCR4 positive (CXCR4+ and CXCR4++) cells increased from 68.6 
± 1.5% in early stage MIN-O lesions to 86.6 ± 0.9% and 93.0 ± 0.7% in intermediate and 
late stage MIN-O lesions, respectively (Table 2). Furthermore, the percentage of strongly 
CXCR4 positive cells was significantly higher in all stages of MIN-O progression compared 
to the percentage found in the control 4T1 tumor lesions (44.6 ± 6.0%; P < 0.001). 
In the MIN-O lesions the percentage CXCR4+ and CXCR4++ cells varied during tumor 
progression (Figure 4A). In the early stage MIN-O lesions 38.4 ± 2.3% of the cells was 
CXCR4+ and 30.3 ± 2.0% of the cells was CXCR4++. Intermediate stage lesions showed a 
similar expression pattern, but the percentage of CXCR4+ cells increased to 53.5 ± 2.8%, 
whereas in late stage lesions the percentage of CXCR4+ cells had decreased to 12.9 ± 1.0%. 
A 2.5-fold (range 2.4 - 2.6) increase in CXCR4++ cells could be seen in the late stage lesions 
when compared to the intermediate and early stage lesions (80.0 ± 1.4% vs. 33.1 ± 3.2% 
and 30.3 ± 2.0%, respectively) (Table 2). 
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Table 2. Staining percentages of populations with different CXCR4 expression.








MIN-O Early stage 6.9 ± 0.8 25.9 ± 0.8 38.4 ± 2.3 30.3 ± 2.0 68.6 ± 1.5
MIN-O Intermediate stage 2.9 ± 0.3 11.4 ± 0.7 53.5 ± 2.8 33.1 ± 3.2 86.6 ± 0.9
MIN-O Late stage 3.0 ± 0.5 4.7 ± 0.5 12.9 ± 1.0 80.0 ± 1.4 93.0 ± 0.7
4T1 1.2 ± 0.4 56.1 ± 5.3 27.0 ± 2.3 18.3 ± 4.3 44.6 ± 6.0
Identification of the amount of CXCR4 expressing lymphocytes 
CXCR4 is not only expressed by tumor cells, but can also be expressed by native 
immune cells such as lymphocytes.20 As the latter can also be present in tumor lesions,12 a 
control staining for lymphocytes to exclude over- or underestimation of the amount of 
CXCR4 positive tumor cells is required. Co-incubation with both MSAP-Ac-TZ14011 and an 
anti-CD45 antibody were used to determine the amount of lymphocytes (CD45+) that were 
CXCR4 positive. Flow cytometric analysis revealed that the percentage of CD45+ lymphocytes 
was highest in the 4T1 tumor cell suspensions (9.95%). On the contrary, in the MIN-O lesions, 
the amount of CD45+ lymphocytes was very low, and only increased slightly from 1.0% in 
early stage to 1.2% in intermediate and 1.3% in late stage lesions. 
Co-staining could be used to specify which CXCR4 positive populations contained the 
CD45+ cells (Figure 4C - F) by differentiating between the different CXCR4 expressing cell 
populations (x-axis) and the CD45 expression of the cells (y-axis). In the MIN-O lesions 
concomitant staining between CXCR4 and CD45 was mainly seen in the CXCR4basal population 
(Figure 4C - E) whereas in the 4T1 controls CD45+ cells were predominantly present in the 
CXCR4basal and CXCR4+ populations (Figure 4F). Although clearly detectable, the percentages 
of CD45+ cells found in the different MIN-O and 4T1 tumor tissue samples are not likely to 
influence the CXCR4 based discrimination between the MIN-O and the 4T1 tumor lesions. 
Fluorescence IHC of CXCR4 expression 
Similar to Ac-TZ14011-FITC,10 MSAP-Ac-TZ14011 could also be used during 
fluorescence IHC applications. Confocal microscopy at 37oC after ex vivo incubation (at 
4oC of fresh tumor slices revealed both membranous and cytoplasmic staining throughout 
the late stage MIN-O tumor lesion (Figure 5A I and 5A II). In the 4T1 control lesions hardly 
any fluorescent staining could be observed under the same conditions (Figure 6). 
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Figure 5. Evaluation of freshly isolated MIN-O tumor slices after A) ex vivo incubation with MSAP-Ac-TZ14011 
and B) after intravenous injection of MSAP-Ac-TZ14011 24 hrs prior to evaluation of the tissue. I: 10x magnification. 
II) 63x magnification. Signal emitted by MSAP-Ac-TZ14011 is depicted in magenta and DAPI (blue) was used to 
visualize the cell nucleus.    
In vivo SPECT/CT and fluorescence imaging 
Flow cytometric and fluorescence IHC data combined allowed an accurate 
differentiation between predominantly CXCR4-basal 4T1 tumors and CXCR4 positive 
MIN-O lesions. In vivo, MIN-O lesions characterized as mainly CXCR4+/CXCR4++ at initial 
screening (see above) could be accurately identified with SPECT/CT imaging after 
intravenous injection of 111In labeled MSAP-Ac-TZ14011 (111In-MSAP-Ac-TZ14011). The 4T1 
tumor lesions showed no tracer accumulation at the same imaging settings (Figure 6A). 
Evaluation of the 111In-MSAP-Ac-TZ14011 uptake levels in the tumor lesions 
(%ID/g) resulted in a T/M ratio that was 3.8-fold higher in the late stage MIN-O lesions 
(4.55 ± 0.67) as compared to the 4T1 lesions (1.20 ± 0.12).  Biodistribution for both models 
was conform previously reported results.15 Quantification of the fluorescent signal intensities 
in these tumor lesions revealed results comparable to the radioactivity measurements. 
The signal intensity was 4.2-fold higher in the late stage MIN-O lesions compared to the 
4T1 tumor lesions (1.09 x 109 ± 1.7 x 108  vs. 2.5 x 108 ± 3.8 x 107 photons/sec/cm2 respectively) 
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(Figure 6B). This 4-fold difference seen with both SPECT/CT and fluorescence imaging was 
in accordance with the differences found in membranous CXCR4 expression (Table 1). 
Ex vivo assessment of tracer distribution
 Ex vivo fluorescent assessment of the tracer distribution in fresh tumor tissue 
segments following the systemic injection of MSAP-Ac-TZ14011 (24 hrs prior to tumor 
excision) predominantly revealed accumulation of the imaging agent in the cytoplasm of 
MIN-O lesions (Figure 5A I and II and Figure 6D), something that was not seen in the 4T1 
controls (Figure 6D). This cytoplasmic staining is in line with the internalization of CXCR4 
receptors over time at 37oC.10 
Differences in staining patterns were observed after direct (ex vivo) incubation of tumor 
tissue samples with MSAP-Ac-TZ14011 (Figure 5A) compared to systemic tracer administration 
(Figure 4B). Whereas direct, ex vivo, incubation of the tumor tissue will probably enable 
visualization of ‘all’ CXCR4 positive cells present, systemic administration will most certainly 
only stain cells that could be reached by the tracer via the vascular network. 
Evaluation of the ανβ3-integrin expression in late stage MIN-O lesions and 4T1 tumor 
lesions previously revealed that the degree of angiogenesis in both MIN-O and 4T1 tumor 
lesions is similar.12 The lesions are overall well perfused, but some regions contained more 
and larger blood vessels than others. This heterogeneity in the vascular physiology will 
likely be of influence on the distribution of the tracer throughout the tumor. 
289Chapter 13
Figure 6. Non-invasive imaging. A) SPECT/CT imaging after intravenous injection of 111In-MSAP-Ac-TZ14011. B) 
in vivo and C) ex vivo fluorescence imaging.  D) fluorescence microscopy (10x magnification). Intermediate stage 
MIN-O: top images. Late stage 4T1: bottom images.
Discussion
Imaging applications using hybrid tracers are rapidly emerging21-24 and have already 
been successfully applied in clinical studies facilitating integrated pre- and intraoperative 
imaging of sentinel nodes.25-28 By adding a receptor targeting moiety, the utility of hybrid 
imaging agents can be expanded to pre-imaging screening of biomarker expression 
levels and subsequent (imaging) target selection. 
In a previous comparison of currently available imaging agents for CXCR4, Ac-
TZ14011 showed great potential in fluorescence imaging and hybrid imaging 
applications.10 Ac-TZ14011 was shown to bind selectively to CXCR4 and could be used to 
visualize CXCR4 positive tumor lesions in vivo.11,12,14,15,29 It must be noted that MSAP-Ac-
TZ14011 derivatives are the only hybrid imaging agents available for CXCR4 targeting.10 
For in vivo imaging experiments with this tracer the use of a relatively low specific activity 
was shown to be beneficial for tumor visualization.10 In a recent review on imaging agents 
for CXCR4 we have demonstrated that tumor models, which more accurately represent 
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the modest five-fold overexpression found in the clinical situation, such as the MIN-O 
model used in this study, better represent the clinically found CXCR4 expression levels in 
tumors.10 As a result the in vivo SPECT/CT images obtained in this study (Figure 6) provide 
less of a black-and-white discrimination between CXCR4 positive tumors and their 
background, than can be obtained using transfected tumor cells with extremely high 
levels of CXCR4 expression.10 
The hybrid nature of the CXCR4 targeting imaging agent MSAP-Ac-TZ14011 has 
allowed us to successfully demonstrate the concept of integrating target selection in fresh 
(biopsy) tumor tissue with in vivo imaging and microscopic validation (Figure 1), all using 
a single imaging agent. 
Similar to the in vitro evaluation of fluorescently labeled imaging agents,14,15 flow 
cytometry could be used to analyze the level of CXCR4 expression in the tumor cell 
suspensions. In this application incubation with MSAP-Ac-TZ14011 allowed effective 
discrimination between MIN-O (stages) and 4T1 tumor lesions using the fluorescent label 
present in the targeting hybrid imaging agent (Figure 4 and Table 2). These findings were 
further confirmed with IHC (Table 2), in vivo SPECT/CT (using the radiolabel) and 
fluorescence imaging (Figure 6); the ratio between the late stage MIN-O and similarly 
sized 4T1 control lesions was comparable with all visualization methods. 
Flow cytometry is already being used in a clinical setting for applications such as 
diagnosis of leukemia and lymphoma30-33 and dependent on the analyzer used, flow 
cytometry enables assessment of up to 15 cell surface parameters in one sample.32 Even 
the small early stage tumors (< 100 mm3), which are comparable in size with human 
biopsy samples, contain sufficient cells for characterization of multiple samples. In this 
study co-incubation of MSAP-Ac-TZ14011 and an anti-CD45 antibody showed that at least 
two markers could be simultaneously evaluated in fresh tumor specimens and that the 
presence of native immune cells in the tumor tissue could be assessed.  For future 
applications in cancer management it will be possible to set up such screens using a 
number of biomarker targeting imaging agents simultaneously. By labeling each agent 
with a different fluorescent dye a tailored selection of the most prominently available 
receptor proteins suitable for imaging can be made. The method of staining and the fact 
that perfusion is essential for good visualization in vivo should, however, be taken into 
account when comparing flow cytometry/IHC to in vivo imaging results.
We have previously demonstrated that CXCR4 expression in MIN-O lesions is 
heterogeneous and that the degree of membranous staining of CXCR4 at IHC increases 
with lesion progression.12 This increase in membranous staining was in concordance with 
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the increase in uptake of 111In-Ac-TZ14011 during MIN-O lesion progression.12 With IHC 
only total staining percentages can be obtained, whereas flow cytometry can also be used 
for the accurate evaluation of cell populations with different expression levels within one 
tumor sample (Table 1).19 As fluorescence intensities vary with varying receptor expression 
on the cells, the (semi-quantitative) signal intensity levels can be directly, linked to 
receptor CXCR4 expression levels.34 Flow cytometric analysis after incubation of the tumor 
cell suspensions with MSAP-Ac-TZ14011 underlined that CXCR4 positivity increased 
during the progression of MIN-O lesions. An increase in the percentage of CXCR4+ cells 
seemed to mark the transition into intermediate stage lesions. Concurrently, invasive late 
stage lesions mainly contained CXCR4++ cells, which is in line with the clinically reported 
higher expression of CXCR4 in more invasive types of breast cancer.6 
One can envision that besides the ability to select the most appropriate targeting 
imaging procedure, the level of overexpression of a biomarker that is associated with e.g. 
malignancy of a tumor,8,36,36 may also influence clinical decision-making. For example, 
CXCR4 expression is linked to a higher tendency to metastasize and higher levels of CXCR4 
expression have been found in (distant) metastasis compared to the primary tumor.35 It 
has also been proposed that CXCR4 expression levels can be used to select subsets of 
tumor lesion that show a more aggressive biological behavior.37 Furthermore, Chu et al.
previously proposed that CXCR4 expression levels allow for the identification of subsets of 
patients who are at risk of developing recurrent disease, even within patient groups with 
an initial good prognosis.36
The orthotopic MIN-O transplantation model used in this study serves as an ideal 
model for the evaluation of tumor progression into an invasive phenotype.17,38 As MIN-O 
strains that metastasize have also been described,16 it will be interesting to investigate 
what the influence of the presence of CXCR4++ cells will be on metastatic ability of 
metastatic MIN-O tumor models.16  
The main goal of this study was to evaluate the concept of using biopsy tissue 
specimens for a personalized selection of the most optimal targeted imaging approach. 
Obviously, the concept described above is not limited to the targeting of CXCR4. A hybrid 
version of any imaging agent targeting a biomarker of choice can potentially be used. 
Possibly, also a cocktail of imaging agents can be used for the simultaneous assessment of 
several markers at once. Use of different fluorescent dyes and/or radioactive isotopes will 
then enable discrimination between biomarkers. In this way, the screening and in vivo 
imaging data can still be used for accurate staging of the tumor lesions. The latter will not 
be possible when identically labeled imaging agents are used. 
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Conclusion
Hybrid imaging agents can be applied during the different steps encountered in the 
clinical management of cancer. Comparable quantitative results have been obtained 
during target selection in biopsy tissue (flow cytometry), in vivo imaging (SPECT/CT and 
fluorescence imaging) and during pathological validation (ex vivo microscopy) of the 
surgically excised tissue (ex vivo microscopic analysis). Incubation with MSAP-Ac-TZ14011 
enabled accurate staging of MIN-O lesion progression via the CXCR4 expression pattern of 
the lesions. Although only CXCR4 was used in this proof of concept study, this approach 
can readily be expanded to other targeting hybrid imaging agents and will help increase 
the clinical applicability of tumor specific imaging approaches.
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The initial clinical implementation of the hybrid surgical guidance concept for SLN 
biopsy procedures was a step in the right direction to achieve clinical benefit from 
intraoperative fluorescence imaging. Nevertheless, the widespread development of 
surgical fluorescence camera’s and the development and clinical implementation of new 
imaging agents are essential for further improvement of surgical efficacy. Current efforts 
that focus on fine-tuning of the clinical utility of the developed technology include: i) 
visualization of tumor induced angiogenesis using hybrid targeting imaging agents, ii) 
tumor bracketing and margin estimation, and iii) image navigation. All may facilitate a 
broader implementation of the hybrid surgical guidance concept, and as such, open doors 
for new (hybrid) imaging applications. 
Visualization of tumor induced angiogenesis using hybrid targeting imaging agents
The CXCR4-based hybrid imaging approach can be further expanded by including a 
different targeting moiety. In recent years, numerous tumor targeting imaging agents 
have been developed, but besides MSAP-Ac-TZ14011 only hybrid agents that target the 
human epidermal growth factor receptor 2 (HER2) or prostate specific membrane antigen 
(PSMA) have been described for use in surgical guidance. Where biomarkers like HER2 and 
PSMA are only expressed in a specific type of cancer, e.g. respectively in breast and 
prostate cancer, overexpression of ανβ3 integrin is involved in the more common event of 
(tumor-induced) angiogenesis. Therefore ανβ3 integrin would be a more widely applicable 
candidate for the specific visualization of tumor tissue. Using a hybrid arginine-glycine-
aspartate (RGD) derivative (111In-MSAP-RGD) that targets ανβ3 integrin, we have shown 
the potential of this biomarker in targeted hybrid imaging applications. Both the primary 
tumor and distant metastases could be preoperatively detected with single photon 
computed tomography/computed tomography (SPECT/CT).1 Intraoperatively, the 
primary tumor and metastases could be detected with fluorescence imaging (Figure 1). As 
ανβ3 integrin is expressed in angiogenic regions of the tumor, this targeting strategy is 
optimal for improving tumor margin delineation, which might possibly aid the surgical 
excision of a lesion. 
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Figure 1. Surgical guidance toward the margins of the primary tumor and distant metastases. A) SPECT/CT 
image depicting both the rim around the primary tumor and distant metastases in the neck area. B) Fluorescence 
imaging depicting the margins of the primary tumor. Note that the organs are shielded. C) Ex vivo fluorescence 
imaging of the tumor and metastases. 
Tumor bracketing and margin estimation
Clinically, tumor lesions can be marked before surgical removal, e.g. in breast cancer, 
and are preferably excised with a surgical safety margin of 0.5 – 1.0 cm to prevent the need 
for re-excisions. Hybrid marker seeds may extend the use of current tumor marking 
approaches, as they can be used to aid in the visualization of these surgical safety margins. 
We have shown that hybrid marker seeds are applicable during the entire pre-, intra- and 
postoperative trajectory (Figure 2).2 The different properties of hybrid marker seeds can 
be used for image guided seed placement, verification of the placement accuracy, 
fluorescence guided excision with the appropriate safety margin and ex vivo verification 
of original specimen orientation. Via inclusion of a cocktail of contrast agents, all these 
properties could be incorporated into a single marker that can be detected with e.g. 
fluorescence imaging, X-ray, ultrasound (US), positron emission tomography (PET), and or 
SPECT. 
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Figure 2. Schematic representation of the combined pre-, intra- and postoperative imaging paradigm that can 
be achieved with hybrid marker seeds. A) Diagnostic imaging procedure. B) Image-guided placement of tumor 
bracketing with marker seeds. C) Preoperative validation of the accuracy of marker placement. D) Intraoperative 
optical detection of the markers. E) Geographical (re)orientation of the excised tissue section at pathology.
Phantom experiments with hybrid markers showed their potential in margin 
estimation.2 Use of a dual emissive fluorescent dye (InP/ZnS quantum dots)3 provided the 
unique opportunity to intraoperatively estimate the pepth at which the seed was placed in 
the tissue.2 By using particles with different visible colors, the original geographic orientation 
of the excised tissue could be determined. Where the dual emissive dye could be used to 
estimate marker depth using two emissions, the same can be achieved by using two 
standard fluorescent dyes with different levels of tissue penetration in a single marker.4 More 
rapid approval for a clinical use of this concept is probably most easily obtained using 
already clinically applied contrast media like the fluorescent dyes FITC and ICG.
Image navigation
Even when fluorescence imaging is combined with preoperative surgical planning 
based on SPECT/CT and intraoperative gamma ray detection, surgical orientation of e.g. 
SLNs can still be difficult. More accurate navigation toward the areas of interest could 
therefore help optimize surgical guidance. 
Other than real time US, CT and or MRI guidance, surgical navigation based on a 
preoperative data set is traditionally performed during rigid procedures in the brain and 
orthopedics. In soft, non-rigid, areas movements occurring during the intervention may 
significantly impair the navigation accuracy. Although this approach remains highly 
challenging, hybrid imaging agents may help overcome this shortcoming of the navigation 
process. The fluorescence signal, which is not able to penetrate through more than one 
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cm of tissue, provides a real-time optical read-out for the navigation accuracy. While the 
technology is likely to remain limited to more rigid areas such as the pelvic area, this 
expansion with navigation may have major impact in the field of surgical guidance. 
Initial pilot experiments show that navigation of a fluorescence laparoscope based 
on 3D SPECT/CT images is feasible and may improve intraoperative localization of areas 
that were defined to be of interest on SPECT/CT (Figure 3).5
Figure 3. Hybrid imaging approach. A)The set-up includes two different input systems: the reference targets are 
placed on the patient and fluorescence endoscope. B) The preoperative SPECT/CT images are acquired with a 
fixed reference target placed on a rigid structure on the patient/phantom (white circle). C) An optimal tracking 
system (OTS) determines the pose of the reference targets. D,E) The preoperative SPECT/CT and the poses 
determined by the OTS are processed by the data-processing unit to a virtual view of the SPECT/CT images from 
the perspective of the endoscope. F) Navigation of the tracked fluorescence endoscopes toward the target 
identified on SPECT/CT results in real-time gradual visualization of the fluorescent signal on a second display, 
thus providing confirmation of the navigation accuracy. 
Obviously, implementation of the hybrid surgical guidance concept is not limited to 
the field of oncology. For instance, the hybrid concept can possibly also be applied in 
visualization of critical structures such as nerves where specific targeting agents can be 
used in sparing the structures during surgical excisions or in the assessment of the 
presence of functional damage. 
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In this thesis the use of (hybrid) imaging agents in combined pre- and intraoperative 
detection of the sentinel lymph node (SLN) and during evaluation of the chemokine 
receptor 4 (CXCR4) expression levels were discussed. A summary is provided below. 
Part I: Hybrid guidance for sentinel lymph node biopsy
SLN biopsy presents physicians with the opportunity to detect early metastatic 
disease. Radiocolloids such as 99mTc-nanocolloid are currently used to preoperatively 
identify SLNs and to provide acoustic gamma probe guidance during their resection. To 
enable optical guidance, additional dyes are commonly injected during surgery. In 
Chapter 2 to 7 new surgical guidance methods that integrate preoperative SLN 
identification with intraoperative optical detection were discussed. 
Chapter 2
Non-targeted hybrid nanoparticles represent a relatively unexploited area of 
chemical/nanotechnological development. In the field of nanotechnology the SLN biopsy 
procedure is appealing, as diagnostics of the SLN provide a clear clinical precedent where 
nano-sized molecules (10 – 100 nm) are preferred. Nano-sized particles induce sufficient 
retention in the SLN, after which the fluorescent dyes and radiolabels attached to these 
particles can be detected in the lymph node. A good example is the hybrid radiocolloid 
ICG-99mTc-nanocolloid, which is formed after the mixing the clinically applied components 
99mTc-nanocolloid and the fluorescent dye indocyanine green (ICG).
Chapter 3
In an orthotopic mouse model for metastatic breast cancer the dynamics of 99mTc-
nanocolloid, ICG and ICG-99mTc-nanocolloid were studied. It was shown that in mice the 
drainage and retention pattern of both the parental and the hybrid radiocolloids were 
highly similar, while free ICG was rapidly cleared. 
Chapter 4
The potential of combined pre- and intraoperative imaging using ICG-99mTc-
nanocolloid was further evaluated in a spontaneous mouse prostate tumor model. To 
provide a more translational tracer formulation, in this study a cocktail-solution of imaging 
agents was used. The stability of the hybrid radiocolloid was found to be higher than that 
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of the non-colloidal ICG-99mTc-human serum albumin complex. Furthermore, in this 
Chapter the first (ex vivo) patient data were presented. 
Results from the two preclinical studies (Chapter 3 and 4) revealed that in mice the 
hybrid approach helped improve fluorescence based guidance and enabled both accurate 
surgical planning and intraoperative detection, based on a single injection.
Chapter 5
In a reproducibility study in 25 patients with melanoma in the head and neck region, 
the trunk, or with penile carcinoma, a clinical comparison between lymphoscintigraphic 
drainage patterns of the European gold standard 99mTc-nanocolloid and the hybrid 
imaging agent ICG-99mTc-nanocolloid was made. Similar to the preclinical situation, this 
study revealed identical drainage patterns. 
Chapter 6
The added value of ICG-99mTc-nanocolloid during laparoscopic procedures was 
shown in eleven patients who underwent a robot-assisted laparoscopic prostatectomy 
and lymph node dissection. Preoperatively, SLNs could be identified with lymphoscinti-
graphy and with single photon emission computed tomography combined with 
computed tomography (SPECT/CT). The hybrid nature of the imaging agent enabled 
intraoperative SLN identification via fluorescence imaging. During surgery, radioguidance 
and fluorescence detection proved to be complementary; Fluorescence particularly 
improved surgical guidance in areas with a high radioactive background signal such as 
the injection site, whereas radioguidance was found to supplement the limiting tissue 
penetration of the fluorescence signal.
Chapter 7
An additional benefit of ICG-99mTc-nanoccolloid is that the optical component can also 
be exploited in ex vivo applications. Ex vivo fluorescence imaging was used to determine 
the location of ICG-99mTc-nanocolloid injection deposits in embedded prostate samples. It 
was found that the location of the deposits of the imaging agent correlates with the 
lymphatic drainage pattern as seen preoperatively on lymphoscintigraphy. From these 
results it could be concluded that the location of intraprostatic deposition of the imaging 
agent influenced the lymphatic drainage pattern, and as such, the SLN procedure as a whole.
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Part II: CXCR4 targeting applications
For specific visualization of tumor cells, imaging agents that target a biomarker 
expressed on a tumor cell are of value. The biomarker CXCR4 is overexpressed in many types 
of cancer and is an emerging target in the field of molecular imaging and therapeutics. 
Preclinical evaluation of differently labeled AC-TZ14011 peptide based CXCR4 targeting 
imaging agents, including hybrid derivatives, were discussed in Chapter 8 to 13. 
Chapter 8
During evaluation of a targeting imaging agent, both the preclinical set-up and the 
receptor affinity of the imaging agent are of influence on the obtained results. Transfected 
cell lines with (very) high levels of CXCR4 expression can best be used for the initial 
evaluation of an imaging agent. When binding to the receptor has been verified, models 
with a level of overexpression that is more comparable to the five-fold overexpression 
found in the clinical situation should be used for further evaluation. The CXCR4 receptor 
affinity of Ac-TZ14011 peptide derivatives can be influenced by the addition of an imaging 
label. While these charge and/or size related alterations slightly decrease the affinity for 
the receptor, it still remains in the nanomolar range and thus sufficient for in vivo use. 
Chapter 9
Functionalization of Ac-TZ14011 with the fluorescent dye FITC enabled evaluation of 
CXCR4 expression levels and receptor localization in vitro in breast cancer cells. CXCR4 
staining was predominantly found on the membrane of the cell and/or in vesicles formed 
after endocytosis. Ac-TZ14011-FITC enabled discrimination between cells with only a 
four-fold difference in CXCR4 expression. Furthermore, the efficacy of Ac-TZ14011-FITC 
was comparable to commercially available anti-CXCR4-antibodies.
Chapter 10
An indium labeled version of the Ac-TZ14011 peptide (111In-DTPA-Ac-TZ14011) could 
be used to evaluate CXCR4 expression levels in a MIN-O mouse tumor model that 
resembles human ductal carcinoma in situ. Longitudinal assessment of CXCR4 expression 
during lesions development enabled discrimination between early preinvasive tumor 
lesions, intermediate and late stage invasive MIN-O tumor lesions. In the MIN-O lesions 
membranous CXCR4 expression was heterogeneous and receptor expression levels 
increased during lesion progression.
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Chapter 11
Addition of a multifunctional single attachment point reagent (MSAP) that contains 
both a DTPA chelate and a fluorescent dye resulted in a hybrid version of Ac-TZ14011 
(MSAP-Ac-TZ14011). Functionalization of Ac-TZ14011 with the MSAP label resulted in a 
lower affinity for the CXCR4 receptor compared to the unlabeled peptide. However, the 
affinity was similar tot that found after functionalization with either the FITC or DTPA label, 
and allowed for visualization of CXCR4 in both the pre- and intraoperative setting.
Chapter 12
Multimerization could be used to minimize the negative influence of the MSAP label 
on the binding affinity of Ac-TZ14011. Unlabeled, the CXCR4 affinity of the dimer and 
tetramer was somewhat lower than the affinity of the monomer. When labeled with the 
hybrid label the CXCR4 affinity of the dimer and tetramer increased. Distribution studies 
revealed that the presence of additional peptides reduced non-specific uptake. 
Chapter 13
The hybrid imaging concept was further extended by using the fluorescent beacon 
on MSAP-Ac-TZ14011 to study the presence of the CXCR4 receptor in fresh tumor tissue 
biopsy specimens. Flow cytometric analysis of these tumor specimens revealed different 
CXCR4 positive populations and could be used to accurately stage the progression of 
MIN-O lesions. These findings were shown to accurately predict visualization of tumor 
tissue using imaging methods such as SPECT/CT and fluorescence imaging. Furthermore, 
the fluorescent signature could be used to validate the CXCR4 staining in tumor samples 
ex vivo. As such, the hybrid nature of MSAP-Ac-TZ14011 enabled integration of biomarker 
screening, in vivo and ex vivo validation of tumor tissue using a single agent.
Chapter 14 (Future perspectives)
Further development of fluorescence camera’s and development and clinical 
implementation of new imaging agents are essential for improvement of surgical accuracy. 
Current efforts have been focused on fine-tuning of the utility of the hybrid surgical 
guidance concept described in this thesis.
The biomarker specific hybrid approach can also be applied for other biomarkers, for 
instance ανβ3 integrin. 111In-MSAP-RGD, which binds to ανβ3 integrin can be used to 
visualize tumor margins and metastases.
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(Breast) tumors can be marked with marker seeds to improve localization during 
surgery. Hybrid marker seeds can be used to expand the currently applied marking 
approach. The fluorescent features can be used for estimation of surgical safety margins.
Even when fluorescence is combined with preoperative imaging and intraoperative 
detection of gamma rays, surgical identification of deeply situated SLNs can still be 
difficult. Pilot experiments have shown that navigation of a fluorescence laparoscope 
based on 3D SPECT/CT images is feasible and can possibly be used to further optimize 
surgical guidance.
Conclusion
The results described in this thesis demonstrate the potential of hybrid imaging 
agents in the translation of preoperative findings to the operating room. The hybrid 
concept was shown to be of additional value during clinical SLN biopsy procedures and 
during the visualization of tumor cells in a preclinical setting. Current expansions of this 
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In dit proefschrift is het gebruik van (hybride) contrastmiddelen voor gecombineerde 
pre- en intra-operatieve detectie van de schildwachtklier (sentinel lymph node; SLN), en 
voor evaluatie van het expressie niveau van de chemokine receptor 4 (CXCR4) in tumor 
weefsel besproken. Een samenvatting vindt u hieronder.
 
Deel I: Hybride geleiding van de SLN biopsie
Een biopsie van de SLN maakt vroege detectie van gemetastaseerde ziekte in het 
lymfesysteem mogelijk. Radioactief gelabelde nanodeeltjes, zoals technetium gelabelde 
albumine aggregaten (99mTc-nanocolloïd), worden momenteel gebruikt voor het preoperatief 
identificeren van de SLN. Tijdens de interventie kan dit radioactieve signaal gebruikt worden 
voor akoestische geleiding met behulp van een gamma stralen detector. Voor optische 
chirurgische geleiding worden veelal extra kleurstoffen geïnjecteerd tijdens de ingreep. 
Gebruik van deze kleurstoffen resulteert echter veelal niet tot verbeterde detectie van de 
SLN. Nieuwe chirurgische geleidingsmethoden die preoperatieve identificatie van de SLN 
integreren met intra-operatieve optische detectie zijn besproken in Hoofdstuk 2 t/m 7.
 
Hoofdstuk 2
Ontwikkeling van niet biomarker gerichte hybride nanodeeltjes vormt een relatief 
nieuwe tak van onderzoek binnen de chemie/nanotechnologie. Binnen dit onderzoeksveld 
vormt de SLN biopsie een aantrekkelijke toepassing, aangezien er tijdens de diagnostiek 
van de SLN een duidelijke voorkeur is voor deeltjes met het formaat van 10-100 nm. Dit 
formaat zorgt voor voldoende retentie in de SLN, waardoor de (fluorescente) kleurstoffen 
en radiolabels die gekoppeld zijn aan dit deeltje ook in de lymfeklier kunnen worden 
gedetecteerd. Een goed voorbeeld hiervan is het hybride ICG-99mTc-nanocolloïd, dat 
bestaat uit een complex van het reeds klinisch toegepaste radioactief gelabelde humaan 




De dynamiek van 99mTc-nanocolloïd, ICG, en ICG-99mTc-nanocolloïd is bestudeerd in 
een orthotoop muismodel voor metastaserende borstkanker. Deze studie toont aan dat 
de drainage en het retentie patroon van beide radiocolloïden in muizen vergelijkbaar zijn, 
terwijl vrij ICG snel geklaard wordt. 
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Hoofdstuk 4
De potentie van gecombineerde pre- en intra-operatieve beeldvorming met behulp 
van het hybride ICG-99mTc-nanocolloïd is verder geëvalueerd in een spontaan muis model 
voor prostaatkanker. Gebruik van een mengsel van de fluorescente kleurstof en het 
radiocolloïd zorgde voor een meer translationele formulering van het contrastmiddel. De 
stabiliteit van het hybride radiocolloïd bleek groter te zijn dan de stabiliteit van een niet-
colloïdaal ICG-99mTc-humaan serum albumine complex. In dit hoofdstuk werden bovendien 
de eerste (ex vivo) resultaten in patiënten gepresenteerd. 
De resultaten van de twee preklinische studies (Hoofdstuk 3 en 4) laten zien dat de 
hybride aanpak bijdraagt aan de verbetering van de op fluorescentie gebaseerde intra-
operatieve geleiding. Tevens kon gecombineerde chirurgische planning en intra-operatieve 
detectie bewerkstelligd worden op basis van een enkele injectie met ICG-99mTc-nanocolloïd. 
 
Hoofdstuk 5
In een reproduceerbaarheidsstudie waarin 25 patiënten met een melanoom in het 
hoofd-halsgebied, de romp, of met peniscarcinoom zijn geïncludeerd, werd een klinische 
vergelijking gemaakt tussen de lymfatische drainage patronen van de Europese gouden 
standaard 99mTc-nanocolloïd en ICG-99mTc-nanocolloïd. Vergelijkbaar met de resultaten van 




De toegevoegde waarde van ICG-99mTc-nanocolloïd tijdens laparoscopische 
procedures werd aangetoond in elf patiënten waarbij een robot geassisteerde 
laparoscopische prostatectomie werd uitgevoerd, in combinatie met een lymfeklier 
dissectie. Pre-operatief kon de SLN worden geïdentificeerd aan de hand van de verkregen 
lymfoscintigrammen en de SPECT/CT beelden, terwijl het hybride karakter van het 
contrastmiddel intra-operatieve optische identificatie van de SLN mogelijk maakte door 
middel van fluorescentie beeldvorming. Tijdens de ingreep bleken detectie van het 
radioactieve en fluorescentie signaal complementair; Fluorescentie verbeterde de 
chirurgische geleiding in gebieden met een hoog radioactief achtergrond signaal, zoals 
rond de plaats van injectie. Radiogeleiding werd gebruikt als aanvulling op de beperkte 
weefselpenetratie van het fluorescentie signaal.
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Hoofdstuk 7
Een additionele eigenschap van ICG-99mTc-nanocolloïd is dat de optische component 
gebruikt kan worden voor de ex vivo evaluatie van de locatie van het ICG-99mTc-nanocoloïd 
injectie depot. Door met fluorescentie beeldvorming de locatie van de injectie deposito’s 
in ingebedde prostaat monsters te bepalen, en deze direct te linken aan het lymfedrainage 
patroon zoals preoperatief gezien op lymfoscintigrafie, kon een correlatie tussen beiden 
worden aangetoond. Uit de resultaten van deze studie kon worden geconcludeerd dat de 
plaatsing van de injectie in de prostaat het lymfedrainage patroon beïnvloedt, en als 
zodanig van invloed is op de SLN biopsie procedure als geheel.
 
Deel II: Chemokine recetor 4 (CXCR4) gerichte toepassingen
Voor de visualisatie van tumorcellen moet men gebruik maken van beeldvormende 
technieken die een specifieke biomarker op een tumorcel zichtbaar maakt. CXCR4 is een 
biomarker die tot over-expressie wordt gebracht in verschillende soorten kanker en is een 
opkomend target binnen de moleculaire beeldvorming een target voor therapie. De pre-
klinische evaluatie van verschillend gelabelde contrastmiddelen gericht tegen CXCR4, 




Bij de beoordeling van een (hybride) biomarker specifiek contrastmiddel zijn zowel 
de pre-klinische set-up als de affiniteit van de probe voor de receptor van invloed op de 
verkregen resultaten. Getransfecteerde cellijnen met zeer hoge CXCR4 expressie niveaus 
kunnen gebruikt worden voor de initiële evaluatie van een contrastmiddel. Tumor 
modellen met een over-expressie niveau dat beter vergelijkbaar is met de viervoudige 
over-expressie die gevonden is in de klinische situatie, kunnen het beste gebruikt worden 
om de klinische relevantie van contrastmiddelen voor CXCR4 te bestuderen.
De affiniteit van Ac-TZ14011 peptide derivaten voor CXCR4 kan worden beïnvloed 
door de toevoeging van een fluorescent label of een radio label. Toevoeging van een label 
vooroorzaakt een afname in affiniteit voor de receptor. De affiniteit blijft echter in alle 




Door functionalisatie van Ac-TZ14011 met de fluorescente kleurstof FITC konden in 
vitro, in borstkanker cellen, CXCR4 receptor expressie niveaus en de lokalisatie van de 
receptor geëvalueerd worden. CXCR4 bleek voornamelijk aanwezig te zijn op het 
celmembraan en/of in endosomen/lysosomen in het cytoplasma na het optreden van 
endocytose. Met Ac-TZ14011-FITC konden cellen met slechts een viervoudige over-
expressie van CXCR4 worden onderscheiden van normale tumorcellen. Bovendien bleek 
de aankleuring na incubatie met Ac-TZ14011-FITC vergelijkbaar met de aankleuring die 
verkregen wordt na incubatie met commercieel verkrijgbare anti-CXCR4-antilichamen.
 
Hoofdstuk 10
Een indium gelabelde variant van het Ac-TZ14011 peptide (111In-DTPA-Ac-TZ14011) 
maakte evaluatie van CXCR4 expressie niveaus mogelijk in het MIN-O muis tumor model 
dat vergelijking vertoont met humaan ductaal carcinoom in situ. Op basis van de CXCR4 
expressie kon onderscheid worden gemaakt tussen een (pre-invasief ) vroeg, overgangs- 
en een (invasief ) laat stadium in de progressie van MIN-O tumorlaesies. De membraneuze 
CXCR4 expressie bleek heterogeen verdeeld over de tumor en de receptor expressie nam 
toe gedurende de progressie van de MIN-O laesies.
 
Hoofdstuk 11
Toevoeging van een groep die zowel het chelaat DTPA als een fluorescerende 
kleurstof bevat (multifunctional single attachment point reagent; MSAP) leidde tot de 
vorming van een hybride versie van Ac-TZ14011 (Ac-TZ14011-MSAP). Deze functionalisatie 
resulteerde in een lagere affiniteit voor de CXCR4 receptor in vergelijking met het niet-
gelabelde Ac-TZ14011 peptide. De affiniteit van het hybride contrastmiddel was echter 
vergelijkbaar met de affiniteit die verkregen was na toevoeging van zowel het FITC- of het 
DTPA-label aan Ac-TZ14011. Met het MSAP-label was het mogelijk om CXCR4 positieve 
tumoren te visualiseren in zowel de pre- als intra-operatieve setting.
 
Hoofdstuk 12
Multimerisatie kan worden gebruikt om de negatieve invloed van het MSAP-label op 
de bindingsaffiniteit van Ac-TZ14011 te minimaliseren. Terwijl de affiniteit voor CXCR4 van 
een ongelabelde dimeer en tetrameer iets lager was dan de affiniteit van de ongelabelde 
Interventional molecular imaging, a hybrid approach320
monomeer, werd een vermindering van de aspecifieke binding gezien voor de MSAP 
gelabelde dimeer en tetrameer in vergelijking met de MSAP-gelabelde monomeer. De 
dimeer bleek minder invloed op de levensvatbaarheid van de cellen te hebben en zorgde 
voor een hogere ratio tussen opname in tumor- en spierweefsel.
Hoofdstuk 13
Het concept van hybride beeldvorming kon verder worden uitgebreid door het 
fluorescente label van MSAP-Ac-TZ14011 te gebruiken voor het bestuderen van de 
aanwezigheid van CXCR4 receptoren in vers MIN-O biopsie weefsel. Met behulp van flow 
cytometrische analyse konden verschillende CXCR4 positieve celpopulaties worden 
aangetoond, wat een nauwkeurige stadiëring van de laesies mogelijk maakte. Deze 
bevindingen werden gebruikt om nauwkeurig te voorspellen of in vivo visualisatie van 
tumor weefsel met behulp van beeldvormende technieken zoals SPECT/CT en 
fluorescentie detectie haalbaar was. Bovendien kon het fluorescente label ook ex vivo 
worden gebruikt om de CXCR4 gerelateerde aankleuring in tumormonsters bevestigen. 
Als zodanig bleek het hybride karakter van MSAP-Ac-TZ14011 geschikt voor integratie van 
biomarker screening, in vivo beeldvorming en ex vivo validatie van tumor weefsel met 
behulp van een enkel contrastmiddel.
Hoofdstuk 14 (toekomst visie)
Verdere ontwikkeling van fluorescentie camera’s en ontwikkeling en klinische 
implementatie van nieuwe contrastmiddelen zullen essentieel zijn voor de verdere 
verbetering van de accuraatheid van een chirurgische ingreep. Momenteel wordt er op 
verschillende manieren geprobeerd om het in dit proefschrift beschreven hybride concept 
verder te optimaliseren en/of uit te breiden. 
De biomarker specifieke hybride imaging aanpak kan ook worden toegepast voor 
andere biomarkers, bijvoorbeeld αvβ3 integrine. Via deze benadering kunnen met 
111In-
MSAP-RGD, welke gericht is tegen αvβ3 integrine, zowel tumor marges als metastasen 
zichtbaar gemaakt worden. 
(Borst) tumoren kunnen worden gemerkt met bv. markeringszaadjes om chirurgische 
lokalisatie te vergemakkelijken. Hybride markeringszaadjes kunnen worden gebruikt voor 
het uitbreiden van de huidige markeringsmethodes en de fluorescentie eigenschappen 
kunnen worden gebruikt voor het inschatten van de chirurgische veiligheidsmarges. 
321Chapter 16
Zelfs wanneer fluorescentie gecombineerd wordt met pre-operatieve beeldvorming 
en intra-operatieve detectie van gamma stralen, kan de chirurgische identificatie van 
bijvoorbeeld diepliggende SLNs nog steeds moeilijk zijn. Pilot experimenten hebben 
laten zien dat, op 3D SPECT/CT gebaseerde, navigatie van een fluorescentie laparoscoop 
haalbaar is en mogelijk de chirurgische geleiding verder kan optimaliseren.
Conclusie
De resultaten beschreven in dit proefschrift laten het potentieel zien van hybride 
contrastmiddelen in de translatie van preoperative bevindingen naar de operatiekamer. 
Het hybride concept bleek van aanvullende waarde tijdens klinische SLN-biopsie 
procedures. Hiernaast is dit hybride concept preklinisch ook al succesvol toegepast voor 
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